

CITATION REPORT

List of articles citing

Innate and adaptive immune cells in the tumor microenvironment

DOI: 10.1038/ni.2703

Nature Immunology, 2013, 14, 1014-22.

Source: <https://exaly.com/paper-pdf/55251149/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2299	Current state of immunotherapy for non-small cell lung cancer. 2017 , 6, 196-211		107
2298	Regulatory T cells in nonlymphoid tissues. <i>Nature Immunology</i> , 2013 , 14, 1007-13	19.1	247
2297	Dendritic cell vaccine and cancer treatment: new patents. 2014 , 8, 26-9		1
2296	MicroRNA-17 inhibits tumor growth by stimulating T-cell mediated host immune response. 2014 , 1, 531-9		30
2295	Tertiary lymphoid tissue: A gateway for T cells in the tumor microenvironment. 2014 , 3, e28850		8
2294	mTOR signaling, Tregs and immune modulation. 2014 , 6, 1295-311		72
2293	Intermittent hypoxia-induced changes in tumor-associated macrophages and tumor malignancy in a mouse model of sleep apnea. 2014 , 189, 593-601		132
2292	Gene therapy for cancer: present status and future perspective. 2014 , 2, 27		135
2291	Iron-induced parafibrin formation in tumors fosters immune evasion. 2014 , 3, e28539		4
2290	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge", Napoli, December 5th-8th 2013. 2014 , 12, 277		10
2289	Impact of the prolymphangiogenic crosstalk in the tumor microenvironment on lymphatic cancer metastasis. 2014 , 2014, 639058		18
2288	Tumor-Infiltrating T Lymphocytes: Pathogenic Role, Clinical Significance, and Differential Programming in the Tumor Microenvironment. 2014 , 5, 607		64
2287	Combinations of immunotherapy and radiation in cancer therapy. 2014 , 4, 325		164
2286	Role of Exosomes Released by Dendritic Cells and/or by Tumor Targets: Regulation of NK Cell Plasticity. 2014 , 5, 91		32
2285	Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. 2014 , 5, 191		50
2284	Trafficking of T cells into tumors. 2014 , 74, 7168-74		225
2283	Occurrence of tertiary lymphoid tissue is associated with T-cell infiltration and predicts better prognosis in early-stage colorectal cancers. 2014 , 20, 2147-58		168

2282	Therapeutic activity of high-dose intratumoral IFN- γ requires direct effect on the tumor vasculature. 2014 , 193, 4254-60	58
2281	Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways. 2014 , 41, 947-59	101
2280	Blocking monoclonal antibodies of TIM proteins as orchestrators of anti-tumor immune response. 2014 , 6, 1124-32	4
2279	Nano-Oncologicals. 2014 ,	4
2278	Differential effects of agonistic 4-1BB (CD137) monoclonal antibody on the maturation and functions of hypoxic dendritic cells. 2014 , 23, 609-16	1
2277	Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. 2014 , 515, 563-7	3354
2276	IL32 is progressively expressed in mycosis fungoides independent of helper T-cell 2 and helper T-cell 9 polarization. 2014 , 2, 890-900	16
2275	Tumor antigen-targeting monoclonal antibody-based immunotherapy: Orchestrating combined strategies for the development of long-term antitumor immunity. 2014 , 3, e955684	36
2274	Genetic evolution of T-cell resistance in the course of melanoma progression. 2014 , 20, 6593-604	106
2273	Emerging immunologic biomarkers: setting the (TNM-immune) stage. 2014 , 20, 2023-5	17
2272	Immunoguiding, the Final Frontier in the Immunotherapy of Cancer. 2014 , 37-51	
2271	A pan-cancer modular regulatory network analysis to identify common and cancer-specific network components. 2014 , 13, 69-84	14
2270	Interferons and their stimulated genes in the tumor microenvironment. 2014 , 41, 156-73	140
2269	The anti-lung cancer activity of SEP is mediated by the activation and cytotoxicity of NK cells via TLR2/4 in vivo. 2014 , 89, 119-30	22
2268	New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. 2014 , 27, 16-25	882
2267	3D cell culture systems modeling tumor growth determinants in cancer target discovery. 2014 , 69-70, 29-41	312
2266	Fragmented sleep accelerates tumor growth and progression through recruitment of tumor-associated macrophages and TLR4 signaling. 2014 , 74, 1329-37	115
2265	Mechanisms of tumor escape from immune system: role of mesenchymal stromal cells. 2014 , 159, 55-72	81

2264	The two faces of IL-6 in the tumor microenvironment. 2014 , 26, 38-47	339
2263	Circulating hematopoietic stem and progenitor cells are myeloid-biased in cancer patients. 2014 , 111, 4221-6	101
2262	The melanoma revolution: from UV carcinogenesis to a new era in therapeutics. 2014 , 346, 945-9	246
2261	Microfluidic platform for the study of intercellular communication via soluble factor-cell and cell-cell paracrine signaling. 2014 , 8, 044104	18
2260	Natural killer cells eradicate galectin-1-deficient glioma in the absence of adaptive immunity. 2014 , 74, 5079-90	50
2259	Gangliosides drive the tumor infiltration and function of myeloid-derived suppressor cells. 2014 , 74, 5449-57	25
2258	Tumor antigen-specific CD4+ T cells in cancer immunity: from antigen identification to tumor prognosis and development of therapeutic strategies. 2014 , 83, 237-46	36
2257	STING contributes to antiglioma immunity via triggering type I IFN signals in the tumor microenvironment. 2014 , 2, 1199-208	128
2256	Cytosolic DNA sensing via the stimulator of interferon genes adaptor: Yin and Yang of immune responses to DNA. 2014 , 44, 2847-53	23
2255	Tumor-associated macrophages: from mechanisms to therapy. 2014 , 41, 49-61	2228
2254	Immune-based therapies in pancreatic and colorectal cancers and biomarkers of responsiveness. 2014 , 14, 1219-28	1
2253	Novel antitumor mechanisms of curcumin: implication of altered tumor metabolism, reconstituted tumor microenvironment and augmented myelopoiesis. 2014 , 13, 717-724	16
2252	Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment. 2014 , 2, 3	371
2251	Chitosan-based thermoreversible hydrogel as an in vitro tumor microenvironment for testing breast cancer therapies. 2014 , 11, 2134-42	28
2250	A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study). 2014 , 12, 108	55
2249	A phase I study of combination vaccine treatment of five therapeutic epitope-peptides for metastatic colorectal cancer; safety, immunological response, and clinical outcome. 2014 , 12, 63	59
2248	Metabolism of stromal and immune cells in health and disease. 2014 , 511, 167-76	298
2247	Angiogenesis and the tumor microenvironment: vascular endothelial growth factor and beyond. 2014 , 41, 235-51	104

2246	Heterogeneity in immune responses: from populations to single cells. 2014 , 35, 219-29	117
2245	The microtubule-depolymerizing agent ansamitocin P3 programs dendritic cells toward enhanced anti-tumor immunity. 2014 , 63, 925-38	46
2244	Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. 2014 , 2, 105	125
2243	A simple and rapid protocol to non-enzymatically dissociate fresh human tissues for the analysis of infiltrating lymphocytes. 2014 ,	20
2242	Antimelanoma CTL recognizes peptides derived from an ORF transcribed from the antisense strand of the 3' untranslated region of TRIT1. 2015 , 1, 14009	1
2241	How anti-PD1 treatments are changing the management of melanoma. 2014 , 1, 165-172	3
2240	T Cell Intrinsic USP15 Deficiency Promotes Excessive IFN- γ Production and an Immunosuppressive Tumor Microenvironment in MCA-Induced Fibrosarcoma. 2015 , 13, 2470-2479	31
2239	Permissive expansion and homing of adoptively transferred T cells in tumor-bearing hosts. 2015 , 137, 359-71	8
2238	Tumor cellular behaviors regulated by controlled microenvironment. 2015 ,	
2237	Combining radiotherapy and immunotherapy for prostate cancer: two decades of research from preclinical to clinical trials. 2015 , 4, 365-375	1
2236	Future perspectives in melanoma research: meeting report from the "Melanoma Bridge": Napoli, December 3rd-6th 2014. 2015 , 13, 374	11
2235	Tumor-infiltrating, interleukin-33-producing effector-memory CD8(+) T cells in resected hepatocellular carcinoma prolong patient survival. 2015 , 61, 1957-67	70
2234	Chemokine (C-X-C motif) receptor 3-positive B cells link interleukin-17 inflammation to protumorigenic macrophage polarization in human hepatocellular carcinoma. 2015 , 62, 1779-90	55
2233	Myeloid Cells as Targets for Therapy in Solid Tumors. 2015 , 21, 343-50	26
2232	Immune-based Therapy Clinical Trials in Hepatocellular Carcinoma. 2015 , 6,	15
2231	Therapeutic cancer vaccines. 2015 , 125, 3401-12	367
2230	Drug Development for Metastasis Prevention. 2015 , 20, 449-73	21
2229	Subverting Subversion: A Review on the Breast Cancer Microenvironment and Therapeutic Opportunities. 2015 , 9, 7-15	7

2228	Critical Role of Tumor Microenvironment in Shaping NK Cell Functions: Implication of Hypoxic Stress. 2015 , 6, 482	82
2227	Tumor Interstitial Fluid Formation, Characterization, and Clinical Implications. 2015 , 5, 115	61
2226	Metastasis: Other Side of the Coin. 2015 , 5, 163	1
2225	Recapitulating the Tumor Ecosystem Along the Metastatic Cascade Using 3D Culture Models. 2015 , 5, 170	21
2224	Dendritic Cells in Oncolytic Virus-Based Anti-Cancer Therapy. 2015 , 7, 6506-25	26
2223	EH2AX as a marker for dose deposition in the brain of wistar rats after synchrotron microbeam radiation. 2015 , 10, e0119924	27
2222	GO-PCA: An Unsupervised Method to Explore Gene Expression Data Using Prior Knowledge. 2015 , 10, e0143196	17
2221	Immune Adjuvant Activity of Pre-Resectional Radiofrequency Ablation Protects against Local and Systemic Recurrence in Aggressive Murine Colorectal Cancer. 2015 , 10, e0143370	28
2220	Effect and Molecular Mechanisms of Traditional Chinese Medicine on Regulating Tumor Immunosuppressive Microenvironment. 2015 , 2015, 261620	39
2219	Immunoediting, Immunosurveillance, Tumor-induced Immunosuppression and Immuno-resistance, Immunomodulation, Immunotherapy, and Immunonutrition in Personalized and Precision Cancer Medicine. 2015 ,	
2218	Pancreatic cancer vaccine: a unique potential therapy. 2015 , 1	
2217	Human Leukocyte Antigen-G (HLA-G) Expression in Cancers: Roles in Immune Evasion, Metastasis and Target for Therapy. 2015 , 21, 782-791	66
2216	The source of matrix-degrading enzymes in human cancer: Problems of research reproducibility and possible solutions. 2015 , 209, 195-8	18
2215	Type I interferons in anticancer immunity. 2015 , 15, 405-14	606
2214	Porous silicon microparticle potentiates anti-tumor immunity by enhancing cross-presentation and inducing type I interferon response. 2015 , 11, 957-966	69
2213	Immune modulation in advanced radiotherapies: Targeting out-of-field effects. 2015 , 368, 246-51	34
2212	Pembrolizumab joins the anti-PD-1 armamentarium in the treatment of melanoma. 2015 , 11, 133-40	9
2211	Prostate cancer and neuroendocrine differentiation: more neuronal, less endocrine?. 2015 , 5, 37	49

2210	Improvement of IFN γ ELISPOT Performance Following Overnight Resting of Frozen PBMC Samples Confirmed Through Rigorous Statistical Analysis. 2014 , 4, 1-18	13
2209	CoD: inferring immune-cell quantities related to disease states. 2015 , 31, 3961-9	6
2208	Tropism of CPMV to Professional Antigen Presenting Cells Enables a Platform to Eliminate Chronic Infections. 2015 , 1, 1050-1054	19
2207	Distinguishing the immunostimulatory properties of noncoding RNAs expressed in cancer cells. 2015 , 112, 15154-9	45
2206	Multiple-purpose immunotherapy for cancer. 2015 , 76, 24-9	11
2205	Primary laryngeal cancer-derived miR-193b induces interleukin-10-expression monocytes. 2015 , 33, 29-33	9
2204	T-cell subsets in peripheral blood and tumors of patients treated with oncolytic adenoviruses. 2015 , 23, 964-973	10
2203	Hallmarks of the ageing lung. 2015 , 45, 807-27	172
2202	Chemokine (C-C Motif) Ligand 5 is Involved in Tumor-Associated Dendritic Cell-Mediated Colon Cancer Progression Through Non-Coding RNA MALAT-1. 2015 , 230, 1883-94	54
2201	Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease. 2015 , 64, 149-59	83
2200	[Breaking immune tolerance in cancer]. 2015 , 102, 34-52	2
2199	Tim-3 fosters HCC development by enhancing TGF- β -mediated alternative activation of macrophages. 2015 , 64, 1593-604	165
2198	Recent Advances in Tumor Targeting Approaches. 2015 , 41-112	4
2197	Modification of Antitumor Immunity and Tumor Microenvironment by Resveratrol in Mouse Renal Tumor Model. 2015 , 72, 617-25	30
2196	Innate immune recognition of cancer. 2015 , 33, 445-74	323
2195	Immune escape mechanisms as a guide for cancer immunotherapy. 2015 , 21, 687-92	523
2194	New perspectives on type I IFNs in cancer. 2015 , 26, 175-8	43
2193	Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. 2015 , 67, 46-57	81

2192	Genetic associations of the interleukin locus at 1q32.1 with clinical outcomes of cutaneous melanoma. 2015 , 52, 231-9	16
2191	Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells. 2015 , 33, 120-5	44
2190	Intra-adrenal murine TH-MYCN neuroblastoma tumors grow more aggressive and exhibit a distinct tumor microenvironment relative to their subcutaneous equivalents. 2015 , 64, 563-72	9
2189	The role of oncolytic virus immunotherapies to subvert cancer immune evasion. 2015 , 11, 675-89	15
2188	Exosomes and their roles in immune regulation and cancer. 2015 , 40, 72-81	378
2187	Inflammation and prostate cancer: friends or foe?. 2015 , 64, 275-86	39
2186	From virotherapy to oncolytic immunotherapy: where are we now?. 2015 , 13, 93-100	38
2185	In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment. 2015 , 33, 7415-7422	116
2184	The importance of the tumor microenvironment in the therapeutic management of cancer. 2015 , 15, 943-54	30
2183	Prognostic Value of the Tumour-Infiltrating Dendritic Cells in Colorectal Cancer: A Systematic Review. 2015 , 22, 9-14	9
2182	Targeting the T-cell co-stimulatory CD27/CD70 pathway in cancer immunotherapy: rationale and potential. 2015 , 7, 655-67	76
2181	Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. 2015 , 6, 7458	265
2180	Immune biomarkers: how well do they serve prognosis in human cancers?. 2015 , 15, 49-59	5
2179	Memory versus effector immune responses in oncolytic virotherapies. 2015 , 377, 1-9	15
2178	Immunotherapy for urothelial cancer: from BCG to checkpoint inhibitors and beyond. 2015 , 15, 509-23	18
2177	Tertiary lymphoid tissue in the tumor microenvironment: from its occurrence to immunotherapeutic implications. 2015 , 34, 123-33	20
2176	PD-L1 inhibition with MPDL3280A for solid tumors. 2015 , 42, 484-7	38
2175	Immunotherapy for lung cancer: for whom the bell tolls?. 2015 , 36, 1411-22	14

2174	Portrait of inflammatory response to ionizing radiation treatment. 2015 , 12, 14	154
2173	Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. 2015 , 16, 64	329
2172	Clinically feasible approaches to potentiating cancer cell-based immunotherapies. 2015 , 11, 851-69	51
2171	Evaluation of Tumor-infiltrating Leukocyte Subsets in a Subcutaneous Tumor Model. 2015 ,	13
2170	Dendritic cells and pluripotency: unlikely allies in the pursuit of immunotherapy. 2015 , 10, 275-86	5
2169	Differential regulation and function of tumor-infiltrating T cells in different stages of breast cancer patients. 2015 , 36, 7907-13	9
2168	The interplay of effector and regulatory T cells in cancer. 2015 , 33, 101-11	88
2167	The new deal: a potential role for secreted vesicles in innate immunity and tumor progression. 2015 , 6, 66	70
2166	Effective Eradication of Glioblastoma Stem Cells by Local Application of an AC133/CD133-Specific T-cell-Engaging Antibody and CD8 T Cells. 2015 , 75, 2166-76	29
2165	TGF β s a Master Regulator of Radiation Therapy-Induced Antitumor Immunity. 2015 , 75, 2232-42	331
2164	TNF Counterbalances the Emergence of M2 Tumor Macrophages. 2015 , 12, 1902-14	158
2163	Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model. 2015 , 135, 2785-2793	15
2162	Cish actively silences TCR signaling in CD8+ T cells to maintain tumor tolerance. 2015 , 212, 2095-113	85
2161	Several immune escape patterns in non-Hodgkin's lymphomas. 2015 , 4, e1026530	62
2160	Tumour islet Foxp3+ T-cell infiltration predicts poor outcome in nonsmall cell lung cancer. 2015 , 46, 1762-72	36
2159	Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy. 2015 , 21, 5427-33	196
2158	Toward improved effectiveness of bladder cancer immunotherapy. 2015 , 7, 1039-42	4
2157	Characterization of T cell repertoire of blood, tumor, and ascites in ovarian cancer patients using next generation sequencing. 2015 , 4, e1030561	44

2156	Identification of shared and unique susceptibility pathways among cancers of the lung, breast, and prostate from genome-wide association studies and tissue-specific protein interactions. 2015 , 24, 7406-20	11
2155	Prognostic and functional importance of the engraftment-associated genes in the patient-derived xenograft models of triple-negative breast cancers. 2015 , 154, 13-22	44
2154	Close Encounters of the Tertiary Kind. 2015 , 43, 418-20	1
2153	Oncogenic Transformation of Dendritic Cells and Their Precursors Leads to Rapid Cancer Development in Mice. 2015 , 195, 5066-76	3
2152	Stromal infiltration of CD8 T cells is associated with improved clinical outcome in HPV-positive oropharyngeal squamous carcinoma. 2015 , 113, 886-93	90
2151	CTL- vs Treg lymphocyte-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with oesophageal squamous cell carcinoma. 2015 , 113, 747-55	69
2150	Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 2015 , 107,	47
2149	Oncolytic viruses: a new class of immunotherapy drugs. 2015 , 14, 642-62	680
2148	Galectin-3 Binding Protein Secreted by Breast Cancer Cells Inhibits Monocyte-Derived Fibrocyte Differentiation. 2015 , 195, 1858-67	32
2147	Tumor microenvironment: Sanctuary of the devil. 2015 , 368, 7-13	380
2146	Are BiTEs the "missing link" in cancer therapy?. 2015 , 4, e1008339	49
2145	Cyclooxygenase-Dependent Tumor Growth through Evasion of Immunity. 2015 , 162, 1257-70	602
2144	CD8/FOXP3-ratio in osteosarcoma microenvironment separates survivors from non-survivors: a multicenter validated retrospective study. 2015 , 4, e990800	88
2143	The Role of Perioperative Pharmacological Adjuncts in Cancer Outcomes: Beta-Adrenergic Receptor Antagonists, NSAIDs and Anti-fibrinolytics. 2015 , 5, 291-304	2
2142	Engineering opportunities in cancer immunotherapy. 2015 , 112, 14467-72	90
2141	Recovery Profiles of T-Cell Subsets Following Low-Dose Total Body Irradiation and Improvement With Cinnamon. 2015 , 93, 1118-26	13
2140	STING: infection, inflammation and cancer. 2015 , 15, 760-70	608
2139	Trastuzumab emtansine (T-DM1) renders HER2+ breast cancer highly susceptible to CTLA-4/PD-1 blockade. 2015 , 7, 315ra188	177

2138	Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- κ B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. 2015 , 75, 5034-45	318
2137	Myeloid-derived cells in tumors: effects of radiation. 2015 , 25, 18-27	91
2136	The origin and function of tumor-associated macrophages. 2015 , 12, 1-4	151
2135	NK cell receptor imbalance and NK cell dysfunction in HBV infection and hepatocellular carcinoma. 2015 , 12, 292-302	97
2134	Combination of radiotherapy and immune checkpoint inhibitors. 2015 , 25, 28-33	107
2133	Radiation and inflammation. 2015 , 25, 4-10	133
2132	Nanoparticle-based immunotherapy for cancer. 2015 , 9, 16-30	322
2131	Network dynamics in the tumor microenvironment. 2015 , 30, 52-9	25
2130	The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. 2015 , 26, 259-71	1372
2129	MicroRNA regulons in tumor microenvironment. 2015 , 34, 3085-94	129
2128	Immune Suppression Mediated by Myeloid and Lymphoid Derived Immune Cells in the Tumor Microenvironment Facilitates Progression of Thyroid Cancers Driven by Hras and Pten Loss. 2016 , 7,	9
2127	Cancer Vaccines: Bench to Bedside. 2016 , 2016, 33-60	3
2126	Potential of Radiofrequency Ablation in Combination with Immunotherapy in the Treatment of Hepatocellular Carcinoma. 2016 , 6,	19
2125	Viruses as nanomedicine for cancer. 2016 , 11, 4835-4847	19
2124	-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors. 2017 , 10, 101-112	43
2123	The Challenge of Malignancies in HIV-1, Beyond Immune Activation and Back to Decreased Immune Surveillance. 2016 , 07,	
2122	A strong host response and lack of MYC expression are characteristic for diffuse large B cell lymphoma transformed from nodular lymphocyte predominant Hodgkin lymphoma. 2016 , 7, 72197-72210	6
2121	Overcoming Therapeutic Resistance by Targeting Cancer Inflammation. 2016 , 35, e168-73	5

2120	Biomarkers for Immunotherapy: Current Developments and Challenges. 2016 , 35, e493-503	61
2119	Immunomediated Pan-cancer Regulation Networks are Dominant Fingerprints After Treatment of Cell Lines with Demethylation. 2016 , 15, 45-64	
2118	Cancer Metabolism: Fueling More than Just Growth. 2016 , 39, 847-854	54
2117	Hallmarks of glioblastoma: a systematic review. 2016 , 1, e000144	77
2116	Long-term intravital imaging of the multicolor-coded tumor microenvironment during combination immunotherapy. 2016 , 5,	29
2115	Therapy of solid tumors using probiotic Symbioflor-2: restraints and potential. 2016 , 7, 22605-22	29
2114	The multifaceted role of autophagy in tumor evasion from immune surveillance. 2016 , 7, 17591-607	46
2113	In Vitro Tumor Models: Advantages, Disadvantages, Variables, and Selecting the Right Platform. 2016 , 4, 12	386
2112	Gene Coexpression Analyses Differentiate Networks Associated with Diverse Cancers Harboring TP53 Missense or Null Mutations. 2016 , 7, 137	16
2111	Tertiary Lymphoid Organs in Cancer Tissues. 2016 , 7, 244	57
2110	New Insights into Regulatory T Cells: Exosome- and Non-Coding RNA-Mediated Regulation of Homeostasis and Resident Treg Cells. 2016 , 7, 574	35
2109	The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment. 2016 , 7, 621	90
2108	Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?. 2016 , 6, 256	28
2107	Taking up Cancer Immunotherapy Challenges: Bispecific Antibodies, the Path Forward?. 2015 , 5,	24
2106	Capitalizing on Cancer Specific Replication: Oncolytic Viruses as a Versatile Platform for the Enhancement of Cancer Immunotherapy Strategies. 2016 , 4,	8
2105	Immunomodulatory Function of the Tumor Suppressor p53 in Host Immune Response and the Tumor Microenvironment. 2016 , 17,	61
2104	PD-1/CTLA-4 Blockade Inhibits Epstein-Barr Virus-Induced Lymphoma Growth in a Cord Blood Humanized-Mouse Model. 2016 , 12, e1005642	72
2103	Associations of C-Reactive Protein, Granulocytes and Granulocyte-to-Lymphocyte Ratio with Mortality from Breast Cancer in Non-Institutionalized American Women. 2016 , 11, e0157482	7

2102	Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting. 2016 , 4,	272
2101	Serum Stability and Affinity Optimization of an M2 Macrophage-Targeting Peptide (M2pep). 2016 , 6, 1403-14	29
2100	Ameliorative effects of Hippic acid on high-fat diet-induced oxidative stress and glucose uptake impairment of T cells. 2016 , 50, 1106-1115	6
2099	Multicentric neoadjuvant pilot Phase II study of cetuximab combined with docetaxel in operable triple negative breast cancer. 2016 , 138, 2274-80	36
2098	IL-8-Positive Tumor-Infiltrating Inflammatory Cells Are a Novel Prognostic Marker in Pancreatic Ductal Adenocarcinoma Patients. 2016 , 45, 671-8	12
2097	Cell spheroids: the new frontiers in in vitro models for cancer drug validation. 2016 , 21, 1553-1560	72
2096	Didymin reverses phthalate ester-associated breast cancer aggravation in the breast cancer tumor microenvironment. 2016 , 11, 1035-1042	18
2095	Effective Delivery of Antigen-Encapsulin Nanoparticle Fusions to Dendritic Cells Leads to Antigen-Specific Cytotoxic T Cell Activation and Tumor Rejection. 2016 , 10, 7339-50	56
2094	Single-cell profiling approaches to probing tumor heterogeneity. 2016 , 139, 243-55	42
2093	Chimeric antigen receptor-modified T cells for the treatment of solid tumors: Defining the challenges and next steps. 2016 , 166, 30-9	81
2092	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. 2016 , 5, e1186323	2
2091	Photodynamic Therapy Mediated by Nontoxic Core-Shell Nanoparticles Synergizes with Immune Checkpoint Blockade To Elicit Antitumor Immunity and Antimetastatic Effect on Breast Cancer. 2016 , 138, 16686-16695	292
2090	The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity. 2016 , 167, 1525-1539.e17	214
2089	Predictive biomarkers for checkpoint inhibitor-based immunotherapy. 2016 , 17, e542-e551	842
2088	Nerve growth factor: role in growth, differentiation and controlling cancer cell development. 2016 , 35, 116	43
2087	Model-based genotype-phenotype mapping used to investigate gene signatures of immune sensitivity and resistance in melanoma micrometastasis. 2016 , 6, 24967	14
2086	Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma. 2016 , 128, 3083-3100	41
2085	Emerging roles of T helper 17 and regulatory T cells in lung cancer progression and metastasis. 2016 , 15, 67	96

2084	Dendritic cell vaccines for melanoma: past, present and future. 2016 , 3, 273-289	12
2083	CD8+ tumor infiltrating lymphocytes strongly correlate with molecular subtype and clinico-pathological characteristics in breast cancer patients from Sudan. 2016 , 1,	4
2082	T-Cell Therapy Enabling Adenoviruses Coding for IL2 and TNF β Induce Systemic Immunomodulation in Mice With Spontaneous Melanoma. 2016 , 39, 343-354	17
2081	Natural killer cells enhance the immune surveillance of cancer. 2016 , 17, 149-154	8
2080	Targeting macrophages to treat pancreatic cancer. 2016 , 17, 552-3	3
2079	Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. 2016 , 113, 4476-81	214
2078	Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer. 2016 , 58, 59-70	78
2077	Cancer Treatment with Anti-PD-1/PD-L1 Agents: Is PD-L1 Expression a Biomarker for Patient Selection?. 2016 , 76, 925-45	100
2076	Malignant melanoma-The cradle of anti-neoplastic immunotherapy. 2016 , 106, 25-54	22
2075	Long non-coding RNA expression profile in minor salivary gland of primary Sjögren's syndrome. 2016 , 18, 109	40
2074	PSGL-1 Is an Immune Checkpoint Regulator that Promotes T Cell Exhaustion. 2016 , 44, 1190-203	66
2073	Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. 2016 , 4, 563-8	199
2072	Personalized in vitro cancer models to predict therapeutic response: Challenges and a framework for improvement. 2016 , 165, 79-92	44
2071	Infiltration of lymphocyte subpopulations into cancer microtissues as a tool for the exploration of immunomodulatory agents and biomarkers. 2016 , 221, 604-17	6
2070	PD-1hi Identifies a Novel Regulatory B-cell Population in Human Hepatoma That Promotes Disease Progression. 2016 , 6, 546-59	172
2069	CD8 engineered cytotoxic T cells reprogram melanoma tumor environment. 2016 , 5, e1086861	7
2068	Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China. 2016 , 59, 349-59	9
2067	Regulation of breast cancer cell behaviours by the physical microenvironment constructed via projection microstereolithography. 2016 , 4, 863-70	15

2066	Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. 2016 , 27, 1482-92	335
2065	Development and characterization of a three-dimensional co-culture model of tumor T cell infiltration. 2016 , 8, 025002	18
2064	Subtypes of HPV-Positive Head and Neck Cancers Are Associated with HPV Characteristics, Copy Number Alterations, PIK3CA Mutation, and Pathway Signatures. 2016 , 22, 4735-45	72
2063	Emerging nanotechnologies for cancer immunotherapy. 2016 , 241, 1116-26	20
2062	Systems immune monitoring in cancer therapy. 2016 , 61, 77-84	29
2061	Recent developments in the use of immunotherapy in non-small cell lung cancer. 2016 , 10, 781-98	23
2060	Clinical RNA sequencing in oncology: where are we?. 2016 , 13, 209-213	3
2059	Oncolytic immunotherapy: an emerging new modality for the treatment of cancer. 2016 , 27, 1805-8	6
2058	Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma. 2016 , 22, 5461-5471	158
2057	Detecting Secreted Analytes from Immune Cells: An Overview of Technologies. 2016 , 1458, 111-24	4
2056	Radiotherapy: Changing the Game in Immunotherapy. 2016 , 2, 286-294	200
2055	Molecular mechanisms of HLA class I-mediated immune evasion of human tumors and their role in resistance to immunotherapies. 2016 , 88, 213-220	26
2054	CD4Foxp3 type 1 regulatory T cells in glioblastoma multiforme suppress T cell responses through multiple pathways and are regulated by tumor-associated macrophages. 2016 , 81, 1-9	20
2053	Engineering T Cells with Customized Therapeutic Response Programs Using Synthetic Notch Receptors. 2016 , 167, 419-432.e16	335
2052	Regulation of the IL-10-driven macrophage phenotype under incoherent stimuli. 2016 , 22, 647-657	35
2051	The Relationship Between Dormant Cancer Cells and Their Microenvironment. 2016 , 132, 45-71	92
2050	The Ecology and Evolution of Cancer: The Ultra-Microevolutionary Process. 2016 , 50, 347-369	57
2049	Interleukin 10 promotes immune response by increasing the survival of activated CD8 T cells in human papillomavirus 16-infected cervical cancer. 2016 , 37, 16093	9

2048	Patient-derived tumour xenografts for breast cancer drug discovery. 2016 , 23, T259-T270	10
2047	CD4-Transgenic Zebrafish Reveal Tissue-Resident Th2- and Regulatory T Cell-like Populations and Diverse Mononuclear Phagocytes. 2016 , 197, 3520-3530	75
2046	Costimulatory and coinhibitory immune checkpoint receptors in head and neck cancer: unleashing immune responses through therapeutic combinations. 2016 , 1, 12	13
2045	Radiotherapy and Immunotherapy Combinations in Non-small Cell Lung Cancer: A Promising Future?. 2016 , 28, 726-731	6
2044	Stimulation of Natural Killer Cell-Mediated Tumor Immunity by an IL15/TGF β Neutralizing Fusion Protein. 2016 , 76, 5683-5695	9
2043	Immune-checkpoint expression in Epstein-Barr virus positive and negative plasmablastic lymphoma: a clinical and pathological study in 82 patients. 2016 , 101, 976-84	49
2042	Systemic DC Activation Modulates the Tumor Microenvironment and Shapes the Long-Lived Tumor-Specific Memory Mediated by CD8+ T Cells. 2016 , 76, 3756-66	19
2041	Adaptive NK Cells with Low TIGIT Expression Are Inherently Resistant to Myeloid-Derived Suppressor Cells. 2016 , 76, 5696-5706	101
2040	Mechanisms of immune evasion and current status of checkpoint inhibitors in non-small cell lung cancer. 2016 , 5, 2567-78	45
2039	HDAC5 controls the functions of Foxp3(+) T-regulatory and CD8(+) T cells. 2016 , 138, 2477-86	50
2038	Mac attack: macrophages as key drivers of cutaneous T-cell lymphoma pathogenesis. 2016 , 25, 105-6	15
2037	Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. 2016 ,	1
2036	Complementing T-cell Function: An Inhibitory Role of the Complement System in T-cell-Mediated Antitumor Immunity. 2016 , 6, 953-5	7
2035	Chemokines and T Cell Trafficking into Tumors: Strategies to Enhance Recruitment of T Cells into Tumors. 2016 , 163-177	2
2034	Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4 tumor-infiltrating lymphocytes. 2016 , 5, e1216289	8
2033	The metabolic fate of acetate in cancer. 2016 , 16, 708-717	146
2032	Hypoxia and Transforming Growth Factor β Cooperate to Induce Fibulin-5 Expression in Pancreatic Cancer. 2016 , 291, 22244-22252	27
2031	An Evolutionary Genetic Perspective on Cancer Biology. 2016 , 47, 25-49	6

2030	Polarization of Tissue-Resident TFH-Like Cells in Human Hepatoma Bridges Innate Monocyte Inflammation and M2b Macrophage Polarization. 2016 , 6, 1182-1195	33
2029	Inflammation Caused by Nanosized Delivery Systems: Is There a Benefit?. 2016 , 13, 3270-8	5
2028	Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. 2016 , 14, 313	15
2027	Cancer Stem Cells. 2016 , 341-366	4
2026	Cancer Stem Cells and Tumor-Associated Macrophages. 2016 , 367-394	1
2025	Macrophage migration inhibitory factor (MIF) is induced by cytotoxic drugs and is involved in immune escape and migration in childhood rhabdomyosarcoma. 2016 , 65, 1465-1476	9
2024	Histone deacetylase inhibitors enhance CD1d-dependent NKT cell responses to lymphoma. 2016 , 65, 1411-1421	26
2023	Non-invasive single-cell biomechanical analysis using live-imaging datasets. 2016 , 129, 3351-64	9
2022	IFN- γ cancer immunotherapy: new kid on the block. 2016 , 8, 877-88	21
2021	Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma. 2016 , 30, 324-336	426
2020	Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. 2016 , 8, 767-74	6
2019	Prevention and treatment of cancers by immune modulating nutrients. 2016 , 60, 1275-94	20
2018	Immune checkpoint blockade as a potential therapeutic target in non-small cell lung cancer. 2016 , 16, 1209-23	14
2017	Immune-Related Adverse Events Associated with Immune Checkpoint Inhibitors. 2016 , 30, 571-584	66
2016	Dendritic cell-elicited B-cell activation fosters immune privilege via IL-10 signals in hepatocellular carcinoma. 2016 , 7, 13453	38
2015	One microenvironment does not fit all: heterogeneity beyond cancer cells. 2016 , 35, 601-629	41
2014	Cytotoxic T Cells in PD-L1-Positive Malignant Pleural Mesotheliomas Are Counterbalanced by Distinct Immunosuppressive Factors. 2016 , 4, 1038-1048	54
2013	Tumor immune microenvironment characterization in clear cell renal cell carcinoma identifies prognostic and immunotherapeutically relevant messenger RNA signatures. 2016 , 17, 231	391

2012	Overcoming resistance to checkpoint blockade therapy by targeting PI3K in myeloid cells. 2016 , 539, 443-447	475
2011	Density of immunogenic antigens does not explain the presence or absence of the T-cell-inflamed tumor microenvironment in melanoma. 2016 , 113, E7759-E7768	234
2010	Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors. 2016 , 113, E7769-E7777	116
2009	Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. 2016 , 34, 556-565	16
2008	NKG2D ligand expression in pediatric brain tumors. 2016 , 17, 1253-1265	14
2007	BTLA identifies dysfunctional PD-1-expressing CD4 T cells in human hepatocellular carcinoma. 2016 , 5, e1254855	26
2006	Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade. 2016 , 4, 1061-1071	78
2005	PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. 2016 , 8, 328rv4	1281
2004	Cell-Intrinsic Barriers of T Cell-Based Immunotherapy. 2016 , 22, 1000-1011	39
2003	Characterization of cytokinome landscape for clinical responses in human cancers. 2016 , 5, e1214789	19
2002	Antitumor Activity of cGAMP via Stimulation of cGAS-cGAMP-STING-IRF3 Mediated Innate Immune Response. 2016 , 6, 19049	119
2001	Imaging-genomics reveals driving pathways of MRI derived volumetric tumor phenotype features in Glioblastoma. 2016 , 16, 611	46
2000	Core-shell nanoscale coordination polymers combine chemotherapy and photodynamic therapy to potentiate checkpoint blockade cancer immunotherapy. 2016 , 7, 12499	484
1999	The tumor microenvironment disarms CD8 T lymphocyte function via a miR-26a-EZH2 axis. 2016 , 5, e1245267	11
1998	Interplay Between Inflammation and Epigenetic Changes in Cancer. 2016 , 144, 69-117	26
1997	CD1b-autoreactive T cells recognize phospholipid antigens and contribute to antitumor immunity against a CD1b T cell lymphoma. 2016 , 5, e1213932	19
1996	Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma. 2016 , 6, 30093	155
1995	BPTF Is Essential for T Cell Homeostasis and Function. 2016 , 197, 4325-4333	18

1994	Bifurcations and Chaotic Dynamics in a Tumour-Immune-Virus System. 2016 , 11, 65-85	12
1993	Cancer immunotherapy: new applications in urologic oncology. 2016 , 26, 535-42	9
1992	Pools of programmed death-ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapies. 2016 , 38, 1176-86	14
1991	Harnessing T cells to fight cancer with BiTE antibody constructs--past developments and future directions. 2016 , 270, 193-208	87
1990	Correlation of metabolic information on FDG-PET with tissue expression of immune markers in patients with non-small cell lung cancer (NSCLC) who are candidates for upfront surgery. 2016 , 43, 1954-61	87
1989	Local iron homeostasis in the breast ductal carcinoma microenvironment. 2016 , 16, 187	55
1988	Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. 2016 , 176, 57-64	23
1987	CD169 identifies an activated CD8(+) T cell subset in regional lymph nodes that predicts favorable prognosis in colorectal cancer patients. 2016 , 5, e1177690	13
1986	Radiobiology of Glioblastoma. 2016 ,	2
1985	Mathematical model of tumor-immune surveillance. 2016 , 404, 312-330	38
1984	Biomanufacturing of Therapeutic Cells: State of the Art, Current Challenges, and Future Perspectives. 2016 , 7, 455-78	45
1983	NK Cells Restrain Spontaneous Antitumor CD8+ T Cell Priming through PD-1/PD-L1 Interactions with Dendritic Cells. 2016 , 197, 953-61	62
1982	Interleukin (IL)-24 transforms the tumor microenvironment and induces anticancer immunity in a murine model of colon cancer. 2016 , 75, 11-20	16
1981	Designing multivalent proteins based on natural killer cell receptors and their ligands as immunotherapy for cancer. 2016 , 16, 1105-12	4
1980	Peripheral Blood Regulatory T-Cell and Type 1 Helper T-Cell Population Decrease after Hepatic Artery Embolization. 2016 , 27, 1561-8	17
1979	ERK1 as a Therapeutic Target for Dendritic Cell Vaccination against High-Grade Gliomas. 2016 , 15, 1975-87	5
1978	Interferon-induced transmembrane protein 1 (IFITM1) overexpression enhances the aggressive phenotype of SUM149 inflammatory breast cancer cells in a signal transducer and activator of transcription 2 (STAT2)-dependent manner. 2016 , 18, 25	46
1977	Increased expression of A Proliferation-inducing Ligand (APRIL) in lung leukocytes and alveolar epithelial cells in COPD patients with non small cell lung cancer: a possible link between COPD and lung cancer?. 2016 , 11, 17	7

1976	Checkpoint Antibodies but not T Cell-Recruiting Diabodies Effectively Synergize with TIL-Inducing Irradiation. 2016 , 76, 4673-83	49
1975	Recreating complex pathophysiologicals in vitro with extracellular matrix surrogates for anticancer therapeutics screening. 2016 , 21, 1521-1531	20
1974	Characterization of the T cell repertoire by deep T cell receptor sequencing in tissues and blood from patients with advanced colorectal cancer. 2016 , 11, 3643-3649	30
1973	The Immune System and Its Contribution to the Radiotherapeutic Response of Glioblastoma. 2016 , 155-175	
1972	2'-5' Oligoadenylate synthetase-like 1 (OASL1) deficiency in mice promotes an effective anti-tumor immune response by enhancing the production of type I interferons. 2016 , 65, 663-75	11
1971	Das Tumorstroma und seine Bedeutung für die Therapie solider Tumoren. 2016 , 31, 216-220	
1970	Cell-free microRNAs in blood and other body fluids, as cancer biomarkers. 2016 , 49, 281-303	61
1969	Plasma 25-hydroxyvitamin D and colorectal cancer risk according to tumour immunity status. 2016 , 65, 296-304	70
1968	Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF- β and miR23a transfer. 2016 , 5, e1062968	186
1967	Impact of Obesity and Metabolic Syndrome on Immunity. 2016 , 7, 66-75	284
1966	Cytokine Activation by Antibody Fragments Targeted to Cytokine-Receptor Signaling Complexes. 2016 , 291, 447-61	9
1965	PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas. 2016 , 47, 52-63	214
1964	A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. 2016 , 76, 1578-90	308
1963	A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study. 2016 , 17, 232-236.e1	103
1962	Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. 2016 , 28, 383-91	146
1961	PGE2 induced in and released by dying cells functions as an inhibitory DAMP. 2016 , 113, 3844-9	79
1960	Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. 2016 , 5, e1085147	94
1959	Inflammatory Cells in Tumor Microenvironment. 2016 , 27-50	

1958	Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer. 2016 , 5, e1145333	9
1957	Anti-CD73 in cancer immunotherapy: awakening new opportunities. 2016 , 2, 95-109	127
1956	Pan-Cancer Immunogenomic Perspective on the Tumor Microenvironment Based on PD-L1 and CD8 T-Cell Infiltration. 2016 , 22, 2261-70	164
1955	Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy. 2016 , 44, 343-54	518
1954	Biomarkers of residual disease after neoadjuvant therapy for breast cancer. 2016 , 13, 487-503	36
1953	Immunosuppressive parameters in serum of ovarian cancer patients change during the disease course. 2016 , 5, e1111505	20
1952	The Role of Microenvironment in the Control of Tumor Angiogenesis. 2016 ,	3
1951	Tumor metabolism, cancer cell transporters, and microenvironmental resistance. 2016 , 31, 859-66	44
1950	Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study. 2016 , 17, 299-308	435
1949	Facilitating T Cell Infiltration in Tumor Microenvironment Overcomes Resistance to PD-L1 Blockade. 2016 , 29, 285-296	227
1948	Rarity of adenomatous polyps in ulcerative colitis and its implications for colonic carcinogenesis. 2016 , 48, 215-22	10
1947	Hepatocellular carcinoma in a cow: detection of tumor-infiltrating T lymphocytes implicated in anti-tumor immune response and partial spontaneous tumor regression. 2016 , 25, 421-427	2
1946	The interplay between the microbiome and the adaptive immune response in cancer development. 2016 , 9, 594-605	39
1945	Adenomatous polyps in ulcerative colitis and colonic Crohn's disease: less frequent, but does this change surveillance strategy?. 2016 , 48, 210-2	0
1944	Immune checkpoint pathways: perspectives on myeloid malignancies. 2016 , 57, 995-1001	3
1943	Medullary carcinoma of the colon: a distinct morphology reveals a distinctive immunoregulatory microenvironment. 2016 , 29, 528-41	42
1942	Advances in Therapeutic Cancer Vaccines. 2016 , 130, 191-249	71
1941	Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. 2016 , 5, e1149674	41

1940	Molecular mechanisms of curcumins suppressing effects on tumorigenesis, angiogenesis and metastasis, focusing on NF- κ B pathway. 2016 , 28, 21-9	41
1939	The Expression Quantitative Trait Loci in Immune Pathways and their Effect on Cutaneous Melanoma Prognosis. 2016 , 22, 3268-80	10
1938	AT2R Gene Delivered by Condensed Polylysine Complexes Attenuates Lewis Lung Carcinoma after Intravenous Injection or Intratracheal Spray. 2016 , 15, 209-18	17
1937	Rationale for anti-CD137 cancer immunotherapy. 2016 , 54, 112-119	60
1936	Combining antibody-drug conjugates and immune-mediated cancer therapy: What to expect?. 2016 , 102, 1-6	75
1935	Immunosuppressive cells in tumor immune escape and metastasis. 2016 , 94, 509-22	168
1934	Systems Immunology. 2016 , 3-44	
1933	Curcumin Micelles Remodel Tumor Microenvironment and Enhance Vaccine Activity in an Advanced Melanoma Model. 2016 , 24, 364-374	79
1932	Targeting the tumor microenvironment to improve natural killer cell-based immunotherapies: On being in the right place at the right time, with resilience. 2016 , 12, 607-11	25
1931	Radiotherapy supports tumor-specific immunity by acute inflammation. 2016 , 5, e1060391	10
1930	CXCL11-Armed oncolytic poxvirus elicits potent antitumor immunity and shows enhanced therapeutic efficacy. 2016 , 5, e1091554	59
1929	T cells in tumor microenvironment. 2016 , 37, 39-45	6
1928	From DNA Damage to Nucleic Acid Sensing: A Strategy to Enhance Radiation Therapy. 2016 , 22, 20-5	53
1927	All that glitters is not gold: the need to consider desirable and undesirable immune aspects of oncolytic virus therapy. 2016 , 5, e1057674	5
1926	Combining anaerobic bacterial oncolysis with vaccination that blocks interleukin-10 signaling may achieve better outcomes for late stage cancer management. 2016 , 12, 599-606	3
1925	Long noncoding RNA: Novel links between gene expression and innate immunity. 2016 , 212, 137-45	51
1924	Tumor-intrinsic oncogene pathways mediating immune avoidance. 2016 , 5, e1086862	81
1923	Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis. 2016 , 18, 497-506	80

1922	Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma. 2016 , 35, 3209-16	160
1921	Anti-metastatic functions of type 1 interferons: Foundation for the adjuvant therapy of cancer. 2017 , 89, 4-11	17
1920	A combinatorial T cell receptor expressed by macrophages in the tumor microenvironment. 2017 , 222, 39-44	14
1919	A second chance for telomerase reverse transcriptase in anticancer immunotherapy. 2017 , 14, 115-128	62
1918	Interactions of hyperhomocysteinemia and T cell immunity in causation of hypertension. 2017 , 95, 239-246	8
1917	Elements of cancer immunity and the cancer-immune set point. 2017 , 541, 321-330	2136
1916	Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy. 2017 , 355,	609
1915	Strategies to overcome therapeutic resistance in renal cell carcinoma. 2017 , 35, 102-110	26
1914	In situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy. 2017 , 1,	278
1913	Sequential administration of a MVA-based MUC1 cancer vaccine and the TLR9 ligand Litenimod (Li28) improves local immune defense against tumors. 2017 , 35, 577-585	12
1912	Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response. 2017 , 2,	48
1911	Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors. 2017 , 114, 740-745	16
1910	Liposomal Delivery Enhances Immune Activation by STING Agonists for Cancer Immunotherapy. 2017 , 1, 1600013	122
1909	Therapeutic Cancer Vaccines. 2017 , 47-78	1
1908	The clinicopathologic significance of lymphocyte subsets in acute myeloid leukemia. 2017 , 39, 129-136	8
1907	Targeting the Lung Cancer Microenvironment: Harnessing Host Responses. 2017 , 309-327	1
1906	PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective. 2017 , 10, 34	63
1905	Tumor-associated macrophages: implications in cancer immunotherapy. 2017 , 9, 289-302	160

1904	Defining an inflamed tumor immunophenotype in recurrent, metastatic squamous cell carcinoma of the head and neck. 2017 , 67, 61-69	35
1903	PD-L1 Is a Therapeutic Target of the Bromodomain Inhibitor JQ1 and, Combined with HLA Class I, a Promising Prognostic Biomarker in Neuroblastoma. 2017 , 23, 4462-4472	59
1902	Promoter Methylation Modulates Indoleamine 2,3-Dioxygenase 1 Induction by Activated T Cells in Human Breast Cancers. 2017 , 5, 330-344	20
1901	Neutrophils as active regulators of the immune system in the tumor microenvironment. 2017 , 102, 343-349	103
1900	T Cell-Associated Immunotherapy for Hepatocellular Carcinoma. 2017 , 41, 609-622	25
1899	Identification of Genomic Somatic Variants in Cancer: From Discovery to Actionability. 2017 , 78, 123-162	2
1898	Checkpoint Inhibition in Head and Neck Cancer: Immune Therapeutic Options, Limitations, and Beyond. 2017 , 79, 24-33	4
1897	Unfolding anti-tumor immunity: ER stress responses sculpt tolerogenic myeloid cells in cancer. 2017 , 5, 5	49
1896	Spatiotemporally restricted arenavirus replication induces immune surveillance and type I interferon-dependent tumour regression. 2017 , 8, 14447	12
1895	The EGR2 targets LAG-3 and 4-1BB describe and regulate dysfunctional antigen-specific CD8+ T cells in the tumor microenvironment. 2017 , 214, 381-400	101
1894	Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy. 2017 , 168, 707-723	2141
1893	Location of tumor affects local and distant immune cell type and number. 2017 , 5, 85-94	11
1892	Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer. 2017 , 143, 1123-1131	20
1891	Biological therapies in nonsmall cell lung cancer. 2017 , 49,	29
1890	Cell-mediated delivery of synthetic nano- and microparticles. 2017 , 259, 92-104	52
1889	Oncolytic viruses: emerging options for the treatment of breast cancer. 2017 , 34, 43	13
1888	Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. 2017 , 123, 1703-1713	31
1887	Combined antiangiogenic and anti-PD-L1 therapy stimulates tumor immunity through HEV formation. 2017 , 9,	348

1886	Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model. 2017 , 19, 930-939	52
1885	Advanced biomaterials and microengineering technologies to recapitulate the stepwise process of cancer metastasis. 2017 , 133, 176-207	65
1884	Tuning cancer fate: the unremitting role of host immunity. 2017 , 7,	25
1883	Innate lymphoid cells and their stromal microenvironments. 2017 , 189, 3-9	3
1882	Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy. 2017 , 11, 676-684	6
1881	Warming the mouse to model human diseases. 2017 , 13, 458-465	88
1880	polysaccharide induces toll-like receptor 4 dependent spleen dendritic cell maturation and anti-cancer immunity. 2017 , 6, e1325981	22
1879	Mechanisms of Immune Tolerance in Leukemia and Lymphoma. 2017 , 38, 513-525	58
1878	The influence of stromal cells and tumor-microenvironment-derived cytokines and chemokines on CD3CD8 tumor infiltrating lymphocyte subpopulations. 2017 , 6, e1323617	9
1877	Epigenetics and immunotherapy: The current state of play. 2017 , 87, 227-239	128
1876	Applying nanomedicine in maladaptive inflammation and angiogenesis. 2017 , 119, 143-158	29
1875	STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy. 2017 , 77, 3619-3631	44
1874	TIM-3 plays a more important role than PD-1 in the functional impairments of cytotoxic T cells of malignant Schwannomas. 2017 , 39, 1010428317698352	11
1873	Digital analysis and epigenetic regulation of the signature of rejection in colorectal cancer. 2017 , 6, e1288330	10
1872	Use of precision methods to accelerate drug development in oncology. 2017 , 2, 109-120	
1871	In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy. 2017 , 9,	331
1870	Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma. 2017 , 77, 3540-3550	213
1869	CCR4 mediated chemotaxis of regulatory T cells suppress the activation of T cells and NK cells via TGF- β pathway in human non-small cell lung cancer. 2017 , 488, 196-203	24

1868	A Modular Antigen Presenting Peptide/Oligonucleotide Nanostructure Platform for Inducing Potent Immune Response. 2017 , 1, e1700015	5
1867	Plastic Heterogeneity of Innate Lymphoid Cells in Cancer. 2017 , 3, 326-335	18
1866	Single-cell RNA-seq enables comprehensive tumour and immune cell profiling in primary breast cancer. 2017 , 8, 15081	459
1865	Inhibition of tumor growth and metastasis by EMMPRIN multiple antigenic peptide (MAP) vaccination is mediated by immune modulation. 2017 , 6, e1261778	9
1864	RNA-Seq based genome-wide analysis reveals loss of inter-chromosomal regulation in breast cancer. 2017 , 7, 1760	34
1863	Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. 2017 , 36, 53	326
1862	[Immunotherapy and radiotherapy]. 2017 , 21, 244-255	11
1861	Workshop Report: Modulation of Antitumor Immune Responses by Dietary and Microbial Metabolites. 2017 , 109,	3
1860	Long noncoding RNA Inc-sox5 modulates CRC tumorigenesis by unbalancing tumor microenvironment. 2017 , 16, 1295-1301	37
1859	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. 2017 , 6, e1339856	6
1858	Transcription Factor Networks derived from Breast Cancer Stem Cells control the immune response in the Basal subtype. 2017 , 7, 2851	16
1857	Recent progress in immunotherapy for urological cancer. 2017 , 24, 735-742	12
1856	The JAK/STAT3 axis: A comprehensive drug target for solid malignancies. 2017 , 45, 13-22	105
1855	Cancer Immunology and Immunotherapy: Taking a Place in Mainstream Oncology Keystone Symposia Meeting Summary. 2017 , 5, 434-438	2
1854	Wnt/beta-catenin pathway: modulating anticancer immune response. 2017 , 10, 101	257
1853	Programmed cell death-1/Programmed cell death ligand-1(PD-1/PD-L1) inhibitors, heralding a new era of immunotherapy in the management of advanced Non-Small Cell Lung Cancer (NSCLC). 2017 , 12, 6-13	8
1852	The influence of tumor-induced immune dysfunction on the immune cell distribution of gold nanoparticles in vivo. 2017 , 5, 1531-1536	11
1851	Tailoring Biomaterials for Cancer Immunotherapy: Emerging Trends and Future Outlook. 2017 , 29, 1606036	178

1850	Replicating viral vector platform exploits alarmin signals for potent CD8 T cell-mediated tumour immunotherapy. 2017 , 8, 15327	37
1849	An in vitro model demonstrates the potential of neoplastic human germ cells to influence the tumour microenvironment. 2017 , 5, 763-770	9
1848	Type I Interferon in Chronic Virus Infection and Cancer. 2017 , 38, 542-557	196
1847	Types of Immune-Inflammatory Responses as a Reflection of Cell-Cell Interactions under Conditions of Tissue Regeneration and Tumor Growth. 2017 , 82, 542-555	16
1846	Anti-PD-L1 Efficacy Can Be Enhanced by Inhibition of Myeloid-Derived Suppressor Cells with a Selective Inhibitor of PI3K. 2017 , 77, 2607-2619	123
1845	MITA modulated autophagy flux promotes cell death in breast cancer cells. 2017 , 35, 73-83	12
1844	IDO1: An important immunotherapy target in cancer treatment. 2017 , 47, 70-77	66
1843	Targeted agents and immunotherapies: optimizing outcomes in melanoma. 2017 , 14, 463-482	654
1842	Surface modulation of polymeric nanocarriers enhances the stability and delivery of proteins and small molecules. 2017 , 12, 729-743	4
1841	Description of the immune microenvironment of chondrosarcoma and contribution to progression. 2017 , 6, e1265716	15
1840	Ultrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA-seq data. 2017 , 49, 482-483	41
1839	Celebrating parasites. 2017 , 49, 483-484	19
1838	Bystander cells enhance NK cytotoxic efficiency by reducing search time. 2017 , 7, 44357	9
1837	CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer. 2017 , 145, 436-445	26
1836	Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?. 2017 , 129, 275-279	67
1835	MicroRNA-6826 and -6875 in plasma are valuable non-invasive biomarkers that predict the efficacy of vaccine treatment against metastatic colorectal cancer. 2017 , 37, 23-30	32
1834	Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery. 2017 , 5, 29-41	190
1833	Signal Transducer and Activator of Transcription 1 Plays a Pivotal Role in RET/PTC3 Oncogene-induced Expression of Indoleamine 2,3-Dioxygenase 1. 2017 , 292, 1785-1797	12

1832	Metronomic chemotherapy: A potent macerator of cancer by inducing angiogenesis suppression and antitumor immune activation. 2017 , 400, 243-251	18
1831	Protein Nanocage Mediated Fibroblast-Activation Protein Targeted Photoimmunotherapy To Enhance Cytotoxic T Cell Infiltration and Tumor Control. 2017 , 17, 862-869	113
1830	Analysis of the prognostic role of an immune checkpoint score in resected non-small cell lung cancer patients. 2017 , 6, e1260214	5
1829	The effect of polymorphisms in PD-1 gene on the risk of epithelial ovarian cancer and patients' outcomes. 2017 , 144, 140-145	12
1828	First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies. 2017 , 23, 3269-3276	191
1827	Immunoplasticity in cutaneous melanoma: beyond pure morphology. 2017 , 470, 357-369	2
1826	Oral squamous cell carcinoma suppressed antitumor immunity through induction of PD-L1 expression on tumor-associated macrophages. 2017 , 222, 651-657	34
1825	Localized Multi-Component Delivery Platform Generates Local and Systemic Anti-Tumor Immunity. 2017 , 27, 1604366	32
1824	Looking beyond drivers and passengers in cancer genome sequencing data. 2017 , 28, 938-945	22
1823	Innate immune signaling and regulation in cancer immunotherapy. 2017 , 27, 96-108	205
1822	A herpesvirus entry mediator mutein with selective agonist action for the inhibitory receptor B and T lymphocyte attenuator. 2017 , 292, 21060-21070	10
1821	Comprehensive single-cell transcriptome analysis reveals heterogeneity in endometrioid adenocarcinoma tissues. 2017 , 7, 14225	16
1820	Immune Metabolism in Health and Tumor. 2017 ,	3
1819	Rationale for neoadjuvant immunotherapy in head and neck squamous cell carcinoma. 2017 , 73, 65-69	28
1818	Enhancing cancer immunotherapy through nanotechnology-mediated tumor infiltration and activation of immune cells. 2017 , 34, 114-122	23
1817	Immune-related adverse events during anticancer immunotherapy: Pathogenesis and management. 2017 , 14, 5671-5680	43
1816	Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma. 2017 , 77, 6119-6130	56
1815	Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy. 2017 , 28, 1158-1168	10

1814	Tumor vasculature normalization by orally fed erlotinib to modulate the tumor microenvironment for enhanced cancer nanomedicine and immunotherapy. 2017 , 148, 69-80	64
1813	Engineering and physical sciences in oncology: challenges and opportunities. 2017 , 17, 659-675	153
1812	Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases. 2017 , 280, 231-248	88
1811	Nanotechnology for Multimodal Synergistic Cancer Therapy. 2017 , 117, 13566-13638	949
1810	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. 2017 , 7, 13380	124
1809	Tumor-infiltrating lymphocytes in Breast Cancer and implications for clinical practice. 2017 , 1868, 527-537	29
1808	Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea. 2017 , 50,	58
1807	CD21CD27 proinflammatory B cells are enriched in breast cancer patients and promote antitumor T cell responses. 2017 , 361, 149-154	2
1806	Mechanisms regulating T-cell infiltration and activity in solid tumors. 2017 , 28, xii18-xii32	175
1805	Antibody-Based Therapeutics in Oncology. 2017 , 521-585	
1804	Host immune response index in gastric cancer identified by comprehensive analyses of tumor immunity. 2017 , 6, e1356150	27
1803	Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model. 2017 , 6, e1338236	22
1802	Optimizing tumor immune response through combination of radiation and immunotherapy. 2017 , 34, 165	8
1801	Ficolin-2 triggers antitumor effect by activating macrophages and CD8 T cells. 2017 , 183, 145-157	8
1800	Overcoming barriers of car T-cell therapy in patients with mesothelin-expressing cancers. 2017 , 9, 767-780	8
1799	Gene expression profiling of calcifications in breast cancer. 2017 , 7, 11427	13
1798	Systemic therapy in advanced melanoma: integrating targeted therapy and immunotherapy into clinical practice. 2017 , 29, 484-492	50
1797	Functional T cells targeting tumor-associated antigens are predictive for recurrence-free survival of patients with radically operated non-small cell lung cancer. 2017 , 6, e1360458	7

1796	Immune cell profiling in cancer: molecular approaches to cell-specific identification. 2017 , 1, 26	42
1795	Advances in immunotherapy in multiple myeloma. 2017 , 29, 460-466	12
1794	Hypoxia inducible factor HIF-1 promotes myeloid-derived suppressor cells accumulation through ENTPD2/CD39L1 in hepatocellular carcinoma. 2017 , 8, 517	179
1793	Cancer vaccines using supramolecular hydrogels of NSAID-modified peptides as adjuvants abolish tumorigenesis. 2017 , 9, 14058-14064	45
1792	Effects of hexavalent chromium on mouse splenic T lymphocytes. 2017 , 45, 166-171	5
1791	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. 2017 , 9, 797-804	23
1790	Cell migration in microengineered tumor environments. 2017 , 17, 4171-4185	31
1789	Multiomics Analysis of Tumor Microenvironment Reveals Gata2 and miRNA-124-3p as Potential Novel Biomarkers in Ovarian Cancer. 2017 , 21, 603-615	31
1788	Human TLR gene family members are differentially expressed in patients with urothelial carcinoma of the bladder. 2017 , 35, 674.e11-674.e17	3
1787	The Challenge for Development of Valuable Immuno-oncology Biomarkers. 2017 , 23, 4970-4979	54
1786	From Famine to Feast: Developing Early-Phase Combination Immunotherapy Trials Wisely. 2017 , 23, 4980-4991	12
1785	Ionizing radiation sensitizes tumors to PD-L1 immune checkpoint blockade in orthotopic murine head and neck squamous cell carcinoma. 2017 , 6, e1356153	61
1784	Inflammatory infiltrates in parathyroid tumors. 2017 , 177, 445-453	2
1783	Immune profiling of melanoma tumors reflecting aggressiveness in a preclinical model. 2017 , 66, 1631-1642	11
1782	Immune Cell Metabolism in Tumor Microenvironment. 2017 , 1011, 163-196	13
1781	Innate and Adaptive Immune Cell Metabolism in Tumor Microenvironment. 2017 , 1011, 211-223	12
1780	Exploring Metabolic Configurations of Single Cells within Complex Tissue Microenvironments. 2017 , 26, 788-800.e6	48
1779	Circulating myeloid-derived suppressor cells increase in patients undergoing neo-adjuvant chemotherapy for breast cancer. 2017 , 66, 1437-1447	44

1778	A guiding map for inflammation. <i>Nature Immunology</i> , 2017 , 18, 826-831	19.1	284
1777	Oncolytic virus-induced cell death and immunity: a match made in heaven?. 2017 , 102, 631-643		27
1776	Metabolic Interactions in the Tumor Microenvironment. 2017 , 27, 863-875		369
1775	Radiation-induced changes in the glycome of endothelial cells with functional consequences. 2017 , 7, 5290		22
1774	Molecular genetics and targeted therapy of WNT-related human diseases (Review). 2017 , 40, 587-606		112
1773	Secreted Tumor Antigens - Immune Biomarkers for Diagnosis and Therapy. 2017 , 17, 1600442		19
1772	Identification of a novel population of highly cytotoxic c-Met-expressing CD8 T lymphocytes. 2017 , 18, 1545-1558		18
1771	The Extracellular Matrix of Tumors: A Focus on Fibronectin and Fibulin-5. 2017 , 1-15		
1770	miR-196b, miR-378a and miR-486 are predictive biomarkers for the efficacy of vaccine treatment in colorectal cancer. 2017 , 14, 1355-1362		17
1769	Antitumor effect of through IL-12 p40 up-regulation in tumor-associated macrophages. 2017 , 114, E7331-E7340		3
1768	Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research. 2017 , 24, 235-251		293
1767	Targeted Bifunctional Proteins and Hybrid Nanoconstructs for Cancer Diagnostics and Therapies. 2017 , 51, 788-803		10
1766	Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. 2017 , 2, e000203		11
1765	De-novo and acquired resistance to immune checkpoint targeting. 2017 , 18, e731-e741		383
1764	T cell receptor sequencing of early-stage breast cancer tumors identifies altered clonal structure of the T cell repertoire. 2017 , 114, E10409-E10417		40
1763	The Next Frontier: Head and Neck Cancer Immunoprevention. 2017 , 10, 681-683		4
1762	The IKK/NF- κ B signaling pathway requires Morgana to drive breast cancer metastasis. 2017 , 8, 1636		59
1761	Anti-SIRP α antibody immunotherapy enhances neutrophil and macrophage antitumor activity. 2017 , 114, E10578-E10585		136

1760	Combining immunotherapies for the treatment of prostate cancer. 2017 , 35, 694-700	18
1759	Fine and Predictable Tuning of TALEN Gene Editing Targeting for Improved T Cell Adoptive Immunotherapy. 2017 , 9, 312-321	29
1758	Breast Cancer Microenvironment and the Metastatic Process. 2017 , 39-48	
1757	Zerumbone modulates CD1d expression and lipid antigen presentation pathway in breast cancer cells. 2017 , 44, 74-84	17
1756	Density of tumor-infiltrating granzyme B-positive cells predicts favorable prognosis in dogs with transitional cell carcinoma. 2017 , 190, 53-56	10
1755	First-Generation Tumor Xenografts: A Link Between Patient-Derived Xenograft Models and Clinical Disease. 2017 , 155-176	1
1754	Drug therapy of advanced cutaneous squamous cell carcinoma: is there any evidence?. 2017 , 29, 129-135	26
1753	Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. 2017 , 23, 5187-5201	211
1752	Distinctive features of tumor-infiltrating $\gamma\delta$ lymphocytes in human colorectal cancer. 2017 , 6, e1347742	70
1751	HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer. 2017 , 117, 451-460	188
1750	Uncovering the underlying mechanism of cancer tumorigenesis and development under an immune microenvironment from global quantification of the landscape. 2017 , 14,	17
1749	Modification of anti-tumor immunity by tolerogenic dendritic cells. 2017 , 50, 370-376	15
1748	Perioperative Inflammation as Triggering Origin of Metastasis Development. 2017 ,	1
1747	Molecular Effects of Stromal-Selective Targeting by uPAR-Retargeted Oncolytic Virus in Breast Cancer. 2017 , 15, 1410-1420	24
1746	Constitutive and acquired mechanisms of resistance to immune checkpoint blockade in human cancer. 2017 , 36, 17-24	18
1745	Patient-Derived Xenograft Models of Human Cancer. 2017 ,	5
1744	Spatial interaction analysis with graph based mathematical morphology for histopathology. 2017 ,	
1743	Adenovirus-mediated CD40L gene transfer increases T _H 1/T _H 17 cell ratio and upregulates death receptors in metastatic melanoma patients. 2017 , 15, 79	28

1742	Cytokine response to the RSV antigen delivered by dendritic cell-directed vaccination in congenic chicken lines. 2017 , 48, 18	5
1741	Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. 2017 , 5, 44	139
1740	RNA Editing in Pathogenesis of Cancer. 2017 , 77, 3733-3739	32
1739	Double-stranded RNA promotes CTL-independent tumor cytolysis mediated by CD11bLy6G intratumor myeloid cells through the TICAM-1 signaling pathway. 2017 , 24, 385-396	23
1738	Anti-PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy. 2017 , 17, 47-59	27
1737	Friend or foe? The tumour microenvironment dilemma in colorectal cancer. 2017 , 1867, 1-18	41
1736	Tumor-targeted delivery of sunitinib base enhances vaccine therapy for advanced melanoma by remodeling the tumor microenvironment. 2017 , 245, 81-94	101
1735	In Situ Characterization of Tissue-Resident Immune Cells by MALDI Mass Spectrometry Imaging. 2017 , 16, 65-76	28
1734	Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy. 2017 , 241, 10-24	42
1733	High-Intensity Focused Ultrasound- and Radiation Therapy-Induced Immuno-Modulation: Comparison and Potential Opportunities. 2017 , 43, 398-411	18
1732	Macrophage Polarization. 2017 , 79, 541-566	1077
1731	Combined Local Pulmonary and Systemic Delivery of AT2R Gene by Modified TAT Peptide Nanoparticles Attenuates Both Murine and Human Lung Carcinoma Xenografts in Mice. 2017 , 106, 385-394	14
1730	Adaptive immunity programmes in breast cancer. 2017 , 150, 25-34	29
1729	Multispectral imaging for highly accurate analysis of tumour-infiltrating lymphocytes in primary melanoma. 2017 , 70, 643-649	12
1728	Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. 2017 , 20, 602-611	53
1727	M2 macrophages do not fly into a "RAGE". 2017 , 66, 13-15	3
1726	Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer. 2017 , 47, 385-393	47
1725	The role of dendritic cells in cancer. 2017 , 39, 307-316	51

1724	Informatics for cancer immunotherapy. 2017 , 28, xii56-xii73	11
1723	Cell Cycle Model System for Advancing Cancer Biomarker Research. 2017 , 7, 17989	6
1722	B16 melanoma expressing EGFP as a self antigen is differentially immunoeedited by tolerogenic thymic epithelial and dendritic cells. 2017 , 21, 388-396	1
1721	Adult Stem Cells and Anticancer Therapy. 2017 , 11, 123-202	2
1720	Immune Cells Enhance Selectivity of Nanosecond-Pulsed DBD Plasma Against Tumor Cells. 2017 , 7, 85-96	16
1719	High IL-1R8 expression in breast tumors promotes tumor growth and contributes to impaired antitumor immunity. 2017 , 8, 49470-49483	17
1718	Developing T-cell therapies for lymphoma without receptor engineering. 2017 , 2017, 622-631	2
1717	. 2017 ,	4
1716	Immune Regulation in Breast Cancer Metastasis and Immunotherapy. 2017 ,	
1715	Developing T-cell therapies for lymphoma without receptor engineering. 2017 , 1, 2579-2590	4
1714	A Self-Assembled Non-Viral vector as Potential Platform for mRNA-Based Vaccines. 2017 , 08,	2
1713	Immunotherapy in Gastrointestinal Cancers. 2017 , 2017, 4346576	45
1712	The Memory Activation of NK Cells: New Methods in Cancer Immunotherapy. 2017 ,	1
1711	Leukocyte-mediated Delivery of Nanotherapeutics in Inflammatory and Tumor Sites. 2017 , 7, 751-763	73
1710	Report from the II Melanoma Translational Meeting of the Spanish Melanoma Group (GEM). 2017 , 5, 390-390	78
1709	Collateral Damage Intended-Cancer-Associated Fibroblasts and Vasculature Are Potential Targets in Cancer Therapy. 2017 , 18,	23
1708	cGAS/STING Pathway in Cancer: Jekyll and Hyde Story of Cancer Immune Response. 2017 , 18,	33
1707	Cancer Immunotherapy: An Emerging Field That Bridges Oncology and Immunology Research. 2017 , 357-394	1

1706	Class (I) Phosphoinositide 3-Kinases in the Tumor Microenvironment. 2017, 9,	23
1705	Cross-Talk between Cancer Cells and the Tumour Microenvironment: The Role of the 5-Lipoxygenase Pathway. 2017, 18,	59
1704	Advanced Strategies in Immune Modulation of Cancer Using Lipid-Based Nanoparticles. 2017, 8, 69	25
1703	Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy. 2017, 8, 71	60
1702	Barriers to Radiation-Induced Tumor Vaccination. 2017, 8, 229	111
1701	Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel. 2017, 8, 267	47
1700	Comparative Gene Expression Analysis of Lymphocytes Treated with Exosomes Derived from Ovarian Cancer and Ovarian Cysts. 2017, 8, 607	12
1699	Molecular Imaging: A Useful Tool for the Development of Natural Killer Cell-Based Immunotherapies. 2017, 8, 1090	29
1698	Inflammasomes and Cancer: The Dynamic Role of the Inflammasome in Tumor Development. 2017, 8, 1132	71
1697	Natural Killer T Cells in Cancer Immunotherapy. 2017, 8, 1178	130
1696	Ameliorating Amyloid- β Fibrils Triggered Inflammation Curcumin-Loaded Polymeric Nanoconstructs. 2017, 8, 1411	31
1695	Toll-Like Receptor 3 Signal in Dendritic Cells Benefits Cancer Immunotherapy. 2017, 8, 1897	40
1694	New Chimeric Antigen Receptor Design for Solid Tumors. 2017, 8, 1934	17
1693	Modulation of the Intratumoral Immune Landscape by Oncolytic Herpes Simplex Virus Virotherapy. 2017, 7, 136	33
1692	Oncolytic Viral Therapy for Mesothelioma. 2017, 7, 179	29
1691	The Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform. 2017, 7, 190	68
1690	Evolutionary Perspective of Tumorigenesis and Antitumor Immunity: A Comparative Approach. 2017, 119-135	1
1689	A synthetic urinary probe-coated nanoparticles sensitive to fibroblast activation protein β for solid tumor diagnosis. 2017, 12, 5359-5372	3

1688	Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer. 2017 , 2,	137
1687	Current Perspective on In Vivo Molecular Imaging of Immune Cells. 2017 , 22,	15
1686	Integrin α activation induces an anti-melanoma host response. 2017 , 12, e0175300	7
1685	Oncolytic potency and reduced virus tumor-specificity in oncolytic virotherapy. A mathematical modelling approach. 2017 , 12, e0184347	27
1684	Study of the tumor microenvironment during breast cancer progression. 2017 , 17, 123	15
1683	Pretreatment antigen-specific immunity and regulation - association with subsequent immune response to anti-tumor DNA vaccination. 2017 , 5, 56	7
1682	Prospects for combined use of oncolytic viruses and CAR T-cells. 2017 , 5, 90	67
1681	Immune Environment and Osteosarcoma. 2017 ,	1
1680	Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy. 2017 , 8, 71249-71284	83
1679	Cancer Immunotherapy. 2017 , 32-65	1
1678	The Process and Regulatory Components of Inflammation in Brain Oncogenesis. 2017 , 7,	51
1677	Adoptive Cell Therapy for Cancer Using T-Cells Genetically Engineered to Express Chimeric Antigen Receptors. 591-601	
1676	Loss of Tff1 Promotes Pro-Inflammatory Phenotype with Increase in the Levels of ROR γ T Lymphocytes and Il-17 in Mouse Gastric Neoplasia. 2017 , 8, 2424-2435	9
1675	The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions. 2017 , 1, 447-456	2
1674	KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation. 2017 , 35, 2268-2278	69
1673	Antiangiogenic therapy and immune checkpoint blockade go hand in hand. 2017 , 5, 497	16
1672	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. 2017 , 8, 106132-106142	109
1671	Tumor-infiltrating immune cells and prognosis in gastric cancer: a systematic review and meta-analysis. 2017 , 8, 62312-62329	36

1670	Bispecific antibody based therapeutics: Strengths and challenges. 2018 , 32, 339-347	69
1669	Targeting complement-mediated immunoregulation for cancer immunotherapy. 2018 , 37, 85-97	28
1668	Exploring the rationale for combining ionizing radiation and immune checkpoint blockade in head and neck cancer. 2018 , 40, 1321-1334	9
1667	Extratumoral PD-1 blockade does not perpetuate obesity-associated inflammation in esophageal adenocarcinoma. 2018 , 418, 230-238	9
1666	CAR-T Cells: Next Generation Cancer Therapeutics. 2018 , 98, 21-31	
1665	Quantitative Analysis of Immune Infiltrates in Primary Melanoma. 2018 , 6, 481-493	51
1664	Biomaterials for Engineering Immune Responses. 2018 , 98, 49-68	0
1663	Turning an old GADDget into a troublemaker. 2018 , 25, 642-644	26
1662	Targeting the Tumor Microenvironment with Immunotherapy for Genitourinary Malignancies. 2018 , 19, 16	5
1661	Targeting Tumor Vasculature with TNF Leads Effector T Cells to the Tumor and Enhances Therapeutic Efficacy of Immune Checkpoint Blockers in Combination with Adoptive Cell Therapy. 2018 , 24, 2171-2181	25
1660	Immunotherapy for Head and Neck Squamous Cell Carcinoma. 2018 , 20, 22	75
1659	. 2018 , 2, 353-359	21
1658	Physiological function of phospholipase D2 in anti-tumor immunity: regulation of CD8 T lymphocyte proliferation. 2018 , 8, 6283	7
1657	Lewis-antigen-containing ICAM-2/3 on Jurkat leukemia cells interact with DC-SIGN to regulate DC functions. 2018 , 35, 287-297	1
1656	A Pan-cancer Landscape of Interactions between Solid Tumors and Infiltrating Immune Cell Populations. 2018 , 24, 3717-3728	136
1655	Tumor heterogeneity, hypoxia, and immune markers in surgically resected non-small-cell lung cancer. 2018 , 39, 636-644	8
1654	Prevalent Homozygous Deletions of Type I Interferon and Defensin Genes in Human Cancers Associate with Immunotherapy Resistance. 2018 , 24, 3299-3308	27
1653	-Catenin peptide vaccines repress hepatocellular carcinoma growth via CD8 T cell activation. 2018 , 7, e1450713	5

1652	Interplay Between Metabolic Sensors and Immune Cell Signaling. 2018 , 109, 115-196	1
1651	T Cell Dysfunction in Cancer. 2018 , 33, 547-562	446
1650	Reverse of non-small cell lung cancer drug resistance induced by cancer-associated fibroblasts via a paracrine pathway. 2018 , 109, 944-955	24
1649	The importance of the vascular endothelial barrier in the immune-inflammatory response induced by radiotherapy. 2018 , 91, 20170762	37
1648	Immunostimulation and Immunosuppression: Nanotechnology on the Brink. 2018 , 2, 1700347	24
1647	Overexpression of COX2 indicates poor survival in urothelial bladder cancer. 2018 , 34, 50-55	17
1646	Glycocalyx-Mimicking Nanoparticles Improve Anti-PD-L1 Cancer Immunotherapy through Reversion of Tumor-Associated Macrophages. 2018 , 19, 2098-2108	46
1645	Personalized cancer vaccine effectively mobilizes antitumor T cell immunity in ovarian cancer. 2018 , 10,	205
1644	Targeting the tumour stroma to improve cancer therapy. 2018 , 15, 366-381	421
1643	Polymeric microneedles for transdermal protein delivery. 2018 , 127, 106-118	160
1642	Colorectal cancer prevention: Immune modulation taking the stage. 2018 , 1869, 138-148	43
1641	Red fluorescent cAMP indicator with increased affinity and expanded dynamic range. 2018 , 8, 1866	36
1640	Combining chemotherapy with PD-1 blockade in NSCLC. 2018 , 186, 130-137	56
1639	IFN- γ and tumor gangliosides: Implications for the tumor microenvironment. 2018 , 325, 33-40	8
1638	[The biological rationale for immunotherapy in cancer]. 2018 , 35, 206-222	4
1637	Potentiating prostate cancer immunotherapy with oncolytic viruses. 2018 , 15, 235-250	34
1636	Epithelial-mesenchymal transition (EMT) signature is inversely associated with T-cell infiltration in non-small cell lung cancer (NSCLC). 2018 , 8, 2918	97
1635	Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles. 2018 , 6, 893-900	16

1634	Nanoliposome C6-Ceramide Increases the Anti-tumor Immune Response and Slows Growth of Liver Tumors in Mice. 2018 , 154, 1024-1036.e9	69
1633	Rapid activation of tumor-associated macrophages boosts preexisting tumor immunity. 2018 , 215, 859-876	104
1632	Exploration of the platelet proteome in patients with early-stage cancer. 2018 , 177, 65-74	39
1631	Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo. 2018 , 22, 501-513.e7	78
1630	Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective. 2018 , 10, 221-234	4
1629	ROS release by PPAR γ Thull fibroblasts reduces tumor load through epithelial antioxidant response. 2018 , 37, 2067-2078	8
1628	Radiation effects on antitumor immune responses: current perspectives and challenges. 2018 , 10, 1758834017742575	142
1627	T-cell Homing Therapy for Reducing Regulatory T Cells and Preserving Effector T-cell Function in Large Solid Tumors. 2018 , 24, 2920-2934	38
1626	The Current Landscape of 3D In Vitro Tumor Models: What Cancer Hallmarks Are Accessible for Drug Discovery?. 2018 , 7, e1701174	50
1625	NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control. 2018 , 172, 1022-1037.e14	674
1624	Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer. 2018 , 53, 1205-1213	6
1623	Promoting the accumulation of tumor-specific T cells in tumor tissues by dendritic cell vaccines and chemokine-modulating agents. 2018 , 13, 335-357	16
1622	Increased immune infiltration and chemokine receptor expression in head and neck epithelial tumors after neoadjuvant immunotherapy with the IRX-2 regimen. 2018 , 7, e1423173	13
1621	Back from the dead: TIL apoptosis in cancer immune evasion. 2018 , 118, 309-311	6
1620	Chemotherapy induces enrichment of CD47/CD73/PDL1 immune evasive triple-negative breast cancer cells. 2018 , 115, E1239-E1248	141
1619	GADD45 Loss Ablates Innate Immunosuppression in Cancer. 2018 , 78, 1275-1292	16
1618	Innate Immune Receptors in the Regulation of Tumor Immunity. 2018 , 407-427	
1617	Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor. 2018 , 172, 534-548.e19	136

1616	Association of tumour-infiltrating regulatory T cells with adverse outcomes in dogs with malignant tumours. 2018 , 16, 330-336	21
1615	Role of immune system in tumor progression and carcinogenesis. 2018 , 119, 5028-5042	26
1614	Precision Molecular Pathology of Bladder Cancer. 2018 ,	
1613	Response to Immunotherapy: Application of Molecular Pathology to Predict Successful Response. 2018 , 181-194	
1612	Precision Molecular Pathology of Liver Cancer. 2018 ,	1
1611	Mechanisms of resistance to immune checkpoint inhibitors. 2018 , 118, 9-16	576
1610	High macrophage PD-L1 expression not responsible for T cell suppression. 2018 , 324, 50-58	5
1609	Immune Cell Infiltration and Tertiary Lymphoid Structures as Determinants of Antitumor Immunity. 2018 , 200, 432-442	89
1608	Hepatocellular Carcinoma Metastasis and Circulating Tumor Cells. 2018 , 153-173	
1607	Integration of radiation and immunotherapy in breast cancer - Treatment implications. 2018 , 38, 66-74	26
1606	Development of a Safe and Effective Vaccinia Virus Oncolytic Vector WR- 2 with a Set of Gene Deletions on Several Viral Pathways. 2018 , 8, 27-40	13
1605	NRF2 and the Hallmarks of Cancer. 2018 , 34, 21-43	555
1604	Analysis of Th22, Th17 and CD4 cells co-producing IL-17/IL-22 at different stages of human colon cancer. 2018 , 103, 1101-1106	22
1603	Whole Exome and Transcriptome Analyses Integrated with Microenvironmental Immune Signatures of Lung Squamous Cell Carcinoma. 2018 , 6, 848-859	19
1602	Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. 2018 , 124, 3819-3829	25
1601	Review of diagnostic, prognostic, and predictive biomarkers in melanoma. 2018 , 35, 487-493	23
1600	Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying Cells. 2018 , 33, 862-873.e5	82
1599	Personal history of infections and immunotherapy: Unexpected links and possible therapeutic opportunities. 2018 , 7, e1466019	3

1598	Integrative Pharmacology: Advancing Development of Effective Immunotherapies. 2018 , 20, 66	7
1597	Inflammation-on-a-Chip: Probing the Immune System Ex Vivo. 2018 , 36, 923-937	41
1596	C-C motif chemokine 22 predicts postoperative prognosis and adjuvant chemotherapeutic benefits in patients with stage II/III gastric cancer. 2018 , 7, e1433517	13
1595	Immune checkpoint blockade therapy. 2018 , 142, 1403-1414	44
1594	The cellular metabolic landscape in the tumor milieu regulates the activity of myeloid infiltrates. 2018 , 15, 421-427	14
1593	Tumor Ablation and Therapeutic Immunity Induction by an Injectable Peptide Hydrogel. 2018 , 12, 3295-3310	94
1592	Mechanistic insights into cancer immunity and immunotherapy. 2018 , 15, 419-420	20
1591	Depleted polymorphonuclear leukocytes in human metastatic liver reflect an altered immune microenvironment associated with recurrent metastasis. 2018 , 67, 1041-1052	7
1590	Prognostic implication of programmed cell death 1 protein and its ligand expressions in endometrial cancer. 2018 , 149, 381-387	24
1589	CD8CXCR5 T cells in tumor-draining lymph nodes are highly activated and predict better prognosis in colorectal cancer. 2018 , 79, 446-452	27
1588	Prognostic Significance of Stromal Versus Intratumoral Infiltrating Lymphocytes in Different Subtypes of Breast Cancer Treated With Cytotoxic Neoadjuvant Chemotherapy. 2018 , 26, 523-532	20
1587	What Is the Predictive Value of Animal Models for Vaccine Efficacy in Humans? Reevaluating the Potential of Mouse Models for the Human Immune System. 2018 , 10,	12
1586	The emerging world of breast cancer immunotherapy. 2018 , 37, 200-206	30
1585	Tumor Metabolic Features Identified by F-FDG PET Correlate with Gene Networks of Immune Cell Microenvironment in Head and Neck Cancer. 2018 , 59, 31-37	27
1584	Depletion of tumor-associated macrophages switches the epigenetic profile of pancreatic cancer infiltrating T cells and restores their anti-tumor phenotype. 2018 , 7, e1393596	44
1583	Clinicopathologic implications of CD8/Foxp3 ratio and miR-574-3p/PD-L1 axis in spinal chordoma patients. 2018 , 67, 209-224	28
1582	Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. 2018 , 29, 193-199	111
1581	Phase Ib Study of Immune Biomarker Modulation with Neoadjuvant Cetuximab and TLR8 Stimulation in Head and Neck Cancer to Overcome Suppressive Myeloid Signals. 2018 , 24, 62-72	39

1580	Infiltration of $\gamma\delta$ T cells, IL-17+ T cells and FoxP3+ T cells in human breast cancer. 2017 , 20, 395-409	13
1579	Type I IFN Receptor Signaling Controls IL7-Dependent Accumulation and Activity of Protumoral IL17A-Producing $\gamma\delta$ T Cells in Breast Cancer. 2018 , 78, 195-204	19
1578	A filamentous bacteriophage targeted to carcinoembryonic antigen induces tumor regression in mouse models of colorectal cancer. 2018 , 67, 183-193	14
1577	Quantification of altered tissue turnover in a liquid biopsy: a proposed precision medicine tool to assess chronic inflammation and desmoplasia associated with a pro-cancerous niche and response to immuno-therapeutic anti-tumor modalities. 2018 , 67, 1-12	19
1576	Non-progressing cancer patients have persistent B cell responses expressing shared antibody paratopes that target public tumor antigens. 2018 , 187, 37-45	49
1575	Toll-like receptor 2 ligand and interferon- β suppress anti-tumor T cell responses by enhancing the immunosuppressive activity of monocytic myeloid-derived suppressor cells. 2017 , 7, e1373231	38
1574	Nonresolving macrophage-mediated inflammation in malignancy. 2018 , 285, 641-653	21
1573	Targeted drug delivery to melanoma. 2018 , 127, 208-221	68
1572	Intratumoral CD8 T-cell Apoptosis Is a Major Component of T-cell Dysfunction and Impedes Antitumor Immunity. 2018 , 6, 14-24	81
1571	Cell therapies for hematological malignancies: don't forget non-gene-modified t cells!. 2018 , 32, 203-224	14
1570	Immunotherapy for Pediatric Malignancies. 2018 ,	
1569	Metabolic Control of CD8 T Cell Fate Decisions and Antitumor Immunity. 2018 , 24, 30-48	104
1568	Metallic Nanoparticles for Cancer Immunotherapy. 2018 , 21, 673-685	101
1567	Implications of the tumor immune microenvironment for staging and therapeutics. 2018 , 31, 214-234	182
1566	Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: Harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation. 2018 , 63, 48-60	89
1565	Allogeneic Stem Cell Transplantation. 2018 , 39-64	0
1564	Primer on Cancer Immunotherapy and the Targeting of Native Proteins. 2018 , 1-28	
1563	Immune checkpoint inhibitors: new strategies to checkmate cancer. 2018 , 191, 133-148	48

1562	Humanized mice in studying efficacy and mechanisms of PD-1-targeted cancer immunotherapy. 2018 , 32, 1537-1549	163
1561	A novel immunization strategy using cytokine/chemokines induces new effective systemic immune responses, and frequent complete regressions of human metastatic melanoma. 2018 , 7, e1386827	3
1560	Reply to: Oncogenesis in Patients With Pancreatic Intraductal Papillary Mucinous Neoplasms: Taking the Thread From the Beginning. 2018 , 267, e72-e73	
1559	Processing Escape Mechanisms Through Altered Proteasomal Cleavage of Epitopes Affect Immune Response in Pulmonary Neuroendocrine Tumors. 2018 , 17, 153303381881841	4
1558	Tumor immunotherapy: New aspects of natural killer cells. 2018 , 30, 173-196	34
1557	The evolving relationship of wound healing and tumor stroma. 2018 , 3,	82
1556	Frameshift events predict anti-PD-1/L1 response in head and neck cancer. 2018 , 3,	123
1555	Spatial and phenotypic immune profiling of metastatic colon cancer. 2018 , 3,	40
1554	SMAD4 promotes TGF- β -independent NK cell homeostasis and maturation and antitumor immunity. 2018 , 128, 5123-5136	41
1553	Immune checkpoint inhibitors in small cell lung cancer. 2018 , 10, S460-S467	36
1552	Cancer Vaccines: Dendritic Cell-Based Vaccines and Related Approaches. 2018 , 260-260	
1551	Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression. 2018 , 24, 3500-3512	38
1550	Evaluation of T cell infiltration in matched biopsy and nephrectomy samples in renal cell carcinoma. 2018 , 97, e12344	4
1549	Combining immunotherapy and radiotherapy in lung cancer. 2018 , 10, S1447-S1460	43
1548	. 2018 , 105 Suppl 1, S35-S42	
1547	Der Einsatz von Checkpoint-Hemmern beim Lungenkarzinom wird breiter. 2018 , 10, 34-42	
1546	A Task Force Against Local Inflammation and Cancer: Lymphocyte Trafficking to and Within the Skin. 2018 , 9, 2454	6
1545	Using Frameshift Peptide Arrays for Cancer Neo-Antigens Screening. 2018 , 8, 17366	8

1544	Non-small-cell lung cancer homing peptide-labeled dendrimers selectively transfect lung cancer cells. 2018 , 10, 1349-1360	8
1543	Sortilin inhibition limits secretion-induced progranulin-dependent breast cancer progression and cancer stem cell expansion. 2018 , 20, 137	30
1542	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. 2017 , 17, 527-540	14
1541	Genetic Models Reveal cis and trans Immune-Regulatory Activities for lincRNA-Cox2. 2018 , 25, 1511-1524.e6	40
1540	Transforming of the Tumor Microenvironment: Implications for TGF- Inhibition in the Context of Immune-Checkpoint Therapy. 2018 , 2018, 9732939	28
1539	Preoperative systemic immune-inflammation index predicts prognosis of patients with oral squamous cell carcinoma after curative resection. 2018 , 16, 365	24
1538	Interstitial Fluid in Gynecologic Tumors and Its Possible Application in the Clinical Practice. 2018 , 19,	5
1537	Automated Tumour Recognition and Digital Pathology Scoring Unravels New Role for PD-L1 in Predicting Good Outcome in ER-/HER2+ Breast Cancer. 2018 , 2018, 2937012	25
1536	Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. 2018 , 8, 17812	24
1535	Neurological and Inflammatory Manifestations in Sjögren's Syndrome: The Role of the Kynurenine Metabolic Pathway. 2018 , 19,	15
1534	SITC 2018 workshop report: Immuno-Oncology Biomarkers: State of the Art. 2018 , 6, 138	16
1533	Neutrophils to lymphocytes ratio as a useful prognosticator for stage II colorectal cancer patients. 2018 , 18, 1202	27
1532	Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade. 2019 , 25, 1612-1623	76
1531	Differential role of CXCR3 in inflammation and colorectal cancer. 2018 , 9, 17928-17936	16
1530	Emerging ways to treat breast cancer: will promises be met?. 2018 , 41, 605-621	33
1529	Peptide-Based Multifunctional Nanomaterials for Tumor Imaging and Therapy. 2018 , 28, 1804492	61
1528	Chondrosarcoma: An overview of clinical behavior, molecular mechanisms mediated drug resistance and potential therapeutic targets. 2018 , 131, 102-109	38
1527	Liposomal Formulations to Modulate the Tumour Microenvironment and Antitumour Immune Response. 2018 , 19,	19

1526	Adoptive T cell therapy: engineering and biomanufacturing chimeric antigen receptor-T cell. 2018 , 22, 26-33	2
1525	Biomaterials for vaccine-based cancer immunotherapy. 2018 , 292, 256-276	93
1524	Molecular imaging to enlighten cancer immunotherapies and underlying involved processes. 2018 , 70, 232-244	28
1523	Degranulation of mast cells induced by gastric cancer-derived adrenomedullin prompts gastric cancer progression. 2018 , 9, 1034	16
1522	The Multiple Layers of the Tumor Environment. 2018 , 4, 802-809	40
1521	Prognostic significance of interferon regulating factor 4 in esophageal squamous cell carcinoma. 2018 , 506, 685-691	2
1520	Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens. 2018 , 13, e0204745	8
1519	Profiling Immune Escape in Hodgkin's and Diffuse large B-Cell Lymphomas Using the Transcriptome and Immunostaining. 2018 , 10,	12
1518	Developing a Bright NIR-II Fluorophore with Fast Renal Excretion and Its Application in Molecular Imaging of Immune Checkpoint PD-L1. 2018 , 28, 1804956	61
1517	High expression of E-cadherin and Ki-67 associated with functional/dysfunctional phenotypes of tumor-infiltrating lymphocytes among Chinese patients with operable breast cancer. 2018 , 46, 5219-5227	4
1516	Targeting macrophages: therapeutic approaches in cancer. 2018 , 17, 887-904	626
1515	Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A systematic review and meta-analysis. 2018 , 97, e11769	54
1514	Sensitivity of CD3/CD28-stimulated versus non-stimulated lymphocytes to ionizing radiation and genotoxic anticancer drugs: key role of ATM in the differential radiation response. 2018 , 9, 1053	27
1513	Key Immunological Functions Involved in the Progression of Epithelial Ovarian Serous Carcinoma Discovered by the Gene Ontology-Based Immunofunctionome Analysis. 2018 , 19,	10
1512	The immune microenvironment in vulvar (pre)cancer: review of literature and implications for immunotherapy. 2018 , 18, 1223-1233	7
1511	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. 2018 , 12, 1753466618794133	27
1510	The Anti-Inflammatory Effects of Vitamin D in Tumorigenesis. 2018 , 19,	68
1509	Effects of modified FOLFOX-6 chemotherapy on cellular immune function in patients with gastric cancer. 2018 , 15, 8635-8640	2

1508	Autophagosome-based strategy to monitor apparent tumor-specific CD8 T cells in patients with prostate cancer. 2018 , 7, e1466766	2
1507	Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis. 2018 , 362, k3529	205
1506	Leutosome: A Biomimetic Nanoplatform Integrating Plasma Membrane Components of Leukocytes and Tumor Cells for Remarkably Enhanced Solid Tumor Homing. 2018 , 18, 6164-6174	68
1505	Immunological and Quality-of-Life Profiles in Women with Breast Cancer: Complementary versus Conventional Care. 2018 , 25, 391-397	
1504	Genetics and biology of prostate cancer. 2018 , 32, 1105-1140	199
1503	Breaking through to the Other Side: Microenvironment Contributions to DCIS Initiation and Progression. 2018 , 23, 207-221	28
1502	Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics. 2018 , 28, 697-712	6
1501	Exosomes, Stem Cells and MicroRNA. 2018 ,	
1500	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. 2018 , 8, 822-835	648
1499	Tumour YAP1 and PTEN expression correlates with tumour-associated myeloid suppressor cell expansion and reduced survival in colorectal cancer. 2018 , 155, 263-272	21
1498	Skin Allografting Activates Anti-tumor Immunity and Suppresses Growth of Colon Cancer in Mice. 2018 , 11, 890-899	1
1497	Myeloid-restricted ablation of Shp2 restrains melanoma growth by amplifying the reciprocal promotion of CXCL9 and IFN- γ production in tumor microenvironment. 2018 , 37, 5088-5100	23
1496	Ultrasound-guided radiofrequency ablation enhances natural killer-mediated antitumor immunity against liver cancer. 2018 , 15, 7014-7020	6
1495	Macrophage-Derived Granulin Drives Resistance to Immune Checkpoint Inhibition in Metastatic Pancreatic Cancer. 2018 , 78, 4253-4269	67
1494	Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients. 2018 , 121, 70-75	29
1493	Targeting glioblastoma-derived pericytes improves chemotherapeutic outcome. 2018 , 21, 667-675	29
1492	Tumor-associated metabolic and inflammatory responses in early stage non-small cell lung cancer: Local patterns and prognostic significance. 2018 , 122, 124-130	16
1491	Application of iNKT Cell-targeted Active Immunotherapy in Cancer Treatment. 2018 , 38, 4233-4239	8

1490	A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. 2018 , 2, 589-599	100
1489	Inhibition of Rspo-Lgr4 Facilitates Checkpoint Blockade Therapy by Switching Macrophage Polarization. 2018 , 78, 4929-4942	71
1488	Molecular mechanisms of the preventable causes of cancer in the United States. 2018 , 32, 868-902	63
1487	Oxygenated lipid signaling in tumor-associated macrophages-focus on colon cancer. 2018 , 37, 289-315	9
1486	Similarities and differences between helminth parasites and cancer cell lines in shaping human monocytes: Insights into parallel mechanisms of immune evasion. 2018 , 12, e0006404	7
1485	Diagnosis of immunomarkers in vivo via multiplexed surface enhanced Raman spectroscopy with gold nanostars. 2018 , 10, 13092-13105	27
1484	An insight into metastasis: Random or evolving paradigms?. 2018 , 214, 1064-1073	3
1483	Osthole inhibits pancreatic cancer progression by directly exerting negative effects on cancer cells and attenuating tumor-infiltrating M2 macrophages. 2018 , 137, 290-298	20
1482	Complementing Cancer Metastasis. 2018 , 9, 1629	21
1481	Nanotherapeutics to Modulate the Compromised Micro-Environment for Lung Cancers and Chronic Obstructive Pulmonary Disease. 2018 , 9, 759	7
1480	The Role of Inflammation and Inflammatory Mediators in the Development, Progression, Metastasis, and Chemoresistance of Epithelial Ovarian Cancer. 2018 , 10,	61
1479	Superagonist IL-15-Armed Oncolytic Virus Elicits Potent Antitumor Immunity and Therapy That Are Enhanced with PD-1 Blockade. 2018 , 26, 2476-2486	67
1478	Biomarkers of response to immune checkpoint blockade in cancer treatment. 2018 , 130, 108-120	46
1477	Extracellular vesicles: important collaborators in cancer progression. 2018 , 62, 149-163	39
1476	Sweet Killers: NK Cells Need Glycolysis to Kill Tumors. 2018 , 28, 183-184	6
1475	Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy. 2018 , 7, e1498439	68
1474	KDM5 histone demethylases repress immune response via suppression of STING. 2018 , 16, e2006134	54
1473	Cytokine-Induced Killer Cells Express CD39, CD38, CD203a, CD73 Ectoenzymes and P1 Adenosinergic Receptors. 2018 , 9, 196	9

1472	Phosphoinositide 3-Kinase Signaling Pathway in Pancreatic Ductal Adenocarcinoma Progression, Pathogenesis, and Therapeutics. 2018 , 9, 335	46
1471	MiR-195/-16 Family Enhances Radiotherapy via T Cell Activation in the Tumor Microenvironment by Blocking the PD-L1 Immune Checkpoint. 2018 , 48, 801-814	52
1470	Toward Biomaterials for Enhancing Immune Checkpoint Blockade Therapy. 2018 , 28, 1802540	69
1469	Biomarkers for Immune Checkpoint Inhibitors in Melanoma. 2018 , 8, 270	35
1468	Platinum-Based Nanovectors Engineered with Immuno-Modulating Adjuvant for Inhibiting Tumor growth and Promoting Immunity. 2018 , 8, 2974-2987	16
1467	Nanoparticle-mediated HMGA1 Silencing Promotes Lymphocyte Infiltration and Boosts Checkpoint Blockade Immunotherapy for Cancer. 2018 , 28, 1802847	19
1466	The Complex Interplay between Chronic Inflammation, the Microbiome, and Cancer: Understanding Disease Progression and What We Can Do to Prevent It. 2018 , 10,	48
1465	A new laboratory-based algorithm to predict microvascular invasion and survival in patients with hepatocellular carcinoma. 2018 , 57, 45-53	14
1464	Dual role of macrophage in tumor immunity. 2018 , 10, 899-909	61
1463	Unique Immune Gene Expression Patterns in Bronchoalveolar Lavage and Tumor Adjacent Non-Neoplastic Lung Tissue in Non-Small Cell Lung Cancer. 2018 , 9, 232	6
1462	Alteration of the Antitumor Immune Response by Cancer-Associated Fibroblasts. 2018 , 9, 414	158
1461	mTOR at the Transmitting and Receiving Ends in Tumor Immunity. 2018 , 9, 578	26
1460	Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids. 2018 , 9, 723	40
1459	Targeting Head and Neck Cancer by Vaccination. 2018 , 9, 830	30
1458	Breast Cancer-Derived Exosomes Alter Macrophage Polarization gp130/STAT3 Signaling. 2018 , 9, 871	78
1457	Targeting Autophagy in the Tumor Microenvironment: New Challenges and Opportunities for Regulating Tumor Immunity. 2018 , 9, 887	46
1456	Integrated Expression Profiles Analysis Reveals Correlations Between the IL-33/ST2 Axis and CD8 T Cells, Regulatory T Cells, and Myeloid-Derived Suppressor Cells in Soft Tissue Sarcoma. 2018 , 9, 1179	7
1455	Genetically Induced Tumors in the Oncopig Model Invoke an Antitumor Immune Response Dominated by Cytotoxic CD8 ⁺ T Cells and Differentiated ⁺ T Cells Alongside a Regulatory Response Mediated by FOXP3 T Cells and Immunoregulatory Molecules. 2018 , 9, 1301	11

1454	Fucosylated Antigens in Cancer: An Alliance toward Tumor Progression, Metastasis, and Resistance to Chemotherapy. 2018 , 8, 39	60
1453	The Shifting Paradigm of Prognostic Factors of Colorectal Liver Metastases: From Tumor-Centered to Host Immune-Centered Factors. 2018 , 8, 181	11
1452	Expression of the Circadian Clock Gene Positively Correlates With Antitumor Immunity and Patient Survival in Metastatic Melanoma. 2018 , 8, 185	34
1451	Ectenin regulates IRF3-mediated innate immune signalling in colorectal cancer. 2018 , 51, e12464	14
1450	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. 2018 , 10,	33
1449	Snail-overexpressing Cancer Cells Promote M2-Like Polarization of Tumor-Associated Macrophages by Delivering MiR-21-Abundant Exosomes. 2018 , 20, 775-788	86
1448	Combinatory therapy adopting nanoparticle-based cancer vaccination with immune checkpoint blockade for treatment of post-surgical tumor recurrences. 2018 , 285, 56-66	16
1447	CCL5-deficiency enhances intratumoral infiltration of CD8 T cells in colorectal cancer. 2018 , 9, 766	28
1446	New Insights into the Tumor Microenvironment Utilizing Protein Array Technology. 2018 , 19,	20
1445	Adjustment of dendritic cells to the breast-cancer microenvironment is subset specific. <i>Nature Immunology</i> , 2018 , 19, 885-897	19.1 97
1444	Protective and therapeutic potential of ginger (<i>Zingiber officinale</i>) extract and [6]-gingerol in cancer: A comprehensive review. 2018 , 32, 1885-1907	85
1443	Phase II Study of Maintenance Pembrolizumab in Patients with Extensive-Stage Small Cell Lung Cancer (SCLC). 2018 , 13, 1393-1399	118
1442	Quantitative Spatial Profiling of PD-1/PD-L1 Interaction and HLA-DR/IDO-1 Predicts Improved Outcomes of Anti-PD-1 Therapies in Metastatic Melanoma. 2018 , 24, 5250-5260	65
1441	A two-phenotype model of immune evasion by cancer cells. 2018 , 455, 191-204	13
1440	Engineering Breast Cancer Microenvironments and 3D Bioprinting. 2018 , 6, 66	56
1439	Microenvironmental Signals and Biochemical Information Processing: Cooperative Determinants of Intratumoral Plasticity and Heterogeneity. 2018 , 6, 44	22
1438	Exosomes Function in Tumor Immune Microenvironment. 2018 , 1056, 109-122	27
1437	Xenogeneic cell therapy provides a novel potential therapeutic option for cancers by restoring tissue function, repairing cancer wound and reviving anti-tumor immune responses. 2018 , 18, 9	11

1436	Zymosan attenuates melanoma growth progression, increases splenocyte proliferation and induces TLR-2/4 and TNF- α expression in mice. 2018 , 15, 5	9
1435	Incorporating Radiation Oncology into Immunotherapy: proceedings from the ASTRO-SITC-NCI immunotherapy workshop. 2018 , 6, 6	17
1434	Lighting a Fire in the Tumor Microenvironment Using Oncolytic Immunotherapy. 2018 , 31, 17-24	68
1433	Anti-angiogenic effects of CD73-specific siRNA-loaded nanoparticles in breast cancer-bearing mice. 2018 , 233, 7165-7177	50
1432	Insights into the role of IL-32 in cancer. 2018 , 38, 24-32	34
1431	Integrating oncolytic viruses in combination cancer immunotherapy. 2018 , 18, 498-513	253
1430	Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. 2018 , 24, 1550-1558	881
1429	Tertiary Lymphoid Structures. 2018 ,	
1428	Notch Signaling in the Tumor Microenvironment. 2018 , 34, 536-548	214
1427	Identification and Characterization of Tertiary Lymphoid Structures in Murine Melanoma. 2018 , 1845, 241-257	13
1426	CD103 Cell Growth Factor Flt3L Enhances the Efficacy of Immune Checkpoint Blockades in Murine Glioblastoma Model. 2018 , 26, 173-182	6
1425	High-dimensional single cell analysis identifies stem-like cytotoxic CD8 T cells infiltrating human tumors. 2018 , 215, 2520-2535	157
1424	Comparison of Burnet's clonal selection theory with tumor cell-clone development. 2018 , 8, 3392-3399	5
1423	Differentially methylated regions in T cells identify kidney transplant patients at risk for de novo skin cancer. 2018 , 10, 81	11
1422	SIRS, CARS and MARS in relationship to cancer cachexia and its clinical implications. 2018 , 26, 54-59	2
1421	Effective nivolumab sequential thoracic radiotherapy in elderly patients with advanced squamous cell lung cancer: did radiation therapy play a role? A case report. 2018 , 11, 4621-4629	6
1420	Pathological Significance and Prognostic Value of Surfactant Protein D in Cancer. 2018 , 9, 1748	14
1419	Immunobiology of the Melanoma Microenvironment. 2018 , 133-142	

1418	Nanoscale metal-organic frameworks enhance radiotherapy to potentiate checkpoint blockade immunotherapy. 2018 , 9, 2351	171
1417	Co-expression of LAG3 and TIM3 identifies a potent Treg population that suppresses macrophage functions in colorectal cancer patients. 2018 , 45, 1002-1009	18
1416	Enrichment and Characterization of the Tumor Immune and Non-immune Microenvironments in Established Subcutaneous Murine Tumors. 2018 ,	3
1415	Spotlight on atezolizumab and its potential as an oncology agent. 2018 , 18, 719-722	2
1414	T-lymphocyte profiles differ between keratoacanthomas and invasive squamous cell carcinomas of the human skin. 2018 , 67, 1147-1157	9
1413	Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML. 2018 , 32, 1643-1656	42
1412	Hypoxia restrains the expression of complement component 9 in tumor-associated macrophages promoting non-small cell lung cancer progression. 2018 , 4, 63	10
1411	Immunotherapy of Cancer. 2019 , 1033-1048.e1	1
1410	The Role of Fibrinogen-Like Protein 2 on Immunosuppression and Malignant Progression in Glioma. 2019 , 111, 292-300	18
1409	The T-win ² technology: immune-modulating vaccines. 2019 , 41, 87-95	10
1408	Effects of exercise training and supplementation with selenium nanoparticle on T-helper 1 and 2 and cytokine levels in tumor tissue of mice bearing the 4 T1 mammary carcinoma. 2019 , 57, 141-147	21
1407	Nanomaterials for modulating innate immune cells in cancer immunotherapy. 2019 , 14, 16-29	25
1406	Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy. 2019 , 16, 28-39	34
1405	Lentivirus-mediated RNA interference targeting programmed death receptor ligand 1 increases the immunologic anti-tumor effect of dendritic cell vaccination against pancreatic cancer in SCID-hu mice. 2019 , 18, 1539-1547	3
1404	NLRP3 inflammasome activation in human vestibular schwannoma: Implications for tumor-induced hearing loss. 2019 , 381, 107770	13
1403	Altered expression of circular RNA in primary Sjögren's syndrome. 2019 , 38, 3425-3433	12
1402	Engineering universal cells that evade immune detection. 2019 , 19, 723-733	59
1401	The Complex Interaction between the Tumor Micro-Environment and Immune Checkpoints in Breast Cancer. 2019 , 11,	24

1400	Integrated Biologics Manufacturing in Stirred-Suspension Bioreactor: A Stem Cell Perspective. 2019	
1399	Current patent and clinical status of stimulator of interferon genes (STING) agonists for cancer immunotherapy. 2019 , 8, 87-90	16
1398	Macrophages induce CD47 upregulation via IL-6 and correlate with poor survival in hepatocellular carcinoma patients. 2019 , 8, e1652540	24
1397	Immuno-evolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease. 2019 , 9, 12286	15
1396	Long Noncoding RNAs of the Arterial Wall as Therapeutic Agents and Targets in Atherosclerosis. 2019 , 119, 1222-1236	8
1395	Immune Profiling of Thyroid Carcinomas Suggests the Existence of Two Major Phenotypes: An ATC-Like and a PDTC-Like. 2019 , 104, 3557-3575	24
1394	Cryopreserved Human Natural Killer Cells Exhibit Potent Antitumor Efficacy against Orthotopic Pancreatic Cancer through Efficient Tumor-Homing and Cytolytic Ability (Running Title: Cryopreserved NK Cells Exhibit Antitumor Effect). 2019 , 11,	6
1393	Reprogramming of Tumor Associated Immune Cells by Phytochemicals: In-vitro Approaches for Cancer Treatment. 2019 , 69-82	
1392	Immune checkpoint inhibitors for small cell lung cancer: opportunities and challenges. 2019 , 12, 4605-4620	14
1391	Oncolytic Viruses: Priming Time for Cancer Immunotherapy. 2019 , 33, 485-501	52
1390	Mesoporous Silica Nanoparticles Doped with Gold Nanoparticles for Combined Cancer Immunotherapy and Photothermal Therapy.. 2019 , 2, 3630-3638	22
1389	Landscape of transcriptomic interactions between breast cancer and its microenvironment. 2019 , 10, 3116	12
1388	Tumor-Infiltrating Lymphocyte Volume Is a Better Predictor of Disease-Free Survival Than Stromal Tumor-Infiltrating Lymphocytes in Invasive Breast Carcinoma. 2019 , 152, 656-665	6
1387	Isoform-specific gene disruptions reveal a role for the V-ATPase subunit a4 isoform in the invasiveness of 4T1-12B breast cancer cells. 2019 , 294, 11248-11258	16
1386	Synthesized natural peptides from amphibian skin secretions increase the efficacy of a therapeutic vaccine by recruiting more T cells to the tumour site. 2019 , 19, 163	10
1385	NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. 2019 , 10, 3251	26
1384	Stealth surface driven accumulation of Trojan Horse for tumor hypoxia relief in combination with targeted cancer therapy. 2019 , 378, 122252	17
1383	Genomics-Guided Immunotherapy for Precision Medicine in Cancer. 2019 , 34, 487-497	15

1382	Computational approaches for characterizing the tumor immune microenvironment. 2019 , 158, 70-84	15
1381	Engineering nanoparticles to locally activate T cells in the tumor microenvironment. 2019 , 4,	115
1380	Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer. 2019 , 5, 131-145	3
1379	IL-9-producing CD8 T cells represent a distinctive subset with different transcriptional characteristics from conventional CD8 T cells, and partially infiltrate breast tumors. 2019 , 115, 105576	4
1378	MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer. 2019 , 79, 5812-5825	3
1377	Inflammasome inhibitors: promising therapeutic approaches against cancer. 2019 , 12, 64	40
1376	Cancer Immunoediting and Hijacking of the Immune System. 2019 , 117-139	
1375	IL-9 Exerts Antitumor Effects in Colon Cancer and Transforms the Tumor Microenvironment. 2019 , 18, 1533033819857737	12
1374	Evolving neoantigen profiles in colorectal cancers with DNA repair defects. 2019 , 11, 42	19
1373	Phase Ib study of the combination of pexidartinib (PLX3397), a CSF-1R inhibitor, and paclitaxel in patients with advanced solid tumors. 2019 , 11, 1758835919854238	48
1372	Dietary Flavonoids for Immunoregulation and Cancer: Food Design for Targeting Disease. 2019 , 8,	40
1371	Gastric cancer patients display a distinctive population of IFN γ IL10 double positive CD8 T cells, which persists longer during prolonged activation. 2019 , 382, 111487	4
1370	Selective targeting of tumor cells and tumor associated macrophages separately by twin-like core-shell nanoparticles for enhanced tumor-localized chemoimmunotherapy. 2019 , 11, 13934-13946	50
1369	Immunosuppressive checkpoint Siglec-15: a vital new piece of the cancer immunotherapy jigsaw puzzle. 2019 , 16, 205-210	13
1368	Nano-engineered lymphocytes for alleviating suppressive tumor immune microenvironment. 2019 , 16, 273-279	4
1367	Contribution of Fc γ Receptor IIB to creating a suppressive tumor microenvironment in a mouse model. 2019 , 68, 1769-1778	1
1366	The Clinicopathological and Prognostic Value of PD-L1 Expression in Cholangiocarcinoma: A Meta-Analysis. 2019 , 9, 897	18
1365	ADP secreted by dying melanoma cells mediates chemotaxis and chemokine secretion of macrophages via the purinergic receptor P2Y12. 2019 , 10, 760	10

- 1364 WNT/ β Catenin Signaling Pathway Regulating T Cell-Inflammation in the Tumor Microenvironment. **2019**, 10, 2293 76
- 1363 Development of a Physiologically-Based Mathematical Model for Quantifying Nanoparticle Distribution in Tumors. **2019**, 2019, 2852-2855 1
- 1362 Characterization of intratumoral and circulating IL-10-producing B cells in gastric cancer. **2019**, 384, 111652 12
- 1361 Identification and Analyses of Extra-Cranial and Cranial Rhabdoid Tumor Molecular Subgroups Reveal Tumors with Cytotoxic T Cell Infiltration. **2019**, 29, 2338-2354.e7 40
- 1360 Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope. **2019**, 68, 1901-1907 3
- 1359 Advances in Engineering Cells for Cancer Immunotherapy. **2019**, 9, 7889-7905 29
- 1358 Nanoformulated Codelivery of Quercetin and Alantolactone Promotes an Antitumor Response through Synergistic Immunogenic Cell Death for Microsatellite-Stable Colorectal Cancer. **2019**, 13, 12511-12524⁵⁰
- 1357 STING activation in cancer immunotherapy. **2019**, 9, 7759-7771 86
- 1356 Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor Immunogenicity. **2019**, 29, 1236-1248.e7 91
- 1355 IFN- γ Down-regulates the PD-1 expression and assist nivolumab in PD-1-blockade effect on CD8+ T-lymphocytes in pancreatic cancer. **2019**, 19, 1053 18
- 1354 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019): part 1 : National Harbor, MD, USA. 6-10 November 2019. **2019**, 7, 282 21
- 1353 Functionalization Of T Lymphocytes With Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles For Magnetically Controlled Immune Therapy. **2019**, 14, 8421-8432 17
- 1352 Lipid droplet-dependent fatty acid metabolism controls the immune suppressive phenotype of tumor-associated macrophages. **2019**, 11, e10698 75
- 1351 Mikrobiom und Immuntherapien bei Tumorerkrankungen. **2019**, 14, 426-432
- 1350 Tissue-Specific Immunity in Homeostasis and Diseases. **2019**, 2019, 7616509 2
- 1349 Rectifying characteristics and solar-blind photoresponse in β Ga₂O₃/ZnO heterojunctions. **2019**, 28, 088503 3
- 1348 IL-36 β Promotes CD8 T Cell Activation and Antitumor Immune Responses by Activating mTORC1. **2019**, 10, 1803 12
- 1347 Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment. **2019**, 59, 236-250 79

1346	A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8 T-cell response and effective tumor control. 2019 , 10, 3874	71
1345	Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function. 2019 , 20,	29
1344	High expression of CD47 in triple negative breast cancer is associated with epithelial-mesenchymal transition and poor prognosis. 2019 , 18, 3249-3255	22
1343	Notch and breast cancer metastasis: Current knowledge, new sights and targeted therapy. 2019 , 18, 2743-2755	15
1342	E2 ubiquitin-conjugating enzymes in cancer: Implications for immunotherapeutic interventions. 2019 , 498, 126-134	19
1341	Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma. 2019 , 136, 57-64	6
1340	Future of cancer immunotherapy using plant virus-based nanoparticles. 2019 , 5, FSO401	19
1339	Hypoxia as a barrier to immunotherapy in pancreatic adenocarcinoma. 2019 , 8, 10	86
1338	Hepatobiliary surgeons meet immunologists: the case of colorectal liver metastases patients. 2019 , 8, 370-377	2
1337	New therapeutic targets for cancer: the interplay between immune and metabolic checkpoints and gut microbiota. 2019 , 8, 23	11
1336	Cancer invasion regulates vascular complexity in a three-dimensional biomimetic model. 2019 , 119, 179-193	18
1335	TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Anti-PD-1 Therapy in Melanoma. 2019 , 7, 1672-1686	40
1334	Emerging Roles for G-protein Coupled Receptors in Development and Activation of Macrophages. 2019 , 10, 2031	11
1333	Neutrophil Extracellular Traps Drive Mitochondrial Homeostasis in Tumors to Augment Growth. 2019 , 79, 5626-5639	52
1332	Cerenkov Luminescence-Induced NO Release from 32P-Labeled ZnFe(CN)5NO Nanosheets to Enhance Radioisotope-Immunotherapy. 2019 , 1, 1061-1076	43
1331	Combined high expression of CD47 and CD68 is a novel prognostic factor for breast cancer patients. 2019 , 19, 238	12
1330	Repolarization of M2 to M1 Macrophages Triggered by Lactate Oxidase Released from Methylcellulose Hydrogel. 2019 , 30, 2697-2702	16
1329	Traditional Chinese Medicine and regulatory roles on epithelial-mesenchymal transitions. 2019 , 14, 34	9

1328	Spontaneous regression of occult breast cancer with axillary lymph node metastasis: A case report. 2019 , 63, 75-79	5
1327	Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix. 2019 , 121, 837-845	56
1326	(PG2) Enhances the M1 Polarization of Macrophages, Functional Maturation of Dendritic Cells, and T Cell-Mediated Anticancer Immune Responses in Patients with Lung Cancer. 2019 , 11,	36
1325	Near-Infrared II Phototherapy Induces Deep Tissue Immunogenic Cell Death and Potentiates Cancer Immunotherapy. 2019 , 13, 11967-11980	135
1324	CAR exosomes derived from effector CAR-T cells have potent antitumour effects and low toxicity. 2019 , 10, 4355	127
1323	Tumor microenvironment and stroma in intestinal adenocarcinomas and associated metastases in Atlantic salmon broodfish (<i>Salmo salar</i>). 2019 , 214, 109891	6
1322	A review on the role of M2 macrophages in bladder cancer; pathophysiology and targeting. 2019 , 76, 105880	24
1321	Trends and Challenges in Tumor Anti-Angiogenic Therapies. 2019 , 8,	78
1320	Mast cells as protectors of health. 2019 , 144, S4-S18	54
1319	Cold Tumors: A Therapeutic Challenge for Immunotherapy. 2019 , 10, 168	338
1318	The Prognostic and Therapeutic Value of PD-L1 in Glioma. 2018 , 9, 1503	52
1317	Preoperative circulating platelet, neutrophil, and lymphocyte counts predict survival in oral cancer. 2019 , 25, 1057-1066	13
1316	Chaperokine Activity of Heat Shock Proteins. 2019 ,	1
1315	RNA-Seq transcriptome analysis shows anti-tumor actions of melatonin in a breast cancer xenograft model. 2019 , 9, 966	15
1314	Multiscale Agent-Based and Hybrid Modeling of the Tumor Immune Microenvironment. 2019 , 7,	61
1313	Semaphorin Signaling in Cancer-Associated Inflammation. 2019 , 20,	18
1312	Multispectral Fluorescence Imaging Allows for Distinctive Topographic Assessment and Subclassification of Tumor-Infiltrating and Surrounding Immune Cells. 2019 , 1913, 13-31	9
1311	Monitoring checkpoint inhibitors: predictive biomarkers in immunotherapy. 2019 , 13, 32-44	20

1310	Exercise-Induced Chaperokine Activity of Hsp70: Possible Role in Chronic Diseases. 2019 , 193-209	1
1309	Saikosaponin A Inhibits Breast Cancer by Regulating Th1/Th2 Balance. 2019 , 10, 624	39
1308	Quantifying Cancer Epithelial-Mesenchymal Plasticity and its Association with Stemness and Immune Response. 2019 , 8,	41
1307	Mikrobiom und Immuntherapien bei Tumorerkrankungen. 2019 , 14, 185-189	
1306	Controlled Delivery of Nitric Oxide for Cancer Therapy. 2019 , 7, 279-303	28
1305	Functional T cell activation by smart nanosystems for effective cancer immunotherapy. 2019 , 27, 28-47	25
1304	Highly luminescent Zn-Cu-In-S/ZnS core/gradient shell quantum dots prepared from indium sulfide by cation exchange for cell labeling and polymer composites. 2019 , 30, 395603	11
1303	Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation. 2019 , 25, 6392-6405	22
1302	Advances in cancer immunotherapy 2019 - latest trends. 2019 , 38, 268	250
1301	CRISPR/Cas9 guided genome and epigenome engineering and its therapeutic applications in immune mediated diseases. 2019 , 96, 32-43	8
1300	Lung adenocarcinoma-intrinsic GBE1 signaling inhibits anti-tumor immunity. 2019 , 18, 108	24
1299	DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. 2019 , 2019, 4325105	11
1298	Assessing the interactions between radiotherapy and antitumour immunity. 2019 , 16, 729-745	95
1297	Blockade of TGF- β signaling: a potential target for cancer immunotherapy?. 2019 , 23, 679-693	27
1296	Molecular and Cell Biology of Cancer. 2019 ,	1
1295	Crosstalk Between Prostate Cancer Stem Cells and Immune Cells: Implications for Tumor Progression and Resistance to Immunotherapy. 2019 , 173-221	1
1294	LIF regulates CXCL9 in tumor-associated macrophages and prevents CD8 T cell tumor-infiltration impairing anti-PD1 therapy. 2019 , 10, 2416	64
1293	A lipid-soluble extract of <i>Pinellia pedatisecta</i> Schott enhances antitumor T cell responses by restoring tumor-associated dendritic cell activation and maturation. 2019 , 241, 111980	9

1292	Generation of monocyte-derived tumor-associated macrophages using tumor-conditioned media provides a novel method to study tumor-associated macrophages in vitro. 2019 , 7, 140	54
1291	Prognostic value of B cells in cutaneous melanoma. 2019 , 11, 36	46
1290	Exosome-mediated communication in the tumor microenvironment contributes to hepatocellular carcinoma development and progression. 2019 , 12, 53	79
1289	Cellular determinants and therapeutic implications of inflammation in pancreatic cancer. 2019 , 201, 202-213	29
1288	Graft-Versus-Tumor Effect in Major Histocompatibility Complex-Mismatched Mouse Liver Transplantation. 2019 , 25, 1251-1264	1
1287	Cancer Stem Cell Resistance to Targeted Therapy. 2019 ,	1
1286	Tumour-associated neutrophils in patients with cancer. 2019 , 16, 601-620	268
1285	A β 1,3/1,6-glucan from <i>Durvillaea Antarctica</i> inhibits tumor progression in vivo as an immune stimulator. 2019 , 222, 114993	12
1284	Chitosan/poly(β -glutamic acid) nanoparticles incorporating IFN- γ for immune response modulation in the context of colorectal cancer. 2019 , 7, 3386-3403	21
1283	Tumor Lymphatic Function Regulates Tumor Inflammatory and Immunosuppressive Microenvironments. 2019 , 7, 1345-1358	11
1282	ROR γ Agonists Enhance the Sustained Antitumor Activity through Intrinsic Tc17 Cytotoxicity and Tc1 Recruitment. 2019 , 7, 1054-1063	4
1281	Disrupted regulation of serpinB9 in circulating T cells is associated with an increased risk for post-transplant skin cancer. 2019 , 197, 341-351	8
1280	Dual-Ligand Modification of PEGylated Liposomes Used for Targeted Doxorubicin Delivery to Enhance Anticancer Efficacy. 2019 , 20, 188	16
1279	Integrated cancer tissue engineering models for precision medicine. 2019 , 14, e0216564	43
1278	Macrophages in Colorectal Cancer Liver Metastases. 2019 , 11,	25
1277	Biohybrid Vaccines for Improved Treatment of Aggressive Melanoma with Checkpoint Inhibitor. 2019 , 13, 6477-6490	29
1276	Mechanisms of Resistance to Immune Checkpoint Blockade: Why Does Checkpoint Inhibitor Immunotherapy Not Work for All Patients?. 2019 , 39, 147-164	248
1275	5-Hydroxytryptamine $1a$ receptors on tumour cells induce immune evasion in lung adenocarcinoma patients with depression via autophagy/pSTAT3. 2019 , 114, 8-24	15

1274	A Metabolism Toolbox for CAR T Therapy. 2019 , 9, 322	25
1273	Myeloid cell-derived LL-37 promotes lung cancer growth by activating Wnt/ β -catenin signaling. 2019 , 9, 2209-2223	19
1272	Tumor mechanisms of resistance to immune attack. 2019 , 164, 61-100	8
1271	Low CD8+ T Cell Infiltration and High PD-L1 Expression Are Associated with Level of CD44+/CD133+ Cancer Stem Cells and Predict an Unfavorable Prognosis in Pancreatic Cancer. 2019 , 11,	55
1270	Facing the future: challenges and opportunities in adoptive T cell therapy in cancer. 2019 , 19, 811-827	15
1269	Engineering Magnetosomes for Ferroptosis/Immunomodulation Synergism in Cancer. 2019 , 13, 5662-5673	137
1268	Cell Counts, rather than Proportion, of CD8/PD-1 Tumor-Infiltrating Lymphocytes in a Tumor Microenvironment Associated with Pathological Characteristics of Chinese Invasive Ductal Breast Cancer. 2019 , 2019, 8505021	6
1267	Targeted TCR Amplification from Single-Cell cDNA Libraries. 2019 , 1979, 197-224	
1266	Self-evolved hydrogen peroxide boosts photothermal-promoted tumor-specific nanocatalytic therapy. 2019 , 7, 3599-3609	33
1265	Double Positive CD4CD8 T Cells Are Enriched in Urological Cancers and Favor T Helper-2 Polarization. 2019 , 10, 622	26
1264	Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma. 2019 , 20,	41
1263	Single Cell Methods. 2019 ,	2
1262	Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy. 2019 , 10, 698	32
1261	The Role of the Immune System in Cutaneous Squamous Cell Carcinoma. 2019 , 20,	48
1260	ER stress-induced mediator C/EBP homologous protein thwarts effector T cell activity in tumors through T-bet repression. 2019 , 10, 1280	42
1259	Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade. 2019 , 68, 1653-1666	119
1258	Nanovaccine based on a protein-delivering dendrimer for effective antigen cross-presentation and cancer immunotherapy. 2019 , 207, 1-9	79
1257	Novel immunotherapeutic approaches for hepatocellular carcinoma treatment. 2019 , 12, 453-470	17

1256	gene alterations identify a subset of diffuse large B-cell lymphoma harboring a T-cell-inflamed phenotype. 2019 , 133, 2279-2290	57
1255	Analysis of the Interaction and Proliferative Activity of Adenocarcinoma, Peripheral Blood Mononuclear and Mesenchymal Stromal Cells after Co-Cultivation In Vitro. 2019 , 9, 502-509	7
1254	A microparticle platform for STING-targeted immunotherapy enhances natural killer cell- and CD8 T cell-mediated anti-tumor immunity. 2019 , 205, 94-105	42
1253	Immunotherapy in colorectal cancer: rationale, challenges and potential. 2019 , 16, 361-375	427
1252	Profiling of gallbladder carcinoma reveals distinct miRNA profiles and activation of STAT1 by the tumor suppressive miRNA-145-5p. 2019 , 9, 4796	15
1251	Diverging inflammasome signals in tumorigenesis and potential targeting. 2019 , 19, 197-214	214
1250	Genomic correlates of response to immune checkpoint blockade. 2019 , 25, 389-402	218
1249	Anticancer potential of naturally occurring immunoepigenetic modulators: A promising avenue?. 2019 , 125, 1612-1628	14
1248	Oxygen in the tumor microenvironment: effects on dendritic cell function. 2019 , 10, 883-896	29
1247	Exosomes in the tumor microenvironment as mediators of cancer therapy resistance. 2019 , 18, 32	166
1246	Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy. 2019 , 25, 656-666	235
1245	Gut microbiota: implications for radiotherapy response and radiotherapy-induced mucositis. 2019 , 13, 485-496	24
1244	Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma. 2019 , 9, 122	41
1243	Chemoresistance mechanisms of breast cancer and their countermeasures. 2019 , 114, 108800	99
1242	Presence of innate lymphoid cells in pleural effusions of primary and metastatic tumors: Functional analysis and expression of PD-1 receptor. 2019 , 145, 1660-1668	45
1241	Pharmacological Modulation of the STING Pathway for Cancer Immunotherapy. 2019 , 25, 412-427	37
1240	An immunosuppressive macrophage profile attenuates the prognostic impact of CD20-positive B cells in human soft tissue sarcoma. 2019 , 68, 927-936	16
1239	Immune Modulation in HLA-G Expressing Head and Neck Squamous Cell Carcinoma in Relation to Human Papilloma Virus Positivity: A Study From Northeast India. 2019 , 9, 58	8

1238	Tailoring Nanomaterials for Targeting Tumor-Associated Macrophages. 2019 , 31, e1808303	135
1237	Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. 2019 , 25, 814-824	188
1236	Complete Blood Count Score Model Integrating Reduced Lymphocyte-Monocyte Ratio, Elevated Neutrophil-Lymphocyte Ratio, and Elevated Platelet-Lymphocyte Ratio Predicts Inferior Clinical Outcomes in Adult T-Lymphoblastic Lymphoma. 2019 , 24, e1123-e1131	16
1235	Improved antitumor activity of cisplatin combined with Ganoderma lucidum polysaccharides in U14 cervical carcinoma-bearing mice. 2019 , 35, 222-229	10
1234	Autophagy as a molecular target for cancer treatment. 2019 , 134, 116-137	113
1233	IL-33 drives the antitumour effects of dendritic cells via upregulating CYLD expression in pulmonary adenocarcinoma. 2019 , 47, 1335-1341	4
1232	A Tumor-Peptide-Based Nanoparticle Vaccine Elicits Efficient Tumor Growth Control in Antitumor Immunotherapy. 2019 , 18, 1069-1080	19
1231	Clinicopathologic and prognostic significance of tumor-infiltrating CD8+ T cells in patients with hepatocellular carcinoma: A meta-analysis. 2019 , 98, e13923	32
1230	The extracellular matrix in tumor progression and metastasis. 2019 , 36, 171-198	192
1229	High Adherence to Surveillance Guidelines in Inflammatory Bowel Disease Patients Results in Low Colorectal Cancer and Dysplasia Rates, While Rates of Dysplasia are Low Before the Suggested Onset of Surveillance. 2019 , 13, 1343-1350	4
1228	Downregulation of A2AR by siRNA loaded PEG-chitosan-lactate nanoparticles restores the T cell mediated anti-tumor responses through blockage of PKA/CREB signaling pathway. 2019 , 133, 436-445	46
1227	Activating cGAS-STING pathway for the optimal effect of cancer immunotherapy. 2019 , 12, 35	98
1226	Precision immunomodulation with synthetic nucleic acid technologies. 2019 , 4, 451-458	19
1225	Induction of human pluripotent stem cell-derived natural killer cells for immunotherapy under chemically defined conditions. 2019 , 515, 1-8	16
1224	Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer. 2019 , 10, 1158-1166	12
1223	Molecular pathogenic pathways in extranodal NK/T cell lymphoma. 2019 , 12, 33	43
1222	Building Potent Chimeric Antigen Receptor T Cells With CRISPR Genome Editing. 2019 , 10, 456	43
1221	Perspectives on immunotherapy via oncolytic viruses. 2019 , 14, 5	13

1220	Mouse-Derived Isograft (MDI) In Vivo Tumor Models I. Spontaneous sMDI Models: Characterization and Cancer Therapeutic Approaches. 2019 , 11,	2
1219	Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. 2019 , 8, e1801320	25
1218	Cellular immunotherapy for acute myeloid leukemia: How specific should it be?. 2019 , 35, 18-31	12
1217	Alteration of Adaptive Immunity in a Colorectal Peritoneal Carcinomatosis Model. 2019 , 10, 367-377	5
1216	Tumor Suppressor miRNA-204-5p Regulates Growth, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer. 2019 , 79, 1520-1534	83
1215	Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment. 2018 , 9, 3154	52
1214	Nanoengineered Immune Niches for Reprogramming the Immunosuppressive Tumor Microenvironment and Enhancing Cancer Immunotherapy. 2019 , 31, e1803322	107
1213	Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment. 2019 , 9, 10	26
1212	High BIN1 expression has a favorable prognosis in malignant pleural mesothelioma and is associated with tumor infiltrating lymphocytes. 2019 , 130, 35-41	15
1211	Prognostic Value of Macrophage Phenotypes in Resectable Non-Small Cell Lung Cancer Assessed by Multiplex Immunohistochemistry. 2019 , 21, 282-293	64
1210	Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8 T-cell Response against Immunosuppressive Tumors. 2019 , 25, 3289-3303	35
1209	Neuropilins in the Context of Tumor Vasculature. 2019 , 20,	37
1208	Macrophage ERP promoted invasion of endometrial cancer cell by mTOR/KIF5B-mediated epithelial to mesenchymal transition. 2019 , 97, 563-576	31
1207	Regulation of autophagy as a therapy for immunosenescence-driven cancer and neurodegenerative diseases: The role of exercise. 2019 , 234, 14883	11
1206	Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape. 2019 , 8, e1568809	15
1205	The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer. 2019 , 11,	35
1204	The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy. 2019 , 129, 3347-3360	44
1203	The efficacy of third generation anti-HER2 chimeric antigen receptor T'cells in combination with PD1 blockade against malignant glioblastoma cells. 2019 , 42, 1549-1557	19

1202	Mismatch Repair Status of Gastric Cancer and Its Association with the Local and Systemic Immune Response. 2019 , 24, e835-e844	8
1201	Targeting of the Cancer-Associated Fibroblast-T-Cell Axis in Solid Malignancies. 2019 , 8,	27
1200	The prognostic impact of traditional Chinese medicine monomers on tumor-associated macrophages in non-small cell lung cancer. 2019 , 17, 729-737	10
1199	ADAPTS: Automated deconvolution augmentation of profiles for tissue specific cells. 2019 , 14, e0224693	7
1198	Dual functions of angiopoietin-like protein 2 signaling in tumor progression and anti-tumor immunity. 2019 , 33, 1641-1656	3
1197	Companion Animals as Models for Inhibition of STAT3 and STAT5. 2019 , 11,	1
1196	Enhanced Anti-melanoma Efficacy of a Pim-3-Targeting Bifunctional Small Hairpin RNA via Single-Stranded RNA-Mediated Activation of Plasmacytoid Dendritic Cells. 2019 , 10, 2721	6
1195	Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment. 2019 , 12, 125	51
1194	Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery. 2019 , 7, 328	20
1193	An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma. 2019 , 10, 5440	28
1192	Single-Cell Profiling Defines Transcriptomic Signatures Specific to Tumor-Reactive versus Virus-Responsive CD4 T Cells. 2019 , 29, 3019-3032.e6	25
1191	Bioactive Compounds: Natural Defense Against Cancer?. 2019 , 9,	51
1190	Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins. 2019 , 8, CNS38	2
1189	CD4 and CD8a PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models. 2019 , 9, 8221-8238	27
1188	Combined Expression of Genetic Adjuvants Via mRNA Electroporation Exerts Multiple Immunostimulatory Effects on Antitumor T Cells. 2019 , 42, 43-50	4
1187	The reciprocal regulation between host tissue and immune cells in pancreatic ductal adenocarcinoma: new insights and therapeutic implications. 2019 , 18, 184	29
1186	Blocking CD47 efficiently potentiated therapeutic effects of anti-angiogenic therapy in non-small cell lung cancer. 2019 , 7, 346	22
1185	Expression of Bioactive Chemerin by Keratinocytes Inhibits Late Stages of Tumor Development in a Chemical Model of Skin Carcinogenesis. 2019 , 9, 1253	6

1184	An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis. 2019 ,	4
1183	A Theranostic Nanoprobe for Hypoxia Imaging and Photodynamic Tumor Therapy. 2019 , 7, 868	4
1182	The Aged Microenvironment Influences the Tumorigenic Potential of Malignant Prostate Epithelial Cells. 2019 , 17, 321-331	19
1181	Immune Checkpoints. 2019 , 19-43	
1180	Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?. 2018 , 20,	46
1179	Rho-ROCK signaling regulates tumor-microenvironment interactions. 2019 , 47, 101-108	20
1178	Organ-on-a-Chip for Cancer and Immune Organs Modeling. 2019 , 8, e1801363	71
1177	Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. 2019 , 18, 197-218	981
1176	Nondestructive, multiplex three-dimensional mapping of immune infiltrates in core needle biopsy. 2019 , 99, 1400-1413	9
1175	Functional Nanomaterials Optimized to Circumvent Tumor Immunological Tolerance. 2019 , 29, 1806087	14
1174	Nanocatalytic Tumor Therapy by Biomimetic Dual Inorganic Nanozyme-Catalyzed Cascade Reaction. 2019 , 6, 1801733	250
1173	Knockdown of FOXP1 promotes the development of lung adenocarcinoma. 2019 , 20, 537-545	9
1172	Protease-activated receptor-1 impedes prostate and intestinal tumor progression in mice: comment. 2019 , 17, 235-238	3
1171	Immunological and Genetic Biomarkers of Sarcomas: Implication for Future Treatment Strategies. 2019 , 591-608	
1170	Intratatumoral IL17-producing cells infiltration correlate with antitumor immune contexture and improved response to adjuvant chemotherapy in gastric cancer. 2019 , 30, 266-273	31
1169	PHA eludes macrophage suppression to activate CD8 T cells. 2019 , 224, 94-101	4
1168	Galectins as potential emerging key targets in different types of leukemia. 2019 , 844, 73-78	3
1167	New insights into the mechanisms of epithelial-mesenchymal transition and implications for cancer. 2019 , 20, 69-84	1131

1166	Meta-Analysis for Correlating Structure of Bioactive Peptides in Foods of Animal Origin with Regard to Effect and Stability. 2019 , 18, 3-30	26
1165	WNT/ β -catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. 2019 , 25, 3074-3083	253
1164	Bioprinting of 3D breast epithelial spheroids for human cancer models. 2019 , 11, 025003	56
1163	Integrating histopathology, immune biomarkers, and molecular subgroups in solid cancer: the next step in precision oncology. 2019 , 474, 463-474	12
1162	Validation of Melanoma Immune Profile (MIP), a Prognostic Immune Gene Prediction Score for Stage II-III Melanoma. 2019 , 25, 2494-2502	13
1161	Comparing the effects of different cell death programs in tumor progression and immunotherapy. 2019 , 26, 115-129	46
1160	Increased tumour cell PD-L1 expression, macrophage and dendritic cell infiltration characterise the tumour microenvironment of ulcerated primary melanomas. 2019 , 33, 667-675	11
1159	The role of the hypoxia-Nrp-1 axis in the activation of M2-like tumor-associated macrophages in the tumor microenvironment of cervical cancer. 2019 , 58, 388-397	44
1158	Intratumoral infiltrating lymphocytes correlate with improved survival in colorectal cancer patients: Independent of oncogenetic features. 2019 , 234, 4768-4777	21
1157	Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. 2019 , 37, 1773-1784	14
1156	PTEN Hamartoma Tumor Syndrome and Immune Dysregulation. 2019 , 12, 361-367	24
1155	The lung microenvironment: an important regulator of tumour growth and metastasis. 2019 , 19, 9-31	347
1154	Immunotherapy of Sarcoma. 2019 ,	
1153	PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer. 2019 , 110, 312-318	134
1152	Combined intracavitary thermotherapy with iron oxide nanoparticles and radiotherapy as local treatment modality in recurrent glioblastoma patients. 2019 , 141, 83-94	60
1151	Mobile Microrobots for Active Therapeutic Delivery. 2019 , 2, 1800064	105
1150	Cancer Immunosurveillance by T Cells. 2019 , 342, 149-173	26
1149	T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma. 2019 , 104, 338-346	26

1148	Construction of integrated microRNA and mRNA immune cell signatures to predict survival of patients with breast and ovarian cancer. 2019 , 58, 34-42	8
1147	TRPM2 modulates neutrophil attraction to murine tumor cells by regulating CXCL2 expression. 2019 , 68, 33-43	22
1146	Beyond the vicious cycle: The role of innate osteoimmunity, automimicry and tumor-inherent changes in dictating bone metastasis. 2019 , 110, 57-68	17
1145	Molecular subtyping of cancer: current status and moving toward clinical applications. 2019 , 20, 572-584	35
1144	Addressing barriers to effective cancer immunotherapy with nanotechnology: achievements, challenges, and roadmap to the next generation of nanoimmunotherapeutics. 2019 , 141, 3-22	26
1143	Target-Specific Imaging of Cathepsin and S100A8/A9 Reflects Specific Features of Malignancy and Enables Estimation of Tumor Malignancy. 2020 , 22, 66-72	1
1142	Advancing Biomarker Development Through Convergent Engagement: Summary Report of the 2nd International Danube Symposium on Biomarker Development, Molecular Imaging and Applied Diagnostics; March 14-16, 2018; Vienna, Austria. 2020 , 22, 47-65	2
1141	Role of therapeutic agents on repolarisation of tumour-associated macrophage to halt lung cancer progression. 2020 , 28, 166-175	7
1140	Immunological and Clinicopathological Significance of MFG-E8 Expression in Patients with Oral Squamous Cell Carcinoma. 2020 , 26, 1263-1268	0
1139	Recent advancements in the study of breast cancer exosomes as mediators of intratumoral communication. 2020 , 235, 691-705	13
1138	New insight on the correlation of metabolic status on F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer. 2020 , 47, 1127-1136	26
1137	Metabolic targeting of HIF-1 α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer. 2020 , 39, 414-427	23
1136	A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. 2020 , 146, 1409-1420	11
1135	Establishment of humanized tumor microenvironment mouse models based on the injection of peripheral blood mononuclear cells and IFN- γ to evaluate the efficacy of PD-L1/PD-1-targeted immunotherapy. 2020 , 21, 130-138	4
1134	Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC). 2020 , 126, 260-270	89
1133	New Approaches on Cancer Immunotherapy. 2020 , 10,	4
1132	Novel Therapeutics for Rare Lymphomas. 2020 ,	0
1131	Immune Responses after Vascular Photodynamic Therapy with Redaporfin. 2019 , 9,	12

1130	Tumor Microenvironment. 2019 , 56,	224
1129	Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy. 2020 , 12, 413-436	27
1128	Photothermal therapy-induced immunogenic cell death based on natural melanin nanoparticles against breast cancer. 2020 , 56, 1389-1392	46
1127	Heat-killed Mycobacterium parafortdonae therapy exerts an anti-cancer immune response via enhanced immune cell mediated oncolytic activity in xenograft mice model. 2020 , 472, 142-150	6
1126	Immuno-Oncology. 2020 ,	1
1125	Modulation of SRSF2 expression reverses the exhaustion of TILs via the epigenetic regulation of immune checkpoint molecules. 2020 , 77, 3441-3452	11
1124	A Novel Antitumor Strategy: Simultaneously Inhibiting Angiogenesis and Complement by Targeting VEGFA/PIGF and C3b/C4b. 2020 , 16, 20-29	8
1123	Natural receptor-based competitive immunoelectrochemical assay for ultra-sensitive detection of Siglec 15. 2020 , 151, 111950	4
1122	Composition and plasticity of triple-negative breast carcinoma-infiltrating regulatory T cells. 2020 , 128, 260-269	3
1121	Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. 2020 , 14, 80-95	6
1120	Brain immunology and immunotherapy in brain tumours. 2020 , 20, 12-25	174
1119	Role of telomerase in the tumour microenvironment. 2020 , 47, 357-364	6
1118	Evolutionary Dynamics of Cooperation in the Public Goods Game with Individual Disguise and Peer Punishment. 2020 , 10, 764-782	11
1117	B7-H3 specific T cells with chimeric antigen receptor and decoy PD-1 receptors eradicate established solid human tumors in mouse models. 2020 , 9, 1684127	17
1116	Cell Reprogramming for Immunotherapy. 2020 ,	1
1115	Evaluation of awareness and understanding of cancer immunotherapy among healthcare professionals in eastern Saudi Arabia. 2020 , 26, 1343-1352	0
1114	Prognostic and Immunological Role of FUN14 Domain Containing 1 in Pan-Cancer: Friend or Foe?. 2019 , 9, 1502	16
1113	Overexpression of Mitochondrial IF1 Prevents Metastatic Disease of Colorectal Cancer by Enhancing Anoikis and Tumor Infiltration of NK Cells. 2019 , 12,	9

1112	LncRNA RP11-361F15.2 promotes osteosarcoma tumorigenesis by inhibiting M2-Like polarization of tumor-associated macrophages of CPEB4. 2020 , 473, 33-49	41
1111	Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. 2020 , 26, 1865-1877	12
1110	Role of the Cyclooxygenase Pathway in the Association of Obstructive Sleep Apnea and Cancer. 2020 , 9,	2
1109	Modulating the wayward T cell: New horizons with immune checkpoint inhibitor treatments in autoimmunity, transplant, and cancer. 2020 , 115, 102546	5
1108	Pretreatment peripheral neutrophils, lymphocytes and monocytes predict long-term survival in hepatocellular carcinoma. 2020 , 20, 937	6
1107	Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy. 2020 , 9,	35
1106	De novo colorectal cancer after liver and kidney transplantation: Microenvironment disturbance. 2020 , 5, 100057	1
1105	Autofluorescence Imaging of 3D Tumor-Macrophage Microscale Cultures Resolves Spatial and Temporal Dynamics of Macrophage Metabolism. 2020 , 80, 5408-5423	8
1104	Inhibition of CDC42 reduces macrophage recruitment and suppresses lung tumorigenesis in vivo. 2021 , 41, 504-510	5
1103	Colorectal Cancer Immunotherapy: Options and Strategies. 2020 , 11, 1624	52
1102	Identification of a prognostic gene signature based on an immunogenomic landscape analysis of bladder cancer. 2020 , 24, 13370-13382	9
1101	The Resistance Mechanisms of Lung Cancer Immunotherapy. 2020 , 10, 568059	14
1100	Tumor resistance mechanisms and their consequences on T cell activation. 2020 , 298, 84-98	12
1099	Arming HSV-Based Oncolytic Viruses with the Ability to Redirect the Host's Innate Antiviral Immunity to Attack Tumor Cells. 2020 , 19, 33-46	8
1098	Biomaterialized Bacterial Outer Membrane Vesicles Potentiate Safe and Efficient Tumor Microenvironment Reprogramming for Anticancer Therapy. 2020 , 32, e2002085	45
1097	Genomic, transcriptomic, and viral integration profiles associated with recurrent/metastatic progression in high-risk human papillomavirus cervical carcinomas. 2020 , 9, 8243-8257	1
1096	Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis. 2020 , 23, 101499	15
1095	Polymer-loaded hydrogels serve as depots for lactate and mimic "cold" tumor microenvironments. 2020 , 8, 6056-6068	5

1094	Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment. 2020 , 12,	29
1093	LAGE3 correlates with tumorigenic immune infiltrates in the clear cell renal cell carcinoma microenvironment. 2020 , 87, 106793	11
1092	Induction of Immune Response Against Metastatic Tumors via Vaccination of Mannan-BAM, TLR Ligands and Anti-CD40 Antibody (MBTA). 2020 , 3, 2000044	3
1091	Tumor-Derived Extracellular Vesicles and the Immune System-Lessons From Immune-Competent Mouse-Tumor Models. 2020 , 11, 606859	6
1090	Actors on the Scene: Immune Cells in the Myeloma Niche. 2020 , 10, 599098	21
1089	PD-1/PD-L1 expression profiles within intrahepatic cholangiocarcinoma predict clinical outcome. 2020 , 18, 303	9
1088	Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment. 2020 , 12,	0
1087	M2 Macrophages Mediate the Resistance of Gastric Adenocarcinoma Cells to 5-Fluorouracil through the Expression of Integrin 3, Focal Adhesion Kinase, and Cofilin. 2020 , 2020, 1731457	5
1086	Prognostic significance of the Controlling Nutritional Status (CONUT) score in surgically treated breast cancer patients. 2020 , 9, 1370-1379	5
1085	Extracellular MicroRNAs as Intercellular Mediators and Noninvasive Biomarkers of Cancer. 2020 , 12,	7
1084	The evolving landscape of predictive biomarkers in immuno-oncology with a focus on spatial technologies. 2020 , 9, e1215	9
1083	Hierarchical Clustering of Cutaneous Melanoma Based on Immunogenomic Profiling. 2020 , 10, 580029	3
1082	Heparanase and the hallmarks of cancer. 2020 , 18, 453	27
1081	IAP inhibitor, Embelin increases VCAM-1 levels on the endothelium, producing lymphocytic infiltration and antitumor immunity. 2020 , 9, 1838812	4
1080	Cell-Based Therapy Manufacturing in Stirred Suspension Bioreactor: Thoughts for cGMP Compliance. 2020 , 8, 599674	10
1079	Development of an Immunogenomic Landscape-Based Prognostic Index of Head and Neck Squamous Cell Carcinoma. 2020 , 7, 586344	2
1078	Mechanisms and Future of Non-Small Cell Lung Cancer Metastasis. 2020 , 10, 585284	13
1077	Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors. 2020 , 68, 36	11

1076	Biodegradable Fe-Doped Vanadium Disulfide Theranostic Nanosheets for Enhanced Sonodynamic/Chemodynamic Therapy. 2020 , 12, 52370-52382	31
1075	Why the Outcome of Anti-Tumor Immune Responses is Heterogeneous: A Novel Idea in the Context of Immunological Heterogeneity in Cancers. 2020 , 42, e2000024	4
1074	A five-immune-related genes-based prognostic signature for colorectal cancer. 2020 , 88, 106866	4
1073	Tumour sensitization via the extended intratumoural release of a STING agonist and camptothecin from a self-assembled hydrogel. 2020 , 4, 1090-1101	64
1072	Network Approaches for Dissecting the Immune System. 2020 , 23, 101354	11
1071	Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors. 2020 , 8, 672	55
1070	TOX correlates with prognosis, immune infiltration, and T cells exhaustion in lung adenocarcinoma. 2020 , 9, 6694-6709	11
1069	Immune Landscape of the Tumor Microenvironment Identifies Prognostic Gene Signature CD4/CD68/CSF1R in Osteosarcoma. 2020 , 10, 1198	17
1068	Emodin reduces Breast Cancer Lung Metastasis by suppressing Macrophage-induced Breast Cancer Cell Epithelial-mesenchymal transition and Cancer Stem Cell Formation. 2020 , 10, 8365-8381	25
1067	Deep learning-based image analysis methods for brightfield-acquired multiplex immunohistochemistry images. 2020 , 15, 100	17
1066	Engineering CAR-T Cells for Next-Generation Cancer Therapy. 2020 , 38, 473-488	115
1065	Leveraging Public Single-Cell and Bulk Transcriptomic Datasets to Delineate MAIT Cell Roles and Phenotypic Characteristics in Human Malignancies. 2020 , 11, 1691	14
1064	A nanoscale metal organic frameworks-based vaccine synergises with PD-1 blockade to potentiate anti-tumour immunity. 2020 , 11, 3858	24
1063	The impaired anti-tumoral effect of immune surveillance cells in the immune microenvironment of gastric cancer. 2020 , 219, 108551	3
1062	Immune signature of tumor-infiltrating immune cells predicts the prognosis and therapeutic effects in squamous cell carcinoma. 2020 , 87, 106802	5
1061	A brief review concerning Chimeric Antigen Receptors T cell therapy. 2020 , 11, 5424-5431	1
1060	Controlling TIME: How MNK Kinases Function to Shape Tumor Immunity. 2020 , 12,	3
1059	Coordinated Cellular Neighborhoods Orchestrate Antitumoral Immunity at the Colorectal Cancer Invasive Front. 2020 , 182, 1341-1359.e19	132

1058	Epigenetic Mechanisms of Resistance to Immune Checkpoint Inhibitors. 2020 , 10,	22
1057	A case of multiple metastatic gastric cancer with primary lesion vanished after administrating nivolumab, and the effect remains even after discontinuance of therapy. 2020 , 9, 187-192	1
1056	Personalized biomedicine in cancer: from traditional therapy to sustainable healthcare. 2020 , 441-457	
1055	Immune Escape After Adoptive T-cell Therapy for Malignant Gliomas. 2020 , 26, 5689-5700	7
1054	Multidirectional Strategies for Targeted Delivery of Oncolytic Viruses by Tumor Infiltrating Immune Cells. 2020 , 161, 105094	4
1053	Loss of survival advantage for deficient mismatch repair in patients with advanced colorectal cancer may be caused by changes in prognostic value of CD8+T cell. 2020 , 18, 196	2
1052	Research Progress and Existing Problems for Abscopal Effect. 2020 , 12, 6695-6706	3
1051	CD52 Is a Prognostic Biomarker and Associated With Tumor Microenvironment in Breast Cancer. 2020 , 11, 578002	11
1050	Cancer-Associated Fibroblasts: Understanding Their Heterogeneity. 2020 , 12,	29
1049	Tumor-Associated Neutrophils and Macrophages-Heterogenous but Not Chaotic. 2020 , 11, 553967	15
1048	Clonal tracing reveals diverse patterns of response to immune checkpoint blockade. 2020 , 21, 263	7
1047	High Abundance of Intratumoral Γ Cells Favors a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis. 2020 , 11, 573920	5
1046	Cell-mediated targeting drugs delivery systems. 2020 , 27, 1425-1437	20
1045	NFE2L2 Is a Potential Prognostic Biomarker and Is Correlated with Immune Infiltration in Brain Lower Grade Glioma: A Pan-Cancer Analysis. 2020 , 2020, 3580719	29
1044	Higher cytolytic score correlates with an immunosuppressive tumor microenvironment and reduced survival in glioblastoma. 2020 , 10, 17580	10
1043	Phase Ib study of anti-CSF-1R antibody emactuzumab in combination with CD40 agonist selicrelumab in advanced solid tumor patients. 2020 , 8,	19
1042	Synergizing sunitinib and radiofrequency ablation to treat hepatocellular cancer by triggering the antitumor immune response. 2020 , 8,	14
1041	Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy. 2020 , 12,	12

1040	Resident Memory T Cells in the Tumor Microenvironment. 2020 , 1273, 39-68	1
1039	Unfolding innate mechanisms in the cancer microenvironment: The emerging role of the mesenchyme. 2020 , 217,	6
1038	Immunogenic chemotherapy in two mouse colon cancer models. 2020 , 111, 3527-3539	5
1037	The MDM2 ligand Nutlin-3 differentially alters expression of the immune blockade receptors PD-L1 and CD276. 2020 , 25, 41	9
1036	LINC00973 is involved in cancer immune suppression through positive regulation of Siglec-15 in clear-cell renal cell carcinoma. 2020 , 111, 3693-3704	10
1035	pH-Channelling in Cancer: How pH-Dependence of Cation Channels Shapes Cancer Pathophysiology. 2020 , 12,	12
1034	The Macrophages-Microbiota Interplay in Colorectal Cancer (CRC)-Related Inflammation: Prognostic and Therapeutic Significance. 2020 , 21,	9
1033	Targeting Molecular Mechanisms Underlying Treatment Efficacy and Resistance in Osteosarcoma: A Review of Current and Future Strategies. 2020 , 21,	51
1032	Identification of microRNAs Targeting the Transporter Associated with Antigen Processing TAP1 in Melanoma. 2020 , 9,	11
1031	Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma. 2020 , 9, 7646-7662	9
1030	Analyzing and validating the prognostic value and mechanism of colon cancer immune microenvironment. 2020 , 18, 324	19
1029	Metformin and cancer immunity. 2020 , 41, 1403-1409	15
1028	A Novel Epitope Quality-Based Immune Escape Mechanism Reveals Patient's Suitability for Immune Checkpoint Inhibition. 2020 , 12, 7881-7890	2
1027	Tumor Immune Microenvironments (TIMEs): Responsive Nanoplatfoms for Antitumor Immunotherapy. 2020 , 8, 804	4
1026	Prognostic value of tertiary lymphoid structure and tumour infiltrating lymphocytes in oral squamous cell carcinoma. 2020 , 12, 24	23
1025	Small but Fierce: Tracking the Role of Extracellular Vesicles in Glioblastoma Progression and Therapeutic Resistance. 2020 , 4, e2000035	1
1024	TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals. 2020 , 11, 1689	27
1023	Intratumoral Adipocyte-High Breast Cancer Enrich for Metastatic and Inflammation-Related Pathways but Associated with Less Cancer Cell Proliferation. 2020 , 21,	27

1022	Like a Rolling Stone: Sting-Cgas Pathway and Cell-Free DNA as Biomarkers for Combinatorial Immunotherapy. 2020 , 12,	4
1021	Nanoscale Metal-Organic Frameworks for Cancer Immunotherapy. 2020 , 53, 1739-1748	53
1020	Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation: Toward Practical Guidelines and Standardization. 2020 , 8, 454	3
1019	Dynamic control of tumor vasculature improves antitumor responses in a regional model of melanoma. 2020 , 10, 13245	2
1018	Immune Checkpoint Inhibitors in pMMR Metastatic Colorectal Cancer: A Tough Challenge. 2020 , 12,	17
1017	CD8+ T-cell lymphocytes infiltration predict clinical outcomes in Wilms' tumor. 2020 , 42, 1010428320975976	5
1016	Intravenous injection of the oncolytic virus M1 awakens antitumor T cells and overcomes resistance to checkpoint blockade. 2020 , 11, 1062	15
1015	Patient-Derived Xenograft and Organoid Models for Precision Medicine Targeting of the Tumour Microenvironment in Head and Neck Cancer. 2020 , 12,	7
1014	The Construction and Analysis of Tumor-Infiltrating Immune Cells and ceRNA Networks in Bladder Cancer. 2020 , 11, 605767	4
1013	Identification and Development of a Novel 4-Gene Immune-Related Signature to Predict Osteosarcoma Prognosis. 2020 , 7, 608368	10
1012	How Repair-or-Dispose Decisions Under Stress Can Initiate Disease Progression. 2020 , 23, 101701	0
1011	Unveiling the immune infiltrate modulation in cancer and response to immunotherapy by MIXTURE-an enhanced deconvolution method. 2021 , 22,	3
1010	Emerging nanomedicines for effective breast cancer immunotherapy. 2020 , 18, 180	19
1009	Chemotherapy-induced changes in bronchoalveolar lavage fluid CD4 + and CD8 + cells of the opposite lung to the cancer. 2020 , 10, 19927	1
1008	Liposome-Based Drug Delivery Systems in Cancer Immunotherapy. 2020 , 12,	24
1007	Interrogating the microenvironmental landscape of tumors with computational image analysis approaches. 2020 , 48, 101411	0
1006	The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment. 2020 , 11, 568931	17
1005	Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation. 2020 , 9, 1737385	10

1004	Using apelin-based synthetic Notch receptors to detect angiogenesis and treat solid tumors. 2020 , 11, 2163	10
1003	Supramolecular prodrug hydrogelator as an immune booster for checkpoint blocker-based immunotherapy. 2020 , 6, eaz8985	54
1002	Experimental analysis of T cell epitopes for designing liver cancer vaccine predicted by system-level immunoinformatics approach. 2020 , 318, G1055-G1069	3
1001	The influence of tumour mutational burden on renal cancer immune infiltration and survival. 2020 , 8, 271	
1000	A Combination of Cowpea Mosaic Virus and Immune Checkpoint Therapy Synergistically Improves Therapeutic Efficacy in Three Tumor Models. 2020 , 30, 2002299	12
999	New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma. 2020 , 51, 100702	32
998	Prognostic impact of indoleamine 2,3-dioxygenase 1 mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma. 2020 , 5, e000646	9
997	Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of tumor response in hepatocellular carcinoma after DEB-TACE. 2020 , 30, 5663-5673	17
996	Cellular Plasticity in Breast Cancer Progression and Therapy. 2020 , 7, 72	20
995	The integration of proportion and cell counts of stromal, not intratumoral, PD-1+ tumor-infiltrating lymphocytes has prognostic significance in esophageal squamous cell carcinoma. 2021 , 34,	
994	Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. 2020 , 31, 1011-1020	44
993	Nanomodified strategies to overcome EGFR-tyrosine kinase inhibitors resistance in non-small cell lung cancer. 2020 , 324, 482-492	5
992	Systematic Multiomic Analysis of Gene Expression and Its Prognostic Value Through the Infiltration of Natural Killer (NK) Cells in Skin Cutaneous Melanoma. 2020 , 9,	1
991	CAR T cell therapy: newer approaches to counter resistance and cost. 2020 , 6, e03779	9
990	Safety and Long-Term Outcome of Intratumoral Injection of OK432-Stimulated Dendritic Cells for Hepatocellular Carcinomas After Radiofrequency Ablation. 2020 , 13, 100777	5
989	The immunoregulatory function of polyphenols: implications in cancer immunity. 2020 , 85, 108428	6
988	Neoadjuvant rituximab modulates the tumor immune environment in patients with high risk prostate cancer. 2020 , 18, 214	15
987	The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis. 2020 , 2020, 5059079	4

986	Tumor-associated tissue eosinophilia predicts favorable clinical outcome in solid tumors: a meta-analysis. 2020 , 20, 454	8
985	Blood and Cancer: Cancer Stem Cells as Origin of Hematopoietic Cells in Solid Tumor Microenvironments. 2020 , 9,	12
984	Epigenetic modulation combined with PD-1/PD-L1 blockade enhances immunotherapy based on MAGE-A11 antigen-specific CD8+T cells against esophageal carcinoma. 2020 , 41, 894-903	6
983	Inosine is an alternative carbon source for CD8-T-cell function under glucose restriction. 2020 , 2, 635-647	48
982	Particulate Matter Exposure: Genomic Instability, Disease, and Cancer Risk. 2020 ,	
981	Inhibition of acute leukemia with attenuated Salmonella typhimurium strain VNP20009. 2020 , 129, 110425	3
980	The Prognostic Value of EMT in Glioma and its Role in the Glioma Immune Microenvironment. 2020 , 70, 1501-1511	6
979	IDO, TDO, and AHR overexpression is associated with poor outcome in diffuse large B-cell lymphoma patients in the rituximab era. 2020 , 99, e19883	4
978	Immune Cell Profiling in Cancer Using Multiplex Immunofluorescence and Digital Analysis Approaches. 2020 ,	
977	Anti-PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells. 2020 , 26, 4699-4712	23
976	Melanoma brain metastases: review of histopathological features and immune-molecular aspects. 2020 , 7, MMT44	2
975	The Role of Tumor-Associated Myeloid Cells in Modulating Cancer Therapy. 2020 , 10, 899	20
974	Functional crosstalk between T cells and monocytes in cancer and atherosclerosis. 2020 , 108, 297-308	9
973	Metabolism in tumor microenvironment: Implications for cancer immunotherapy. 2020 , 1, 47-68	27
972	Thyroid cancer metastasis is associated with an overabundance of defective follicular helper T cells. 2020 , 128, 487-496	4
971	Cancer Cell-Intrinsic Expression of MHC Class II Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma. 2020 , 204, 2295-2307	25
970	Characteristics of Tumor-Infiltrating Lymphocytes Prior to and During Immune Checkpoint Inhibitor Therapy. 2020 , 11, 364	30
969	DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data. 2020 , 636, 49-76	1

968	Therapeutic drugs and drug delivery systems targeting stromal cells for cancer therapy: a review. 2020 , 28, 714-726	5
967	Cellular, transcriptomic and isoform heterogeneity of breast cancer cell line revealed by full-length single-cell RNA sequencing. 2020 , 18, 676-685	16
966	PD1 Blockade in Cancer: Impact on Myeloid Cells. 2020 , 6, 443-444	0
965	Carcinoma and Sarcoma Microenvironment at a Glance: Where We Are. 2020 , 10, 76	9
964	Comprehensive review of targeted therapy for colorectal cancer. 2020 , 5, 22	312
963	Patient-derived cancer modeling for precision medicine in colorectal cancer: beyond the cancer cell line. 2020 , 21, 495-502	2
962	Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma. 2020 , 15, 1677-1691	24
961	Tumor Microenvironment. 2020 ,	6
960	Targeting Toll-like receptor 3 in dendritic cells for cancer immunotherapy. 2020 , 20, 937-946	11
959	Establishment of a Prognostic Model Using Immune-Related Genes in Patients With Hepatocellular Carcinoma. 2020 , 11, 55	10
958	ITCH as a potential therapeutic target in human cancers. 2020 , 67, 117-130	14
957	RIPK3 Orchestrates Fatty Acid Metabolism in Tumor-Associated Macrophages and Hepatocarcinogenesis. 2020 , 8, 710-721	36
956	PD-L1 Expression and Tumor-infiltrating Lymphocytes in Breast Cancer: Clinicopathological Analysis in Women Younger than 40 Years Old. 2020 , 34, 639-647	9
955	Activation of the Kynurenine Pathway in Human Malignancies Can Be Suppressed by the Cyclin-Dependent Kinase Inhibitor Dinaciclib. 2020 , 11, 55	13
954	Insights Into Lung Cancer Immune-Based Biology, Prevention, and Treatment. 2020 , 11, 159	34
953	Artificial intelligence as the next step towards precision pathology. 2020 , 288, 62-81	80
952	Melanoma-Secreted Lysosomes Trigger Monocyte-Derived Dendritic Cell Apoptosis and Limit Cancer Immunotherapy. 2020 , 80, 1942-1956	11
951	Development and validation of an immune-related prognostic signature in lung adenocarcinoma. 2020 , 9, 5960-5975	33

950	Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications. 2020 , 156, 214-235	98
949	FDG PET/CT for Assessment of Immune Therapy: Opportunities and Understanding Pitfalls. 2020 , 50, 518-531	9
948	Cancer and HIV-1 Infection: Patterns of Chronic Antigen Exposure. 2020 , 11, 1350	6
947	Centrosome dysfunction: a link between senescence and tumor immunity. 2020 , 5, 107	16
946	Nanomedicine and Onco-Immunotherapy: From the Bench to Bedside to Biomarkers. 2020 , 10,	13
945	Reactive Oxygen Species and Antitumor Immunity-From Surveillance to Evasion. 2020 , 12,	34
944	Sex differences in the association between tumor growth and T cell response in a melanoma mouse model. 2020 , 69, 2157-2162	3
943	Top Notch Targeting Strategies in Cancer: A Detailed Overview of Recent Insights and Current Perspectives. 2020 , 9,	56
942	Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment. 2020 , 8,	7
941	AI Egen-coupled upconversion nanoparticles eradicate solid tumors through dual-mode ROS activation. 2020 , 6, eabb2712	58
940	Calculation of immune cell proportion from batch tumor gene expression profile based on support vector regression. 2020 , 18, 2050030	0
939	Organoid Models of Tumor Immunology. 2020 , 41, 652-664	85
938	Role of LATS1/2 in Prognosis of Advanced Gastric Cancer and Its Relationship With the Tumor Immune Microenvironment. 2020 , 10, 1406	1
937	Tumor Microenvironment. 2020 ,	
936	Overexpression of the human cytomegalovirus UL111A is correlated with favorable survival of patients with gastric cancer and changes T-cell infiltration and suppresses carcinogenesis. 2020 , 146, 555-568	3
935	Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer. 2020 , 153, 104683	85
934	Multistability in the epithelial-mesenchymal transition network. 2020 , 21, 71	14
933	Clinical relevance of the comparative expression of immune checkpoint markers with the clinicopathological findings in patients with primary and chemoreduced retinoblastoma. 2020 , 69, 1087-1099	5

932	Tumor-Derived Lactic Acid Contributes to the Paucity of Intratumoral ILC2s. 2020 , 30, 2743-2757.e5	20
931	Stereotatic radiotherapy in metastatic non-small cell lung cancer: Combining immunotherapy and radiotherapy with a focus on liver metastases. 2020 , 142, 70-79	6
930	The Immune Microenvironment and Neoantigen Landscape of Aggressive Salivary Gland Carcinomas Differ by Subtype. 2020 , 26, 2859-2870	31
929	Impact of RAS mutations on the immune infiltrate of colorectal liver metastases: A preliminary study. 2020 , 108, 715-721	6
928	Multiplex immunohistochemistry assay to evaluate the melanoma tumor microenvironment. 2020 , 635, 21-31	2
927	Multiplexed immunohistochemistry for immune cell phenotyping, quantification and spatial distribution in situ. 2020 , 635, 51-66	8
926	Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma. 2020 , 26, 249-271	9
925	Heliovaccination: Solar mediated immunity against cancer. 2020 , 29, 477-480	0
924	Bioinformatics Analysis to Screen the Key Prognostic Genes in Tumor Microenvironment of Bladder Cancer. 2020 , 2020, 6034670	8
923	Mechanisms of Resistance to PD-1 Checkpoint Blockade. 2020 , 80, 459-465	4
922	A gastric cancer cell derived extracellular compounds suppresses CD161CD3 lymphocytes and aggravates tumor formation in a syngeneic mouse model. 2020 , 120, 136-145	1
921	Colibactin-positive Escherichia coli induce a procarcinogenic immune environment leading to immunotherapy resistance in colorectal cancer. 2020 , 146, 3147-3159	22
920	Down-regulation of the human major histocompatibility complex class I chain-related gene A (MICA) and its receptor is mediated by microRNA-146b-5p and is a potential mechanism of immunoediting in papillary thyroid carcinoma. 2020 , 113, 104379	6
919	PD-1/PD-L1-dependent immune response in colorectal cancer. 2020 , 235, 5461-5475	38
918	Vascularized Biomaterials to Study Cancer Metastasis. 2020 , 9, e1901459	9
917	Astrocytic trans-Differentiation Completes a Multicellular Paracrine Feedback Loop Required for Medulloblastoma Tumor Growth. 2020 , 180, 502-520.e19	39
916	Combined effect of silver nanoparticles and aluminium chloride, butylparaben or diethylphthalate on the malignancy of MDA-MB-231 breast cancer cells and tumor-specific immune responses of human macrophages and monocyte-derived dendritic cells. 2020 , 65, 104774	1
915	Possibilities of Improving the Clinical Value of Immune Checkpoint Inhibitor Therapies in Cancer Care by Optimizing Patient Selection. 2020 , 21,	11

914	Cytokine profiling of tumor-infiltrating T lymphocytes by flow cytometry. 2020 , 631, 1-20	
913	A Four-Chemokine Signature Is Associated with a T-cell-Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer. 2020 , 26, 1997-2010	37
912	Bioinformatic identification of renal cell carcinoma microenvironment-associated biomarkers with therapeutic and prognostic value. 2020 , 243, 117273	25
911	Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions. 2020 , 2020, 9037217	26
910	Persistence of adoptively transferred T cells with a kinetically engineered IL-2 receptor agonist. 2020 , 11, 660	42
909	Angiocrine endothelium: from physiology to cancer. 2020 , 18, 52	27
908	A Comprehensive Picture of Extracellular Vesicles and Their Contents. Molecular Transfer to Cancer Cells. 2020 , 12,	48
907	Loading of Primary Human T Lymphocytes with Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles Does Not Impair Their Activation after Polyclonal Stimulation. 2020 , 9,	5
906	Neuropilin: Handyman and Power Broker in the Tumor Microenvironment. 2020 , 1223, 31-67	15
905	NRF2 as a regulator of cell metabolism and inflammation in cancer. 2020 , 41, 405-416	38
904	Pancreatic cancer-derived exosomes induce apoptosis of T lymphocytes through the p38 MAPK-mediated endoplasmic reticulum stress. 2020 , 34, 8442-8458	22
903	The interplay between innate and adaptive immunity in cancer shapes the productivity of cancer immunosurveillance. 2020 , 108, 363-376	19
902	Mikrobiom und Immuntherapien bei Tumorerkrankungen. 2020 , 23, 48-52	
901	Immunocyte density in parathyroid carcinoma is correlated with disease relapse. 2020 , 43, 1453-1461	0
900	Advancements in prophylactic and therapeutic nanovaccines. 2020 , 108, 1-21	34
899	The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. 2020 , 86, 102015	75
898	The Agpat4/LPA axis in colorectal cancer cells regulates antitumor responses via p38/p65 signaling in macrophages. 2020 , 5, 24	17
897	BTK Has Potential to Be a Prognostic Factor for Lung Adenocarcinoma and an Indicator for Tumor Microenvironment Remodeling: A Study Based on TCGA Data Mining. 2020 , 10, 424	50

896	Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients. 2020 , 10, 691	8
895	Development of a prognostic index of colon adenocarcinoma based on immunogenomic landscape analysis. 2020 , 8, 284	3
894	microRNAs identified in prostate cancer: Correlative studies on response to ionizing radiation. 2020 , 19, 63	17
893	Dissecting the Tumor-Immune Landscape in Chimeric Antigen Receptor T-cell Therapy: Key Challenges and Opportunities for a Systems Immunology Approach. 2020 , 26, 3505-3513	9
892	Tumor associated macrophages in the molecular pathogenesis of ovarian cancer. 2020 , 84, 106471	11
891	Clinical Significance of Expression in Pediatric Acute Myeloid Leukemia. 2020 , 4, e346	2
890	Topological Tumor Graphs: A Graph-Based Spatial Model to Infer Stromal Recruitment for Immunosuppression in Melanoma Histology. 2020 , 80, 1199-1209	14
889	A Th1/IFN γ Gene Signature Is Prognostic in the Adjuvant Setting of Resectable High-Risk Melanoma but Not in Non-Small Cell Lung Cancer. 2020 , 26, 1725-1735	6
888	The β / Axis Is Involved in Regulation of Dendritic Cells and Is Associated with Clinical Outcomes in Advanced Lung Adenocarcinoma. 2020 , 2020, 4360930	5
887	Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival. 2020 , 4, 274-286	18
886	Transcriptome analysis reveals the link between lncRNA-mRNA co-expression network and tumor immune microenvironment and overall survival in head and neck squamous cell carcinoma. 2020 , 13, 57	16
885	Immunological Aspects of the Tumor Microenvironment and Epithelial-Mesenchymal Transition in Gastric Carcinogenesis. 2020 , 21,	21
884	Tumor Targeted Nanocarriers for Immunotherapy. 2020 , 25,	18
883	Nanoparticle mediated cancer immunotherapy. 2021 , 69, 307-324	19
882	Progress in Nanorobotics for Advancing Biomedicine. 2021 , 68, 130-147	15
881	Tumour microenvironment (TME) characterization identified prognosis and immunotherapy response in muscle-invasive bladder cancer (MIBC). 2021 , 70, 1-18	25
880	Single-cell RNA sequencing reveals heterogeneous tumor and immune cell populations in early-stage lung adenocarcinomas harboring EGFR mutations. 2021 , 40, 355-368	42
879	A Review of the Current State of Nanomedicines for Targeting and Treatment of Cancers: Achievements and Future Challenges. 2021 , 4, 2000186	2

878	Artificial intelligence and the interplay between tumor and immunity. 2021 , 211-235	0
877	Distribution pattern of tumor infiltrating lymphocytes and tumor microenvironment composition as prognostic indicators in anorectal malignant melanoma. 2021 , 34, 141-160	4
876	Combination therapy with PD-1/PD-L1 blockade in non-small cell lung cancer: strategies and mechanisms. 2021 , 219, 107694	20
875	High intratumoral CD8 T-cell infiltration is associated with improved survival in prostate cancer patients undergoing radical prostatectomy. 2021 , 81, 20-28	12
874	Baseline immunity and impact of chemotherapy on immune microenvironment in cervical cancer. 2021 , 124, 414-424	9
873	Notch Signaling in Embryology and Cancer. 2021 ,	0
872	Immune microenvironment of the gene signature reflecting the standardised uptake value on F-fluorodeoxyglucose positron emission tomography/computed tomography in head and neck squamous cell carcinoma. 2021 , 35, 65-75	1
871	Interleukin-35 has a tumor-promoting role in hepatocellular carcinoma. 2021 , 203, 219-229	6
870	The regulatory function of mixed lineage kinase 3 in tumor and host immunity. 2021 , 219, 107704	0
869	Nanomedicine enables spatiotemporally regulating macrophage-based cancer immunotherapy. 2021 , 268, 120552	6
868	Cancer evolution: A means by which tumors evade treatment. 2021 , 133, 111016	9
867	Cell primitive-based biomimetic functional materials for enhanced cancer therapy. 2021 , 50, 945-985	31
866	Corn-like Au/Ag nanorod-mediated NIR-II photothermal/photodynamic therapy potentiates immune checkpoint antibody efficacy by reprogramming the cold tumor microenvironment. 2021 , 268, 120582	24
865	Understanding the tumor microenvironment for effective immunotherapy. 2021 , 41, 1474-1498	32
864	A signature of 17 immune-related gene pairs predicts prognosis and immune status in HNSCC patients. 2021 , 14, 100924	8
863	Innate and Innate-Like Cells: The Future of Chimeric Antigen Receptor (CAR) Cell Therapy. 2021 , 42, 45-59	8
862	Combining Photothermal Therapy-Induced Immunogenic Cell Death and Hypoxia Relief-Benefited M1-Phenotype Macrophage Polarization for Cancer Immunotherapy. 2021 , 4, 2000191	5
861	Overcoming immune resistance by sequential prodrug nanovesicles for promoting chemoimmunotherapy of cancer. 2021 , 36, 101025	16

860	Acid-activatable micelleplex delivering siRNA-PD-L1 for improved cancer immunotherapy of CDK4/6 inhibition. 2021 , 32, 1929-1936	7
859	Prognostic value of modified systemic inflammatory score in patients with newly diagnosed high-grade gliomas. 2021 , 201, 106428	0
858	Nano-immunotherapy: Unique mechanisms of nanomaterials in synergizing cancer immunotherapy. 2021 , 36, 101023	16
857	Development and validation of a CTNNB1-associated metabolic prognostic model for hepatocellular carcinoma. 2021 , 25, 1151-1165	11
856	Potential predictive value of change in inflammatory cytokines levels subsequent to initiation of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer. 2021 , 138, 155363	5
855	Blueprint for cancer research: Critical gaps and opportunities. 2021 , 71, 107-139	7
854	Recent Progress in Magnetically Actuated Microrobots for Targeted Delivery of Therapeutic Agents. 2021 , 10, e2001596	13
853	DNA scaffolds enable efficient and tunable functionalization of biomaterials for immune cell modulation. 2021 , 16, 214-223	18
852	Adenosine Signaling in the Tumor Microenvironment. 2021 , 1270, 145-167	4
851	Tumor Microenvironment. 2021 ,	
850	Cytotoxic CD8 T cells in cancer and cancer immunotherapy. 2021 , 124, 359-367	101
849	Immune landscape and therapeutic strategies: new insights into PD-L1 in tumors. 2021 , 78, 867-887	5
848	Current methods in translational cancer research. 2021 , 40, 7-30	7
847	The microRNA target site landscape is a novel molecular feature associating alternative polyadenylation with immune evasion activity in breast cancer. 2021 , 22,	4
846	A novel miR1983-TLR7-IFN γ circuit licenses NK cells to kill glioma cells, and is under the control of galectin-1. 2021 , 10, 1939601	1
845	Overcoming barriers in photodynamic therapy harnessing nano-formulation strategies. 2021 , 50, 9152-9201	56
844	Molecules in Signal Pathways. 2021 , 139-154	
843	CKMT1B is a potential prognostic biomarker and associated with immune infiltration in Lower-grade glioma. 2021 , 16, e0245524	5

842	Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma. 2021 , 70, 1705-1719	26
841	CD45ROCD8 T cell-derived exosomes restrict estrogen-driven endometrial cancer development via the ER α /miR-765/PLP2/Notch axis. 2021 , 11, 5330-5345	7
840	Comprehensive Characterization of Tumor Microenvironment Differences in Cancer between Male and Female Patients.	
839	SOX1 Is a Backup Gene for Brain Neurons and Glioma Stem Cell Protection and Proliferation. 2021 , 58, 2634-2642	3
838	A snapshot of the PD-1/PD-L1 pathway. 2021 , 12, 2735-2746	20
837	Phosphoinositide 3-Kinase Signaling in the Tumor Microenvironment: What Do We Need to Consider When Treating Chronic Lymphocytic Leukemia With PI3K Inhibitors?. 2020 , 11, 595818	3
836	IL-10 Signaling in the Tumor Microenvironment of Ovarian Cancer. 2021 , 1290, 51-65	6
835	The role of CCR2 in prognosis of patients with endometrial cancer and tumor microenvironment remodeling. 2021 , 12, 3467-3484	1
834	Cell-Based Tracers as Trojan Horses for Image-Guided Surgery. 2021 , 22,	3
833	Immune-Related lncRNA Predicts the Prognosis of Colon Adenocarcinoma. 2021 , 11, 2288-2295	
832	Immunotherapy in colorectal cancer: current achievements and future perspective. 2021 , 17, 3837-3849	10
831	Longitudinal Intravital Imaging of Tumor-Infiltrating Lymphocyte Motility in Breast Cancer Models. 2021 , 24, 463-473	0
830	Identification of prognostic hypoxia-related genes signature on the tumor microenvironment in esophageal cancer. 2021 , 18, 7743-7758	2
829	Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response. 2021 , 10, 1969075	2
828	DTX@VTX NPs synergy PD-L1 immune checkpoint nanoinhibitor to reshape immunosuppressive tumor microenvironment for enhancing chemo-immunotherapy. 2021 , 9, 7544-7556	0
827	T cells drive negative feedback mechanisms in cancer associated fibroblasts, promoting expression of co-inhibitory ligands, CD73 and IL-27 in non-small cell lung cancer. 2021 , 10, 1940675	5
826	Transcriptomic characterization reveals prognostic molecular signatures of sorafenib resistance in hepatocellular carcinoma. 2021 , 13, 3969-3993	3
825	Clinical and Immunological Aspects of Pneumococcal Vaccination in Patients with Multiple Myeloma. 2021 , 19, 79-85	

824	SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected & Non-injected Lesions. 2021 , 4, 2000243	7
823	Effect of P2X purinergic receptors in tumor progression and as a potential target for anti-tumor therapy. 2021 , 17, 151-162	2
822	S100A8/A9 mediate the reprogramming of normal mammary epithelial cells induced by dynamic cell-cell interactions with adjacent breast cancer cells. 2021 , 11, 1337	4
821	Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer. 2021 , 6, 4	17
820	Prognostic significance of BIRC7/Livin, Bcl-2, p53, Annexin V, PD-L1, DARC, MSH2 and PMS2 in colorectal cancer treated with FOLFOX chemotherapy with or without aspirin. 2021 , 16, e0245581	3
819	The Emerging Role of Nerves and Glia in Colorectal Cancer. 2021 , 13,	6
818	S100A9-Imaging Enables Estimation of Early Therapy-Mediated Changes in the Inflammatory Tumor Microenvironment. 2021 , 9,	1
817	Inflammatory cells in tumor microenvironment. 2021 , 75-112	
816	Role of Infections and Tissue Inflammation in the Pathology of the Fallopian Tube and High-Grade Serous Ovarian Cancer. 2021 , 271-312	
815	Revisiting immunogenic cell death to improve treatment response in cancer. 2021 , 65-90	0
814	Industrial Perspective on Immunotherapy. 2021 , 1295, 327-347	
813	Single Cell Genomics for Tumor Heterogeneity. 2021 , 1187, 205-214	
812	Prognostic and immunological significance of metastasis associated lung adenocarcinoma transcript 1 among different kinds of cancers. 2021 , 12, 4247-4258	1
811	Cytosolic Delivery of Thiolated Neoantigen Nano-Vaccine Combined with Immune Checkpoint Blockade to Boost Anti-Cancer T Cell Immunity. 2021 , 8, 2003504	10
810	Current Advances in Immunotherapy for Glioblastoma. 2021 , 23, 21	9
809	A gene expression signature associated with B cells predicts benefit from immune checkpoint blockade in lung adenocarcinoma. 2021 , 10, 1860586	13
808	The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors. 2021 , 121, 1746-1803	66
807	Cancer Testis Antigens and Immunotherapy: A new Dawn. 2021 , 251, 02033	

806	Bioinformatics analysis of the prognosis and biological significance of VCAN in gastric cancer. 2021 , 9, 547-559	4
805	Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. 2021 , 11, 4530	12
804	IL17A critically shapes the transcriptional program of fibroblasts in pancreatic cancer and switches on their protumorigenic functions. 2021 , 118,	7
803	Immunostimulant hydrogel for the inhibition of malignant glioma relapse post-resection. 2021 , 16, 538-548	35
802	Multi-Omics Data Analysis of Gene Expressions and Alterations, Cancer-Associated Fibroblast and Immune Infiltrations, Reveals the Onco-Immune Prognostic Relevance of STAT3/CDK2/4/6 in Human Malignancies. 2021 , 13,	15
801	Potential of Photodynamic Therapy Based on Sugar-Conjugated Photosensitizers. 2021 , 10,	6
800	Prognostic Signatures Based on Thirteen Immune-Related Genes in Colorectal Cancer. 2020 , 10, 591739	6
799	Combination of radiotherapy and vaccination overcomes checkpoint blockade resistance. 2016 , 7, 43039-43051	51
798	Cellular plasticity and metastasis in breast cancer: a pre- and post-malignant problem. 2019 , 5,	5
797	Macrophage Metabolism at the Crossroad of Metabolic Diseases and Cancer. 2020 ,	4
796	Towards tumor immunodiagnostics. 2016 , 4, 263	10
795	Beyond PD-L1 testing-emerging biomarkers for immunotherapy in non-small cell lung cancer. 2017 , 5, 376	57
794	CXCL5/CXCL8 is a promising potential prognostic and tumor microenvironment-related cluster in hepatocellular carcinoma. 2020 , 11, 1364-1380	6
793	Immune Checkpoint Inhibitors: Basics and Challenges. 2019 , 26, 3009-3025	102
792	Comprehensive Bioinformatics Analysis Identifies Tumor Microenvironment and Immune-related Genes in Small Cell Lung Cancer. 2020 , 23, 381-391	5
791	Immunoediting is not a primary transformation event in a murine model of MLL-ENL AML. 2018 , 1, e2018000792	
790	Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade. 2020 , 11, 339	36
789	Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies. 2020 , 9,	6

788	The Role of Immune Checkpoints after Cellular Therapy. 2020 , 21,	4
787	Microenvironment Analysis of Prognosis and Molecular Signature of Immune-Related Genes in Lung Adenocarcinoma. 2021 , 28, 561-578	6
786	[Advances of PD-1/PD-L1 signaling pathway in immune escape and treatment for ?non-small cell lung cancer]. 2014 , 17, 734-40	4
785	Recent Improvements in Genomic and Transcriptomic Understanding of Anaplastic and Poorly Differentiated Thyroid Cancers. 2020 , 35, 44-54	8
784	IL-6 Activities in the Tumour Microenvironment. Part 1. 2019 , 7, 2391-2398	29
783	Biomarkers of immunotherapy in non-small cell lung cancer. 2020 , 20, 139	1
782	MUC1-induced immunosuppression in colon cancer can be reversed by blocking the PD1/PDL1 signaling pathway. 2020 , 20, 317	3
781	Impact of the immune system and immunotherapy in colorectal cancer. 2015 , 6, 208-23	98
780	Programmed cell death protein-1/programmed cell death ligand-1 pathway inhibition and predictive biomarkers: understanding transforming growth factor-beta role. 2015 , 4, 728-42	40
779	Translational development of difluoromethylornithine (DFMO) for the treatment of neuroblastoma. 2015 , 4, 226-38	50
778	Melanoma: oncogenic drivers and the immune system. 2015 , 3, 265	15
777	A New Perspective on the Heterogeneity of Cancer Glycolysis. 2018 , 26, 10-18	12
776	Tumor immune response and immunotherapy in gastric cancer. 2020 , 54, 20-33	31
775	Microfluidic endothelium-on-a-chip development, from in vivo to in vitro experimental models. 2020 , 61, 15-23	4
774	Immune response and the tumor microenvironment: how they communicate to regulate gastric cancer. 2014 , 8, 131-9	88
773	A new aspect of an old friend: the beneficial effect of metformin on anti-tumor immunity. 2020 , 53, 512-520	6
772	Downregulation of Nitric Oxide Collaborated with Radiotherapy to Promote Anti-Tumor Immune Response via Inducing CD8+ T Cell Infiltration. 2020 , 16, 1563-1574	7
771	Cancer systems immunology. 2020 , 9,	3

770	A 14 immune-related gene signature predicts clinical outcomes of kidney renal clear cell carcinoma. 2020 , 8, e10183	5
769	Correlation between subsets of tumor-infiltrating immune cells and risk stratification in patients with cervical cancer. 2019 , 7, e7804	10
768	A prognostic gene model of immune cell infiltration in diffuse large B-cell lymphoma. 2020 , 8, e9658	4
767	Impact of Breast Tumor Onset on Blood Count, Carcinoembryonic Antigen, Cancer Antigen 15-3 and Lymphoid Subpopulations Supported by Automatic Classification Approach: A Pilot Study. 2021 , 28, 10732748211048612	1
766	Establishment and verification of a prognostic tumor microenvironment-based and immune-related gene signature in colon cancer. 2021 , 12, 2172-2191	1
765	Trial watch: intratumoral immunotherapy. 2021 , 10, 1984677	7
764	Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. 2021 ,	8
763	Characterizing the tumor microenvironment in rare renal cancer histological types. 2021 ,	1
762	A call to action: molecular pathology in Brazil. 2021 , 4,	1
761	Simultaneous Inhibition of PD-1 and Stimulation of CD40 Signaling Pathways by Anti-PD-L1/CD40L Bispecific Fusion Protein Synergistically Activate Target and Effector Cells. 2021 , 22,	0
760	Relationship between Th17 immune response and cancer. 2021 , 12, 845-867	5
759	Bioinspired and Biomimetic Delivery Platforms for Cancer Vaccines. 2021 , e2103790	12
758	Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. 2021 ,	35
757	Therapeutic Potential of SphK1 Inhibitors Based on Abnormal Expression of SphK1 in Inflammatory Immune Related-Diseases. 2021 , 12, 733387	3
756	KIF2C Is a Novel Prognostic Biomarker and Correlated with Immune Infiltration in Endometrial Cancer. 2021 , 2021, 1434856	3
755	Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. 2021 , 13, eabb6981	11
754	Senescence and Immunoregulation in the Tumor Microenvironment. 2021 , 9, 754069	4
753	TPD52L2 Is a Prognostic Biomarker and Correlated With Immune Infiltration in Lung Adenocarcinoma. 2021 , 12, 728420	1

752	Prognostic Value of Interleukin-32 Expression and Its Correlation with the Infiltration of Natural Killer Cells in Cutaneous Melanoma. 2021 , 10,	0
751	Re-Expression of Poly/Oligo-Sialylated Adhesion Molecules on the Surface of Tumor Cells Disrupts Their Interaction with Immune-Effector Cells and Contributes to Pathophysiological Immune Escape. 2021 , 13,	2
750	Overcoming TGF β -mediated immune evasion in cancer. 2021 ,	17
749	Rv3628 is an effective adjuvant via activation of dendritic cells for cancer immunotherapy. 2021 , 23, 288-302	0
748	Engineered Removal of PD-1 From the Surface of CD19 CAR-T Cells Results in Increased Activation and Diminished Survival. 2021 , 8, 745286	2
747	Multi-parameter optical imaging of immune cell activity in chimeric antigen receptor T-cell and checkpoint blockade therapies.	
746	High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy. 2021 , 12,	1
745	TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment. 2021 , 12, 759953	9
744	New Prognostic Biomarkers and Drug Targets for Skin Cutaneous Melanoma Comprehensive Bioinformatic Analysis and Validation. 2021 , 11, 745384	1
743	Identification and validation of an immune-associated RNA-binding proteins signature to predict clinical outcomes and therapeutic responses in colon cancer patients. 2021 , 19, 314	1
742	Understanding and improving cellular immunotherapies against cancer: From cell-manufacturing to tumor-immune models. 2021 , 179, 114003	2
741	OLR1 is a prognostic factor and correlated with immune infiltration in breast cancer. 2021 , 101, 108275	0
740	Cancer Vaccines: Fundamentals and Strategies. 2014 , 163-185	
739	MicroRNA Regulated Stress Responses in Cancer. 2015 , 107-126	
738	Ultrasensitive detection of TCR hypervariable region in solid-tissue RNA-seq data.	
737	Permissive/Protective Interplay of Microbiota with T Cell Adaptive Immune Response in Colon Cancer. 2016 , 4,	
736	Basic Immunobiology. 2017 , 1-93	
735	Development of Cancer Vaccine and Targeted Immune Checkpoint Therapies. 2017 , 225-241	

- 734 In vivo optical imaging of anti-tumor immune response. **2017**,
- 733 Informatics for Cancer Immunotherapy. 1
- 732 Immunotherapy Options for Cancer. **2017**, 3,
- 731 A pan-cancer landscape of interactions between solid tumors and infiltrating immune cell populations.
- 730 Immunotherapy in Head and Neck Squamous Cell Carcinoma (HNSCC). **2018**, 365-396
- 729 BET Bromodomain Targeting Suppresses the PD-1/PD-L1 Pathway in Triple-negative Breast Cancer and Elicits Anti-tumor Immune Response. 1
- 728 New Progress in Breast Cancer Immunotherapy. **2018**, 08, 47-52
- 727 Influence of immunological nutrition on treatment of patients with oncological profile. **2018**, 1, 19-24
- 726 Comprehensive analysis of immune evasion in breast cancer by single-cell RNA-seq. 2
- 725 Systemic Inflammatory Response in Pancreatic Ductal Adenocarcinoma. 1
- 724 Computational modeling of the crosstalk between macrophage polarization and tumor cell plasticity in the tumor microenvironment.
- 723 Radiation and Immunotherapy for Sarcoma. **2019**, 47-65
- 722 Protective low avidity anti-tumour CD8+ T cells are selectively attenuated by regulatory T cells.
- 721 Immunotherapy with mRNA vaccination and immunomodulation nanomedicine for cancer therapy. **2019**, 551-600
- 720 Harnessing the Immune System to Target Cancer Cells. **2019**, 137-151
- 719 Single-cell profiling of tumor-reactive CD4+T-cells reveals unexpected transcriptomic diversity.
- 718 Viral infection overcomes ineffectiveness of anti-tumoral CD8+ T cell mediated cytotoxicity. 0
- 717 Evolving neoantigen profiles in colorectal cancers with DNA repair defects. 1

- 716 Multivariate AND-gate substrate probes as enhanced contrast agents for fluorescence-guided surgery.
- 715 Inflammatory cytokines and alpha-fetoprotein concentrations for predicting survival in patients with hepatocellular carcinoma.. **2019**, 8, 1680-1689 0
- 714 Inosine is an alternative carbon supply that supports effector T cell proliferation and antitumor function under glucose restriction.
- 713 Immunotherapy in Hodgkin Lymphoma and Other CD30+ Lymphomas. **2020**, 27-46
- 712 How repair-or-dispose decisions under stress can initiate disease progression.
- 711 Tumor-Associated Macrophages: Are Macrophages Enemy or Friendly?. **2019**, 7, 1-4
- 710 Targeting histone modifications in cancer immunotherapy. **2020**, 373-394
- 709 Immunopathology and Immunotherapy of Melanoma. **2020**, 305-332
- 708 *Listeria monocytogenes* personalized cancer vaccines drive therapeutic immune responses to cancer derived neoantigens.
- 707 Tumor-associated Tissue Eosinophilia Predicts Favorable Clinical Outcome in Solid Tumors: A Meta-analysis.
- 706 Cancer Cell Intrinsic Expression of MHCII Regulates the Immune Microenvironment and Response to Anti-PD-1 Therapy in Lung Adenocarcinoma.
- 705 Profiles of immune infiltration and its relevance to survival outcome in meningiomas. **2020**, 40, 3
- 704 Transient cell-in-cell formation underlies tumor resistance to immunotherapy. 0
- 703 Identification of () as a Prognostic Biomarker of Tumor Progression and Immune Evasion for Lung Cancer and Evaluation of Organosulfur Compounds from L. as Therapeutic Candidates. **2021**, 9, 6
- 702 The Scavenger Receptor MARCO Expressed by Tumor-Associated Macrophages Are Highly Associated With Poor Pancreatic Cancer Prognosis. **2021**, 11, 771488 4
- 701 Development and validation of genomic and epigenomic signatures associated with tumor immune microenvironment in hepatoblastoma. **2021**, 21, 1156 1
- 700 Immune Checkpoint Inhibitors for Genitourinary Cancers: Treatment Indications, Investigational Approaches and Biomarkers. **2021**, 13, 0
- 699 The value of a new prognostic model developed by lymphocyte-monocyte ratio and platelet-monocyte ratio in peripheral T-cell lymphoma. **2021**, 21, 573

698	Engineering DNA Nanostructures to Manipulate Immune Receptor Signaling and Immune Cell Fates. 2021 , e2101844	2
697	Cellular transformers for targeted therapy. 2021 , 179, 114032	3
696	Bacteria in cancer therapy: Strategies to improvement and future directions. 2020 , 191-202	
695	Cognitive Privacy: AI-enabled Privacy using EEG Signals in the Internet of Things. 2020 ,	2
694	Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment. 2020 , 8, 5935-5943	1
693	Characterizing Immune Responses in Whole Slide Images of Cancer With Digital Pathology and Pathomics. 2020 , 8, 133-148	3
692	Overexpression of CD155 is associated with PD-1 and PD-L1 expression on immune cells, rather than tumor cells in the breast cancer microenvironment. 2020 , 8, 5932-5940	
691	Cancer Immunology and Immuno-Oncology (Innate vs. Adaptive Cell Immunity). 2021 , 05, 032-049	
690	The role of Th22 cells, from tissue repair to cancer progression. 2022 , 149, 155749	1
689	Wnt signaling pathway in cancer immunotherapy. 2022 , 525, 84-96	3
688	Criteria to make animal studies more relevant to treating human cancer. 2021 , 74, 25-31	0
687	3D-3-Culture: Tumor Models to Study Heterotypic Interactions in the Tumor Microenvironment. 2020 , 117-130	1
686	Current Perspectives on Cancer Immunotherapy in Bone. 2020 , 421-437	
685	Cell-mediated and cell membrane-coated nanoparticles for drug delivery and cancer therapy. 2020 , 3, 879-911	7
684	Introduction. 2020 , 1-14	
683	Knowledge-based classification of fine-grained immune cell types in single-cell RNA-Seq data with ImmClassifier.	
682	FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer. 2021 , 12, 758648	0
681	Aberrant Methylation and Immune Microenvironment Are Associated With Overexpressed Fibronectin 1: A Diagnostic and Prognostic Target in Head and Neck Squamous Cell Carcinoma. 2021 , 8, 753563	1

680	Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy. 2021 , 60, 26320-26326	11
679	Integrated analysis of expression, prognostic value and immune infiltration of GSDMs in hepatocellular carcinoma. 2021 , 13, 24117-24135	4
678	Current Perspectives on the Immunosuppressive Niche and Role of Fibrosis in Hepatocellular Carcinoma and the Development of Antitumor Immunity. 2021 , 221554211056853	1
677	Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy. 2021 , 133, 26524	
676	Monitoring Immune Cell Function Through Optical Imaging: a Review Highlighting Transgenic Mouse Models. 2021 , 1	1
675	Activating NK- receptors, homing selectins and inhibitory Siglecs recognize EBOLA-GP and HPV-L1NK.	
674	SQ3370 Activates Cytotoxic Drug via Click Chemistry at Tumor and Elicits Sustained Responses in Injected & Non-injected Lesions.	
673	Systemic immune mediators predict therapeutic response and tumor-infiltrating lymphocyte intensity in triple-negative breast cancer.	
672	Polysaccharides from the fungus <i>Inonotus obliquus</i> activate macrophages into a tumoricidal phenotype via interaction with TLR2, TLR4 and Dectin-1a.	2
671	The application of the natural killer cells, macrophages and dendritic cells in treating various types of cancer. 2021 ,	
670	KRAS mutations are negatively correlated with immunity in colon cancer. 2020 , 13, 750-768	3
669	Immunological parameters as a new lead in the diagnosis of ovarian cancer. 2015 , 7, 67-72	3
668	Exercise in Regulation of Inflammation-Immune Axis Function in Cancer Initiation and Progression. 2015 , 29, 908-20, 922	46
667	Expression of STING and MIF in tumor infiltration lymphocytes as prognostic factors in patients with ESCC. 2017 , 10, 10066-10074	1
666	Assessment for prognostic value of differentially expressed genes in immune microenvironment of clear cell renal cell carcinoma. 2020 , 12, 5416-5432	4
665	Immunotherapy in non-small cell lung cancer: Update and new insights. 2021 , 7, 1-21	4
664	Nab-paclitaxel promotes the cancer-immunity cycle as a potential immunomodulator. 2021 , 11, 3445-3460	2
663	High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma. 2021 , 14, 6961-6974	

662	A Immune-Related Signature Associated with TME Can Serve as a Potential Biomarker for Survival and Sorafenib Resistance in Liver Cancer. 2021 , 14, 5065-5083	2
661	Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway. 2021 , 10, 2005280	1
660	Nano-engineered immune cells as "guided missiles" for cancer therapy. 2021 , 341, 60-79	3
659	The combination therapy of oncolytic HSV-1 armed with anti-PD-1 antibody and IL-12 enhances anti-tumor efficacy. 2021 , 15, 101287	2
658	High endothelial venule is a surrogate biomarker for T-cell inflamed tumor microenvironment and prognosis in gastric cancer. 2021 , 9,	3
657	High DSCC1 Level Predicts Poor Prognosis of Lung Adenocarcinoma. 2021 , Volume 14, 6961-6974	
656	Role of Tumor-Associated Neutrophils in the Molecular Carcinogenesis of the Lung. 2021 , 13,	1
655	The Hippo Signaling Pathway: The Trader of Tumor Microenvironment. 2021 , 11, 772134	1
654	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker GPSM3 in Low-Grade Gliomas. 2021 , 11,	
653	Stapled Liposomes Enhance Cross-Priming of Radio-Immunotherapy. 2021 , e2107161	4
652	Hypoxic Characteristic Genes Predict Response to Immunotherapy for Urothelial Carcinoma.. 2021 , 9, 762478	0
651	Degradation-resistant Implanted Biomaterials Establish an Immunosuppressive Microenvironment that Induces T Cell Exhaustion by Recruiting Myeloid Cells. 2021 ,	0
650	Marker-free characterization of single live circulating tumor cell full-length transcriptomes.	
649	MicroRNAs: Their Role in Metabolism, Tumor Microenvironment, and Therapeutic Implications in Head and Neck Squamous Cell Carcinoma. 2021 , 13,	1
648	Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.. 2021 , 280, 121297	3
647	A Ferroptosis and Pyroptosis Molecular Subtype-Related Signature Applicable for Prognosis and Immune Microenvironment Estimation in Hepatocellular Carcinoma. 2021 , 9, 761839	10
646	Prognostic value of SEC61G in lung adenocarcinoma: a comprehensive study based on bioinformatics and in vitro validation. 2021 , 21, 1216	0
645	Review of Functionalized Nanomaterials for Photothermal Therapy of Cancers. 2021 , 4, 11353-11385	13

644	Identification of an Immune-Related Biomarker Model Based on the CircRNA-Associated Regulatory Network for Esophageal Carcinoma. 2021 , 2021, 1334571	0
643	Cancer-Immunity Cycle and Therapeutic Interventions- Opportunities for Including Pet Dogs With Cancer. 2021 , 11, 773420	1
642	Immunotherapy for Triple-Negative Breast Cancer.. 2021 , 13,	3
641	NPM1 is a Novel Therapeutic Target and Prognostic Biomarker for Ewing Sarcoma.. 2021 , 12, 771253	0
640	Nomogram to Predict Tumor-Infiltrating Lymphocytes in Breast Cancer Patients.. 2021 , 8, 761163	1
639	Pushing Past the Blockade: Advancements in T Cell-Based Cancer Immunotherapies. 2021 , 12, 777073	0
638	Pyroptosis-related gene mediated modification patterns and immune cell infiltration landscapes in cutaneous melanoma to aid immunotherapy. 2021 , 13, 24379-24401	4
637	A platform of patient-derived microtumors identifies treatment response and therapeutic vulnerabilities of ovarian cancer.	
636	Simultaneous delivery of immune stimulatory gene and checkpoint blocker via targeted nanoparticles to strengthen anti-tumor immunity. 2021 , 100151	0
635	The Role of Innate Immune Cells in Tumor Invasion and Metastasis. 2021 , 13,	2
634	Intratumoral co-injection of the poly I:C-derivative BO-112 and a STING agonist synergize to achieve local and distant anti-tumor efficacy. 2021 , 9,	3
633	Bacterial-Based Methods for Cancer Treatment: What We Know and Where We Are. 2021 , 1	3
632	Correlation between aryl hydrocarbon receptor and IL-17 and Foxp3 T-cell infiltration in bladder cancer. 2021 , 102, 249-259	1
631	Distinct roles but cooperative effect of TLR3/9 agonists and PD-1 blockade in converting the immunotolerant microenvironment of irreversible electroporation-ablated tumors. 2021 , 18, 2632-2647	3
630	Bioinformatics prediction and experimental verification identify MAD2L1 and CCNB2 as diagnostic biomarkers of rhabdomyosarcoma. 2021 , 21, 634	0
629	Microenvironment-associated gene HSD11B1 may serve as a prognostic biomarker in clear cell renal cell carcinoma: a study based on TCGA, RT-qPCR, Western blotting, and immunohistochemistry. 2021 , 12, 10891-10904	8
628	Tumour-infiltrating bystander CD8 T cells activated by IL-15 contribute to tumour control in non-small cell lung cancer. 2021 ,	0
627	Tumor-Associated Macrophages: New Horizons for Pituitary Adenoma Researches.. 2021 , 12, 785050	1

626	Molecular characterization of type I IFN-induced cytotoxicity in bladder cancer cells reveals biomarkers of resistance.. 2021 , 23, 547-559	0
625	Untethered Microrobots for Active Drug Delivery: From Rational Design to Clinical Settings. 2021 , e2102253	5
624	Availability of Pluripotent Stem Cells from Normal Cells in Cancer Science. 2021 , 231-245	
623	mA regulator-mediated methylation modification patterns and tumor immune microenvironment in sarcoma.. 2022 , 13,	0
622	Safety and tolerability of andeciximab as monotherapy and in combination with an anti-PD-1 antibody in Japanese patients with gastric or gastroesophageal junction adenocarcinoma: a phase 1b study.. 2022 , 10,	0
621	Factors Determining Long-Term Antitumor Responses to Immune Checkpoint Blockade Therapy in Melanoma.. 2021 , 12, 810388	4
620	CRISPR-based in situ engineering tumor cells to reprogram macrophages for effective cancer immunotherapy. 2022 , 42, 101359	4
619	Up-converted nano-gasholder with precise nitric oxide release remodels immunosuppressive microenvironment and potentiates tumor immunotherapy. 2022 , 42, 101381	2
618	Microbiotic nanomedicine for tumor-specific chemotherapy-synergized innate/adaptive antitumor immunity. 2022 , 42, 101377	7
617	A Immune-Related Signature Associated with TME Can Serve as a Potential Biomarker for Survival and Sorafenib Resistance in Liver Cancer. 2021 , Volume 14, 5065-5083	2
616	High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma.. 2022 , 15, 609-621	0
615	Monocytes engineered with iSNAP inhibit human B-lymphoma progression.	
614	Macrophage-Mediated Melanoma Reduction after HP-NAP Treatment in a Zebrafish Xenograft Model.. 2022 , 23,	0
613	A prognostic model based on immune-related long noncoding RNAs for patients with epithelial ovarian cancer.. 2022 , 15, 8	1
612	Diffuse large B-cell lymphoma-derived exosomes push macrophage polarization toward M2 phenotype via GP130/STAT3 signaling pathway.. 2021 , 352, 109779	1
611	Combination of Anti-Angiogenics and Checkpoint Inhibitors for Renal Cell Carcinoma: Is the Whole Greater Than the Sum of Its Parts?. 2022 , 14,	0
610	An efficient and robust HPLC method to determine the sialylation levels of human epithelial cells.. 2022 , 17, e0257178	
609	Bioinformatics analysis of C3 in brain low-grade gliomas as potential therapeutic target and promoting immune cell infiltration.. 2022 , 39, 27	

608	The emerging role of Arid5a in cancer: A new target for tumors. 2022,	
607	The Role of m6A Epigenetic Modification in the Treatment of Colorectal Cancer Immune Checkpoint Inhibitors.. 2021, 12, 802049	0
606	Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy.. 2022, 17, 73-89	1
605	Risk factor analysis and nomogram for predicting in-hospital mortality in ICU patients with sepsis and lung infection.. 2022, 22, 17	1
604	IL-1A is associated with postoperative survival and immune contexture in clear cell renal cell carcinoma.. 2022,	1
603	Injectable Hydrogel as a Unique Platform for Antitumor Therapy Targeting Immunosuppressive Tumor Microenvironment.. 2021, 12, 832942	3
602	Spindle and Kinetochore-associated Family Genes are Prognostic and Predictive Biomarkers in Hepatocellular Carcinoma. 2022, 000, 000-000	
601	LRRK2 correlates with macrophage infiltration in pan-cancer.. 2021, 114, 316-327	3
600	Revisiting the outstanding questions in cancer nanomedicine with a future outlook. 2022, 4, 634-653	0
599	Vectorized Treg-depleting β TLA-4 elicits antigen cross-presentation and CD8 T cell immunity to reject 'cold' tumors.. 2022, 10,	3
598	Tumour infiltrating lymphocyte density differs by meningioma type and is associated with prognosis in atypical meningioma.. 2022,	0
597	Therapeutic Metabolic Reprograming Using microRNAs: From Cancer to HIV Infection.. 2022, 13,	0
596	Uncovering mediators of collagen degradation in the tumor microenvironment.. 2022, 13, 100101	3
595	Prognostic Value of Programmed Death Ligand-1 Expression in Solid Tumors Irrespective of Immunotherapy Exposure: A Systematic Review and Meta-Analysis.. 2022, 1	
594	Tumour microenvironment and heterotypic interactions in pancreatic cancer.. 2022, 1	0
593	Engineered implantable vaccine platform for continuous antigen-specific immunomodulation.. 2022, 281, 121374	1
592	The ubiquitination-dependent and -independent functions of cereblon in cancer and neurological diseases.. 2022, 167457	2
591	Chitosan derivatives functionalized dual ROS-responsive nanocarriers to enhance synergistic oxidation-chemotherapy.. 2022, 282, 119087	2

590	The interactions of paclitaxel with tumour microenvironment.. 2022 , 105, 108555	5
589	Immune modulating nanoparticles depleting tumor-associated macrophages to enhance immune checkpoint blockade therapy. 2022 , 435, 134779	1
588	Nuclear Transporting Factor 2 as a Novel Biomarker of Head and Neck Squamous Cell Carcinoma and Associated with T/B Cell Receptor Signaling Pathway.. 2022 , 2022, 2885323	0
587	The Role of Long Non-Coding RNAs in the Tumor Immune Microenvironment.. 2022 , 13, 851004	1
586	Diagnostic, Therapeutic, and Prognostic Value of the mA Writer Complex in Hepatocellular Carcinoma.. 2022 , 10, 822011	2
585	Effective Combinations of Immunotherapy and Radiotherapy for Cancer Treatment.. 2022 , 12, 809304	2
584	Robust Prediction of Prognosis and Immunotherapeutic Response for Clear Cell Renal Cell Carcinoma Through Deep Learning Algorithm.. 2022 , 13, 798471	0
583	Retreatment with nivolumab for patients with recurrent and/or metastatic head and neck cancer.. 2022 , 1-7	1
582	Retinoic Acid Metabolism-Related Enzyme Signature Identified Prognostic and Immune Characteristics in Sarcoma.. 2021 , 9, 780951	
581	Accumulation of dysfunctional tumor-infiltrating PD-1+ DCs links PD-1/PD-L1 blockade immunotherapeutic response in cervical cancer.. 2022 , 11, 2034257	1
580	Tailoring Chemoimmunostimulant Bioscaffolds for Inhibiting Tumor Growth and Metastasis after Incomplete Microwave Ablation. 2021 ,	1
579	Multi-omic machine learning predictor of breast cancer therapy response. 2021 ,	15
578	CAMML: Multi-Label Immune Cell-Typing and Stemness Analysis for Single-Cell RNA-sequencing. 2022 , 27, 199-210	
577	Immunogenetic mechanisms in the treatment of cancer. 2022 , 321-338	
576	Role of macrophages in tumor development. 2022 , 113-164	
575	Glioblastoma Microenvironment and Cellular Interactions.. 2022 , 14,	1
574	Photothermal and Photodynamic Therapy of Tumors with Plasmonic Nanoparticles: Challenges and Prospects.. 2022 , 15,	2
573	Depleting Tumor Infiltrating B Cells to Boost Antitumor Immunity with Tumor Immune-Microenvironment Reshaped Hybrid Nanocage.. 2022 ,	1

572	Novel Immune-Related Ferroptosis Signature in Esophageal Cancer: An Informatics Exploration of Biological Processes Related to the TMEM161B-AS1/hsa-miR-27a-3p/GCH1 Regulatory Network.. 2022 , 13, 829384	2
571	A Patient With Failed Liver Transplantation After the Use of PD-1 Blockade Combined With Lenvaxen.. 2022 , 9, 712466	
570	Proteasomal Processing Immune Escape Mechanisms in Platinum-Treated Advanced Bladder Cancer.. 2022 , 13,	
569	Multi-faced roles of reactive oxygen species in anti-tumor T cell immune responses and combination immunotherapy. 77-98	1
568	The Prognostic Value of GNG7 in Colorectal Cancer and Its Relationship With Immune Infiltration.. 2022 , 13, 833013	0
567	More than a Bubble: Extracellular Vesicle microRNAs in Head and Neck Squamous Cell Carcinoma.. 2022 , 14,	4
566	Instructive Hydrogels for Primary Tumor Cell Culture: Current Status and Outlook.. 2022 , e2102479	0
565	Integrated Analysis of miR-7-5p-Related ceRNA Network Reveals Potential Biomarkers for the Clinical Outcome of Gastric Cancer.. 2022 , 2022, 8204818	
564	STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma.. 2022 , 14,	0
563	Advance of SOX Transcription Factors in Hepatocellular Carcinoma: From Role, Tumor Immune Relevance to Targeted Therapy.. 2022 , 14,	0
562	Tumor associated macrophages reprogramed by targeted bifunctional bioorthogonal nanozymes for enhanced tumor immunotherapy. 2022 ,	2
561	Epigenetics of Dendritic Cells in Tumor Immunology.. 2022 , 14,	1
560	The Role of Immune Checkpoint Molecules on Macrophages in Cancer, Infection, and Autoimmune Pathologies.. 2022 , 13, 837645	0
559	lLnc: Prioritizing Long Non-coding RNAs for Pan-cancer Analysis of Immune Cell Infiltration.	
558	Boosting Tumor Immunotherapy by Bioactive Nanoparticles via Ca ²⁺ Interference Mediated TME Reprogramming and Specific PD-L1 Depletion. 2201275	4
557	N6-methyladenosine-related lncRNAs is a potential marker for predicting prognosis and immunotherapy in ovarian cancer.. 2022 , 159, 17	1
556	The interaction of CD4 helper T cells with dendritic cells shapes the tumor microenvironment and immune checkpoint blockade response.. 2022 ,	8
555	Construction of immune-related lncRNA signature to predict aggressiveness, immune landscape, and drug resistance of colon cancer.. 2022 , 22, 127	1

554	Sensitizing immune unresponsive colorectal cancers to immune checkpoint inhibitors through MAVS overexpression.. 2022 , 10,	2
553	Pan-cancer analysis reveals sex-specific signatures in the tumor microenvironment.. 2022 ,	1
552	Effect of CRISPR/Cas9-Edited PD-1/PD-L1 on Tumor Immunity and Immunotherapy.. 2022 , 13, 848327	0
551	The Prognostic Value of Lysine Acetylation Regulators in Hepatocellular Carcinoma.. 2022 , 9, 840412	1
550	Tumor immunology CRISPR screening: present, past, and future.. 2021 ,	1
549	Identification of a Mitochondria-Related Gene Signature to Predict the Prognosis in AML.. 2022 , 12, 823831	1
548	Comprehensive analysis of tumor immune microenvironment and prognosis of m6A-related lncRNAs in gastric cancer.. 2022 , 22, 316	1
547	SIRP α and PD1 expression on tumor-associated macrophage predict prognosis of intrahepatic cholangiocarcinoma.. 2022 , 20, 140	0
546	MYBL2 is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer.. 2022 , 15, 3003-3030	1
545	Diverse Chromobox Family Members: Potential Prognostic Biomarkers and Therapeutic Targets in Head and Neck Squamous Cell Carcinoma.. 2022 , 15, 2463-2474	2
544	A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell.. 2022 , 600, 94-100	0
543	Comprehensive Analysis Identifies Ameloblastin-Related Competitive Endogenous RNA as a Prognostic Biomarker for Testicular Germ Cell Tumour.. 2022 , 14,	0
542	Cancer cell membrane-derived nanoparticles block the expression of immune checkpoint proteins on cancer cells and coordinate modulatory activity on immunosuppressive macrophages.. 2022 ,	0
541	Emodin suppresses hepatocellular carcinoma growth by regulating macrophage polarization via microRNA-26a/transforming growth factor beta 1/protein kinase B.. 2022 , 13, 9548-9563	0
540	CD155/SRC complex promotes hepatocellular carcinoma progression via inhibiting the p38 MAPK signalling pathway and correlates with poor prognosis.. 2022 , 12, e794	2
539	Emerging Immunotherapy for Hepatocellular Carcinoma: A Guide for Hepatologists.. 2022 ,	7
538	JAK-STAT1 Signaling Pathway Is an Early Response to Infection and Contributes to Immune Escape and Gastric Carcinogenesis.. 2022 , 23,	0
537	Self-degradable poly(β -amino ester)s promote endosomal escape of antigen and agonist.. 2022 , 345, 91-100	0

536	A bioluminescence reporter mouse model for visualizing and quantifying CD8+ T cells in vivo.. 2022 , 27, 100781	
535	Targeted delivery of a STING agonist to brain tumors using bioengineered protein nanoparticles for enhanced immunotherapy.. 2022 , 16, 232-248	3
534	Integrated Analysis of Angiogenesis-Mediated Tumor Immune Microenvironment Pattern in Hepatocellular Carcinoma (HCC) and a Novel Prognostic Model Construction to Predict Patient Outcome.. 2021 , 27, e934937	0
533	Arming Immune Cell Therapeutics with Polymeric Prodrugs. 2021 , e2101944	
532	Identification and Development of Subtypes with Poor Prognosis in Gastric Cancer Based on Both Hypoxia and Immune Cell Infiltration.. 2021 , 14, 9379-9399	1
531	DOK1 and DOK2 regulate CD8+ T cell signaling and memory formation without affecting tumor cell killing.	
530	Tumor-Associated Neutrophil Extracellular Traps Regulating Nanocarrier-Enhanced Inhibition of Malignant Tumor Growth and Distant Metastasis.. 2021 , 13, 59683-59694	1
529	Immune Score Indicator for the Survival of Melanoma Patients Based on Tumor Microenvironment.. 2021 , 14, 10397-10416	0
528	Immunotherapy against Gliomas.	
527	NKG7 is a T-cell intrinsic therapeutic target for improving antitumor cytotoxicity and cancer immunotherapy.. 2021 ,	2
526	CRYAB predicts clinical prognosis and is associated with immunocyte infiltration in colorectal cancer.. 2021 , 9, e12578	1
525	Matrix Metalloproteinases Shape the Tumor Microenvironment in Cancer Progression.. 2021 , 23,	18
524	Myeloid-Derived Suppressor Cells in Prostate Cancer: Present Knowledge and Future Perspectives.. 2021 , 11,	1
523	Novel Multikernel Trick for Predicting Pan-CancerDistant Metastatic Sites Using a Feature Extraction Strategy. 2021 ,	
522	Rethinking the chemokine cascade in brain metastasis: Preventive and therapeutic implications.. 2021 ,	1
521	Clinical Impact of Immune Cells and Their Spatial Interactions in Diffuse Large B-Cell Lymphoma Microenvironment.. 2021 ,	1
520	Cold Physical Plasma in Cancer Therapy: Mechanisms, Signaling, and Immunity.. 2021 , 2021, 9916796	4
519	The Immune Regulatory Role of Protein Kinase CK2 and Its Implications for Treatment of Cancer.. 2021 , 9,	1

518	Multifunctional Immunoliposomes Enhance the Immunotherapeutic Effects of PD-L1 Antibodies against Melanoma by Reprogramming Immunosuppressive Tumor Microenvironment.. 2021 , e2105118	0
517	CRISPR Screens to Identify Regulators of Tumor Immunity. 2022 , 6,	1
516	Ginsenosides are active ingredients in Panax ginseng with immunomodulatory properties from cellular to organismal levels. 2021 ,	3
515	MAP3K8 Is a Prognostic Biomarker and Correlated With Immune Response in Glioma.. 2021 , 8, 779290	1
514	Complementing Cancer Photodynamic Therapy with Ferroptosis through Iron Oxide Loaded Porphyrin-Grafted Lipid Nanoparticles.. 2021 , 15, 20164-20180	9
513	Macrophages-based immune-related risk score model for relapse prediction in stage I-III non-small cell lung cancer assessed by multiplex immunofluorescence.. 2022 , 11, 523-542	0
512	Autoimmunity regulation within the tumor microenvironment. 2022 , 51-71	
511	Single-Cell Sequencing and Its Applications in Liver Cancer.. 2022 , 12, 857037	1
510	Identification of a pyroptosis-related prognostic signature in breast cancer.. 2022 , 22, 429	0
509	Is Candida albicans an opportunistic oncogenic pathogen?. 2022 , 18, e1010413	0
508	Cellular Conversations in Glioblastoma Progression, Diagnosis and Treatment.. 2022 , 1	0
507	Comprehensive Landscape of Prognostic Significance and Immune Characteristics of Myosins in Squamous Cell Carcinoma of the Head and Neck.. 2022 , 2022, 5501476	
506	Robust delivery of RIG-I agonists using extracellular vesicles for anti-cancer immunotherapy.. 2022 , 11, e12187	2
505	Identification of a Tumor Immunological Phenotype-Related Gene Signature for Predicting Prognosis, Immunotherapy Efficacy, and Drug Candidates in Hepatocellular Carcinoma.. 2022 , 13, 862527	0
504	Table_1.DOCX. 2019 ,	
503	Data_Sheet_1.doc. 2018 ,	
502	Data_Sheet_1.DOCX. 2018 ,	
501	Presentation_1.pptx. 2019 ,	

500 Image_1.TIF. 2020,

499 Image_2.TIF. 2020,

498 Image_3.TIF. 2020,

497 Table_1.XLSX. 2020,

496 Presentation_1.PDF. 2020,

495 Table_1.PDF. 2020,

494 Data_Sheet_1.PDF. 2020,

493 Image_1.JPEG. 2019,

492 Image_2.jpg. 2019,

491 Image_3.JPEG. 2019,

490 image_1.PDF. 2018,

489 image_2.PDF. 2018,

488 table_1.PDF. 2018,

487 table_2.PDF. 2018,

486 table_3.PDF. 2018,

485 Image_1.tif. 2020,

484 Image_2.tif. 2020,

483 Table_1.docx. 2020,

482 data_sheet_1.docx. 2018,

481 Presentation_1.PPTX. 2020,

480 Table_1.xlsx. 2020,

479 image_1.tiff. 2018,

478 image_2.tiff. 2018,

477 image_3.tiff. 2018,

476 Data_Sheet_1.pdf. 2019,

475 Data_Sheet_1.PDF. 2018,

474 Table_1.XLS. 2018,

473 Table_2.XLS. 2018,

472 Data_Sheet_1.docx. 2020,

471 Image_1.TIF. 2020,

470 Image_2.TIF. 2020,

469 Image_3.TIF. 2020,

468 Table_1.DOCX. 2020,

467 Table_2.DOCX. 2020,

466 Table_3.XLSX. 2020,

465 Table_4.XLSX. 2020,

464 Table_5.XLSX. 2020,

463 Table_6.XLSX. 2020,

462 Table_7.XLSX. 2020,

461 Table_8.XLSX. 2020,

460 Table_9.XLSX. 2020,

459 Data_Sheet_1.PDF. 2020,

458 Table_1.DOCX. 2020,

457 Table_2.DOCX. 2020,

456 Table_3.docx. 2020,

455 Image_1.JPEG. 2020,

454 Image_2.JPEG. 2020,

453 Image_3.JPEG. 2020,

452 Image_4.JPEG. 2020,

451 Image_5.JPEG. 2020,

450 Table_1.xlsx. 2020,

449 Table_1.XLSX. 2019,

448 Table_1.docx. 2020,

447 DataSheet_1.pdf. 2020,

446 DataSheet_2.pdf. **2020**,

445 Image_1.tif. **2020**,

444 data_sheet_1.PDF. **2018**,

443 Data_Sheet_1.zip. **2020**,

442 Data_Sheet_1.PDF. **2020**,

441 Data_Sheet_2.PDF. **2020**,

440 Data_Sheet_3.docx. **2020**,

439 Image_1.JPEG. **2020**,

438 Table_1.docx. **2020**,

437 Data_Sheet_1.pdf. **2019**,

436 Image_1.tif. **2019**,

435 Image_2.TIF. **2019**,

434 Table_1.docx. **2019**,

433 ROS-triggered Nanoinducer based on Dermatan sulfate enhances immunogenic cell death in melanoma.. **2022**,

3

432 Heterogeneity of the tumor immune microenvironment and its clinical relevance.. **2022**, 11, 24

1

431 MUC20 as a novel prognostic biomarker in ccRCC correlating with tumor immune microenvironment modulation.. **2022**, 12, 695-712

430 Immune infiltration and a ferroptosis-related gene signature for predicting the prognosis of patients with cholangiocarcinoma.. **2022**, 14, 1204-1219

429 Immunotherapeutic Significance of a Prognostic Alternative Splicing Signature in Bladder Cancer.. **2022**, 21, 15330338221090093

0

428	Novel prognostic biomarkers, METTL14 and YTHDF2, associated with RNA methylation in Ewing's sarcoma.. 2022 , 12, 7041	
427	The ER-Mitochondria Interface as a Dynamic Hub for T Cell Efficacy in Solid Tumors.. 2022 , 10, 867341	0
426	Prognostic and Immunotherapeutic Roles of KRAS in Pan-Cancer.. 2022 , 11,	0
425	IL2RB Is a Prognostic Biomarker Associated with Immune Infiltrates in Pan-Cancer.. 2022 , 2022, 2043880	0
424	Spatial Characterization of Tumor-Infiltrating Lymphocytes and Breast Cancer Progression.. 2022 , 14,	2
423	F12 as a reliable diagnostic and prognostic biomarker associated with immune infiltration in papillary thyroid cancer.. 2022 , 14,	
422	Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to enhance the efficacy of adoptive T cell therapy.. 2022 , 8, eabi8075	0
421	Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading. 2022 , 12,	0
420	Multiparameter Longitudinal Imaging of Immune Cell Activity in Chimeric Antigen Receptor T Cell and Checkpoint Blockade Therapies.	0
419	CCL19 has potential to be a potential prognostic biomarker and a modulator of tumor immune microenvironment (TIME) of breast cancer: a comprehensive analysis based on TCGA database.. 2022 , 14, 4158-4175	0
418	Immune Infiltration Characteristics and a Gene Prognostic Signature Associated With the Immune Infiltration in Head and Neck Squamous Cell Carcinoma.. 2022 , 13, 848841	1
417	Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy.. 2022 , 14,	1
416	Regulation of intrinsic and extrinsic metabolic pathways in tumour-associated macrophages.. 2022 ,	0
415	GAS5 represses endometrial cancer development via promoting anti-tumor function of tumor-associated macrophages.. 2022 ,	0
414	Characterizing the landscape of cervical squamous cell carcinoma immune microenvironment by integrating the single-cell transcriptomics and RNA-Seq. 2022 , 10,	0
413	Near-Infrared Bioluminescence Imaging of Macrophage Sensors for Cancer Detection In Vivo. 2022 , 10,	1
412	Somatic FOXC1 insertion mutation remodels the immune microenvironment and promotes the progression of childhood acute lymphoblastic leukemia.. 2022 , 13, 431	0
411	High-throughput single-cell sequencing in cancer research.. 2022 , 7, 145	1

410	Two distinct receptor-binding domains of human glycyl-tRNA synthetase 1 displayed on extracellular vesicles activate M1 polarization and phagocytic bridging of macrophages to cancer cells.. 2022 , 539, 215698	0
409	Mapping and Validation of scRNA-Seq-Derived Cell-Cell Communication Networks in the Tumor Microenvironment.. 2022 , 13, 885267	1
408	hsa-miR-9-5p-Mediated TSPAN9 Downregulation Is Positively Related to Both Poor Hepatocellular Carcinoma Prognosis and the Tumor Immune Infiltration. 2022 , 2022, 1-10	0
407	Novel design of multifunctional nanozymes based on tumor microenvironment for diagnosis and therapy. 2022 , 114456	2
406	DIRAS2 Is a Prognostic Biomarker and Linked With Immune Infiltrates in Melanoma. 2022 , 12,	0
405	CAF-derived midkine promotes EMT and cisplatin resistance by upregulating lncRNA ST7-AS1 in gastric cancer.. 2022 ,	0
404	Sex steroid modulation of macrophages within the prostate tumor microenvironment.. 2022 , 10, 98-110	
403	Cell membrane-engineered nanoparticles for cancer therapy.	0
402	Effects of RNA modification "writers" of GALNT2 on the tumor microenvironment in cervical squamous cell carcinoma. 2022 ,	
401	???-?????????: ??????????. 2022 ,	
400	Identification of Immune Infiltration-Related ceRNAs as Novel Biomarkers for Prognosis of Patients With Primary Open-Angle Glaucoma. 2022 , 13,	
399	NANOG confers resistance to complement-dependent cytotoxicity in immune-edited tumor cells through up-regulating CD59. 2022 , 12,	1
398	High Expression of TIMELESS Predicts Poor Prognosis: A Potential Therapeutic Target for Skin Cutaneous Melanoma. 2022 , 9,	
397	Nanomedicines and nanomaterials for cancer therapy: progress, challenge and perspectives. 2022 , 137147	2
396	Suppressors of Cytokine Signaling and Hepatocellular Carcinoma. 2022 , 14, 2549	0
395	Trimodal Imaging-Guided Photothermal-Immunotherapy of Triple-Negative Breast Cancer Enhanced by Ph-Responsive and Cancer Membrane-Coated Polydopamin-Caco3 Nanoparticles.	
394	Exploration of Different Hypoxia Patterns and Construction of a Hypoxia-Related Gene Prognostic Index in Colorectal Cancer. 2022 , 13,	
393	Ferroptosis and Tumor Drug Resistance: Current Status and Major Challenges. 13,	0

392	Calf Thymus Polypeptide Restrains the Growth of Colorectal Tumor via Regulating the Intestinal Microbiota-Mediated Immune Function. 13,	0
391	The Evasion Mechanisms of Cancer Immunity and Drug Intervention in the Tumor Microenvironment. 13,	4
390	Intracellular acetyl CoA potentiates the therapeutic efficacy of anti-tumor CD8+ T cells.	1
389	Epigenetics Regulates Antitumor Immunity in Melanoma. 2022, 13,	1
388	Engineering Bioinspired Nanomedicines to Mitigate the Resistance to Cancer Immunotherapy.	2
387	A Novel lncRNA Panel for Risk Stratification and Immune Landscape in Breast Cancer Patients. Volume 15, 5253-5272	
386	In Situ MicroRNA Conversion Augmented Tumor-Localized Immunochemotherapy.	1
385	Spatio-temporal delivery of both intra- and extracellular toll-like receptor agonists for enhancing antigen-specific immune responses. 2022,	0
384	Novel Strategy for Optimized Nanocatalytic Tumor Therapy: From an Updated View. 2200024	1
383	A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). 2022,	0
382	Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression. 12,	0
381	Cluster of differentiation frequency on antigen presenting-cells: The next step to cervical cancer prognosis?. 2022, 108, 108896	0
380	Antitumor activity of recombinant oncolytic vaccinia virus with human IL2. 2022, 17, 1084-1091	1
379	MicroRNAs Targeting Tumor Microenvironment and Immune Modulation. 2022, 93-108	
378	Single-cell RNA-seq analysis reveals BHLHE40-driven pro-tumour neutrophils with hyperactivated glycolysis in pancreatic tumour microenvironment. gutjnl-2021-326070	1
377	Biomaterials-Mediated Tumor Infarction Therapy. 10,	1
376	Alternative CAR Therapies: Recent Approaches in Engineering Chimeric Antigen Receptor Immune Cells to Combat Cancer. 2022, 10, 1493	2
375	Mitochondrial Homeostasis-Related lncRNAs are Potential Biomarkers for Predicting Prognosis and Immune Response in Lung Adenocarcinoma. 13,	

- 374 Coronaviral Infection and Interferon Response: The Virus-Host Arms Race and COVID-19. **2022**, 14, 1349 0
- 373 Tumour-Natural Killer and CD8 T Cells Interaction Model with Delay+. **2022**, 10, 2193 0
- 372 A Comprehensive Analysis of HAVCR1 as a Prognostic and Diagnostic Marker for Pan-Cancer. 13,
- 371 PD-L2 Serves as a Potential Prognostic Biomarker That Correlates With Immune Infiltration and May Predict Therapeutic Sensitivity in Lower-Grade Gliomas. 12, 0
- 370 A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer. **2022**, 14, 2895 0
- 369 Recapitulating Tumor Hypoxia in a Cleanroom-Free, Liquid-Pinning-Based Microfluidic Tumor Model. 0
- 368 The immune cell atlas of human neuroblastoma. **2022**, 3, 100657 2
- 367 Modeling the Tumor Microenvironment in Patient-Derived Xenografts: Challenges and Opportunities. **2022**, 329-344
- 366 Cationic poly(amino acid) surface functionalized manganese nanoparticles for nitric oxide-based immunotherapy and magnetic resonance imaging. 0
- 365 Heparanase: A Paramount Enzyme for Cancer Initiation, Progression, and Metastasis. **2022**, 197-217
- 364 The tumor immune microenvironment in peritoneal carcinomatosis. **2022**, 1
- 363 Characterization of IL-10-producing regulatory B cells in thymoma. 1-9
- 362 Identification of a differentiation-related prognostic nomogram based on single-cell RNA sequencing in clear cell renal cell carcinoma. **2022**, 12, 1
- 361 Crosstalk of RNA Adenosine Modification-Related Subtypes, Establishment of a Prognostic Model, and Immune Infiltration Characteristics in Ovarian Cancer. 13, 0
- 360 Polypyrrole Nanoenzymes as Tumor Microenvironment Modulators to Reprogram Macrophage and Potentiate Immunotherapy. 2201703 5
- 359 Aging and Susceptibility to Pulmonary Disease. 3509-3522 0
- 358 A Novel Computational Framework for Predicting the Survival of Cancer Patients With PD-1/PD-L1 Checkpoint Blockade Therapy. 12, 0
- 357 Dynamic Immune Function Changes Before and After the First Radioactive Iodine Therapy After Total Resection of Differentiated Thyroid Carcinoma. 13, 0

- 356 Tumor immunotherapy: Mechanisms and clinical applications. **2022**, 1,
- 355 Roles of exosomal circRNAs in tumour immunity and cancer progression. **2022**, 13, 1
- 354 Case Report: Complete Remission of a Patient With Metastatic Gastric Cancer Treated With Nivolumab Combined With Chemotherapy After Palliative Surgery. 13, 0
- 353 Cancer-associated fibroblasts strengthen cell proliferation and EGFR TKIs resistance through aryl hydrocarbon receptor dependent signals in non-small cell lung cancer. **2022**, 22,
- 352 Harnessing Immune Response Using Reactive Oxygen Species-Generating/Eliminating Inorganic Biomaterials for Disease Treatment. **2022**, 114456 0
- 351 Chromosome instability and aneuploidy as context-dependent activators or inhibitors of antitumor immunity. 13, 0
- 350 Computational Characterizing Necroptosis Reveals Implications for Immune Infiltration and Immunotherapy of Hepatocellular Carcinoma. 12,
- 349 Gallic acid induces T-helper-1-like Treg cells and strengthens immune checkpoint blockade efficacy. **2022**, 10, e004037 0
- 348 An Immunity-Related Gene Model Predicts Prognosis in Cholangiocarcinoma. 12, 0
- 347 Identifying Differential Expression Genes and Prognostic Signature Based on Subventricular Zone Involved Glioblastoma. 13, 0
- 346 Identification of chromosomal instability-associated genes as hepatocellular carcinoma progression-related biomarkers to guide clinical diagnosis, prognosis and therapy. **2022**, 105896
- 345 EBAG9-silencing exerts an immune checkpoint function without aggravating adverse effects. **2022**, 1
- 344 A Novel M6A-Related Genes Signature Can Impact the Immune Status and Predict the Prognosis and Drug Sensitivity of Lung Adenocarcinoma. 13, 1
- 343 Increased MPO in Colorectal Cancer Is Associated With High Peripheral Neutrophil Counts and a Poor Prognosis: A TCGA With Propensity Score-Matched Analysis. 12, 0
- 342 Prevalence and prognostic significance of PD-L1, TIM-3 and B7-H3 expression in endometrial serous carcinoma. 0
- 341 Tumor-derived exosomes in the cancer immune microenvironment and cancer immunotherapy. **2022**, 215823 0
- 340 High expression of ZFP36L2 correlates with the prognosis and immune infiltration in lower-grade glioma. 13,
- 339 Prediction of Prognosis in Patients With Endometrial Carcinoma and Immune Microenvironment Estimation Based on Ferroptosis-Related Genes. 9,

338	AP3S1 is a Novel Prognostic Biomarker and Correlated With an Immunosuppressive Tumor Microenvironment in Pan-Cancer. 10,	0
337	Characterization of Immune-Related Molecular Subtypes and a Prognostic Signature Correlating With the Response to Immunotherapy in Patients With Gastric Cancer. 13,	
336	Deoxythymidylate Kinase as a Promising Marker for Predicting Prognosis and Immune Cell Infiltration of Pan-cancer. 9,	
335	Identification of ENO1 as a prognostic biomarker and molecular target among ENOs in bladder cancer. 2022 , 20,	0
334	TLR agonist rMBP-NAP inhibits B16 melanoma tumor growth via induction of DCs maturation and T-cells cytotoxic response.	
333	A Fatty Acid Metabolism Signature Associated With Clinical Therapy in Clear Cell Renal Cell Carcinoma. 13,	0
332	Trends in iron oxide nanoparticles: a nano-platform for theranostic application in breast cancer. 1-21	0
331	Multimodal oncolytic bacteria by coating with tumor cell derived nanoshells. 2022 , 45, 101537	1
330	Discovery of CN0 as a novel proteolysis-targeting chimera (PROTAC) degrader of PARP1 that can activate the cGAS/STING immunity pathway combined with daunorubicin. 2022 , 70, 116912	0
329	EphA10 drives tumor progression and immune evasion by regulating the MAPK/ERK cascade in lung adenocarcinoma. 2022 , 110, 109031	2
328	The Role of Tumor Microenvironment and Immune Response in Colorectal Cancer Development and Prognosis. 28,	0
327	Biphasic response of CD8 T cell to asparagine restriction maximizes its metabolic fitness and antitumoral functionality.	
326	The expression pattern of Immune checkpoints after chemo/radiotherapy in the tumor microenvironment. 13,	0
325	Multi-omics Analysis Identifying CD58 Plays Important Role on Prognosis of Colorectal Cancer.	
324	Baseline and post-treatment biomarkers of resistance to anti-PD-1 therapy in acral and mucosal melanoma: an observational study. 2022 , 10, e004879	0
323	Activation of Stimulation of Interferon Genes (STING) Signal and Cancer Immunotherapy. 2022 , 27, 4638	1
322	Simulations of tumor growth and response to immunotherapy by coupling a spatial agent-based model with a whole-patient quantitative systems pharmacology model. 2022 , 18, e1010254	1
321	Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma. 13,	0

320 Grundlagen der Tumorimmunologie. **2022**, 1-15

319 High preoperative white blood cell count determines poor prognosis and is associated with an immunosuppressive microenvironment in colorectal cancer. 12,

318 ??????????????. **2022**,

317 Identification of immune-related ferroptosis prognostic marker and in-depth bioinformatics exploration of multi-omics mechanisms in thyroid cancer. 9,

316 Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma. **2022**, 101, e29561

315 Metabolic reprogramming and crosstalk of cancer-related fibroblasts and immune cells in the tumor microenvironment. 13,

314 Targeting PD-1/PD-L1 in cancer immunotherapy: an effective strategy for treatment of triple-negative breast cancer (TNBC) patients. **2022**,

313 Identification and Characterization of Genes Related to the Prognosis of Hepatocellular Carcinoma Based on Single-Cell Sequencing. 28,

312 Ferroptosis-related lncRNAs signature to predict the survival and immune evasion for lung squamous cell carcinoma. 13,

311 Single-cell atlas of diverse immune populations in the advanced biliary tract cancer microenvironment. **2022**, 6,

310 Correlation between hematological parameters and PET/CT metabolic parameters in patients with head and neck cancer. **2022**, 17,

309 M6A-related lncRNAs predict clinical outcome and regulate the tumor immune microenvironment in hepatocellular carcinoma. **2022**, 22,

308 RPP40 is a prognostic biomarker and correlated with tumor microenvironment in uterine corpus endometrial carcinoma. 12,

307 Reduction Sensitive Polymers Delivering Cationic Platinum Drugs as STING Agonists for Enhanced Chemo-Immunotherapy. 2204589

306 Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. 12,

305 Anti-Tumor Effect of Parasitic Protozoans. **2022**, 9, 395

304 Detection and Quantification of Nanoparticle-Induced Intracellular ROS in Live Cells by Laser Scanning Confocal Microscopy. **2022**,

303 The Landscape of Early Growth Response Family Members 1-4 in Hepatocellular Carcinoma: Their Biological Roles and Diagnostic Utility. **2022**, 2022, 1-8

302	BTLA+CD200+ B cells dictate the divergent immune landscape and immunotherapeutic resistance in metastatic vs. primary pancreatic cancer.	0
301	The combined prognostic model of copper-dependent to predict the prognosis of pancreatic cancer. 13,	0
300	The systemic-level repercussions of cancer-associated inflammation mediators produced in the tumor microenvironment. 13,	2
299	The Role of Alternative Splicing in Cancer: Regulatory Mechanism, Therapeutic Strategy, and Bioinformatics Application.	
298	The comprehensive expression and functional analysis of m6A modification Readers in hepatocellular carcinoma. 2022 , 14, 6269-6298	0
297	Downregulated TICAM1 is a prognostic biomarker and associated with immune tolerance of Wilms tumor patients. 2022 , 15,	
296	Bourgeoning Cancer Targets. 2022 , 17,	1
295	Immunogenomic-Based Analysis of Hierarchical Clustering of Diffuse Large Cell Lymphoma. 2022 , 2022, 1-16	0
294	Construction of immune-related signature and identification of S100A14 determining immune-suppressive microenvironment in pancreatic cancer. 2022 , 22,	
293	Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. 9,	2
292	Road testing new CAR design strategies in multiple myeloma. 13,	0
291	Pan-cancer analyses identify DCBLD2 as an oncogenic, immunological, and prognostic biomarker. 13,	0
290	mRNAsi-related metabolic risk score model identifies poor prognosis, immunoevasive contexture, and low chemotherapy response in colorectal cancer patients through machine learning. 13,	1
289	Immunotherapy in advanced NSCLC without driver mutations: available therapeutic alternatives after progression and future treatment options. 2022 ,	1
288	Transplantable Syngeneic Murine Tumor Models. 2022 , 11-62	
287	Ultrasensitive Detection of GRP78 in Exosomes and Observation of Migration and Proliferation of Cancer Cells by Application of GRP78-Containing Exosomes. 2022 , 14, 3887	0
286	Construction of a prognostic model related to copper dependence in breast cancer by single-cell sequencing analysis. 13,	0
285	Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. 12,	1

- 284 Neuroimmune crosstalk and its impact on cancer therapy and research. **2022**, 13,
- 283 Emerging Immunotherapy: Liver Cancer Microenvironment for Treatment.
- 282 Pituitary hormone β MSH promotes tumor-induced myelopoiesis and immunosuppression. 1
- 281 Visceral Surgery Profoundly Affects the Cellular and Humoral Components of the Anti-Tumour Immune Response in a Murine Pancreatic Adenocarcinoma Model. **2022**, 14, 3850 0
- 280 Macrophage phenotype-switching in cancer. **2022**, 931, 175229 1
- 279 Comprehensive Analysis of the Role of SLC2A3 on Prognosis and Immune Infiltration in Head and Neck Squamous Cell Carcinoma. **2022**, 2022, 1-18 0
- 278 Exploration of shared TF-miRNA-mRNA and mRNA-RBP-pseudogene networks in type 2 diabetes mellitus and breast cancer. 13, 0
- 277 Prognostic characteristics and clinical response to immunotherapy targeting programmed cell death 1 for patients with advanced gastric cancer with liver metastases. 13, 0
- 276 Construction and verification of a hypoxia-related nine-gene prognostic model in uveal melanoma based on integrated single-cell and bulk RNA sequencing analyses. **2022**, 223, 109214 0
- 275 Tannins in Terminalia bellirica inhibits hepatocellular carcinoma growth via re-educating tumor-associated macrophages and restoring CD8+T cell function. **2022**, 154, 113543 0
- 274 Understanding the Molecular Kinetics in NSCLC Through Computational Method. **2022**, 129-163 0
- 273 Identification of Immune Infiltration and Effective Immune Biomarkers in Acute Lung Injury by Bioinformatics Analysis. **2022**, 31, 096368972211244 0
- 272 Immunobiology of Testicular Cancer. **2022**, 0
- 271 Predicting efficacy of 5-fluorouracil therapy via a mathematical model with fuzzy uncertain parameters. **2022**, 12, 202 0
- 270 A tractable microscopy- and flow cytometry-based method to measure natural killer cell-mediated killing and infiltration of tumor spheroids. **2022**, 0
- 269 The Causal Relationship between White Blood Cells Counts and Hepatocellular Carcinoma: A Mendelian Randomization Study. 0
- 268 Integrated analysis and validation reveal ACAP1 as a novel prognostic biomarker associated with tumor immunity in lung adenocarcinoma. **2022**, 20, 4390-4401 0
- 267 The CCR1 and CCR5 CC chemokine receptors in Penaeus vannamei are annexed by bacteria to attenuate shrimp survival. **2023**, 139, 104561 0

266	Identification and validation of roles of lysyl oxidases in the predictions of prognosis, chemotherapy and immunotherapy in glioma. 13,	0
265	The prognostic value of MicroRNAs associated with fatty acid metabolism in head and neck squamous cell carcinoma. 13,	0
264	Establishment of Nomogram Model for Minimally Invasive Treatment of Small Hepatocellular Carcinoma Based on CD8+T Cell Counts. Volume 15, 925-940	0
263	The Relationship between the Prognostic Marker LIMA1 in Head and Neck Squamous Cell Carcinoma and Immune Infiltration. 2022, 2022, 1-14	0
262	A comprehensive review of SHP2 and its role in cancer.	1
261	Guest Edited Collection: Epigenetics within the tumor microenvironment. 2022, 12,	0
260	Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy. 11,	0
259	Emerging roles of TRIM27 in cancer and other human diseases. 10,	0
258	Integration of single-cell RNA sequencing and bulk RNA sequencing to reveal an immunogenic cell death-related 5-gene panel as a prognostic model for osteosarcoma. 13,	0
257	Multiparametric immune profiling of advanced cervical cancer to predict response to programmed death-1 inhibitor combination therapy: an exploratory study of the CLAP trial.	1
256	Bioinformatics-Based Analysis: Noncoding RNA-Mediated COL10A1 Is Associated with Poor Prognosis and Immune Cell Infiltration in Pancreatic Cancer. 2022, 2022, 1-16	1
255	Construction of immune cell infiltration protein network based on clinical low grade glioma cases. 12,	0
254	Associating resistance to immune checkpoint inhibitors with immunological escape in colorectal cancer. 12,	0
253	Self-Splittable Transcytosis Nanoraspberry for NIR-II Photo-Immunometabolic Cancer Therapy in Deep Tumor Tissue. 2204067	0
252	The role of polyamine metabolism in remodeling immune responses and blocking therapy within the tumor immune microenvironment. 13,	0
251	HAUS1 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma.	0
250	Pan-cancer analysis reveals interleukin-17 family members as biomarkers in the prediction for immune checkpoint inhibitor curative effect. 13,	0
249	Identification of the prognostic, diagnostic, and biological significance of the miR-148a-3p/cathepsin A axis in hepatocellular carcinoma.	0

- 248 Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 2nd-4th, 2021, Italy). **2022**, 20, ○
- 247 Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis. ○
- 246 Immune-checkpoint inhibitor therapy response evaluation using oncophysics-based mathematical models. ○
- 245 Colorectal cancer: Metabolic interactions reshape the tumor microenvironment. **2022**, 1877, 188797 ○
- 244 Multi-functional extracellular vesicles: Potentials in cancer immunotherapy. **2022**, 215934 ○
- 243 IL-12-expressing highly immunogenic recombinant modified vaccinia virus Ankara reprograms tumor-infiltrating myeloid cells to overcome immune resistance. ○
- 242 Cancer Resistance to Immunotherapy: Molecular Mechanisms and Tackling Strategies. **2022**, 23, 10906 ○
- 241 Gut microbiota modulate radiotherapy-associated antitumor immune responses against hepatocellular carcinoma Via STING signaling. **2022**, 14, ○
- 240 OCRL is a novel prognostic biomarker and its association with immunoregulation in breast cancer. ○
- 239 The new progress in cancer immunotherapy. ○
- 238 Status of factors of innate immunity in exposed people who subsequently developed cancer. **2022**, ○
- 237 MND1 functions as a potential prognostic biomarker associated with cell cycle and immune infiltration in kidney renal clear cell carcinoma. **2022**, 14, 7416-7442 ○
- 236 Oncogenic Merkel cell polyomavirus T antigen truncating mutations are mediated by APOBEC3 activity in Merkel cell carcinoma. ○
- 235 Transforming growth factor- β in tumour development. 9, 1
- 234 Integrated computer analysis and a self-built Chinese cohort study identified GSTM2 as one survival-relevant gene in human colon cancer potentially regulating immune microenvironment. 12, ○
- 233 Relationships of Ferroptosis and Pyroptosis-Related Genes with Clinical Prognosis and Tumor Immune Microenvironment in Head and Neck Squamous Cell Carcinoma. **2022**, 2022, 1-47 ○
- 232 The immune-related gene-based prognostic index predicts the prognosis and effect of immune checkpoint inhibitors in hepatocellular carcinoma. ○
- 231 Respuesta biológica en las pacientes con cáncer de mama tratadas con radioterapia intraoperatoria. **2022**, 100433 ○

230	Three Pillars or Three Illusions of Oncoimmunology. 2022 , 1-19	0
229	Imaging strategies for monitoring the immune response.	1
228	Stromal Interaction Molecule 1 (STIM1) is a potential prognostic biomarker and correlated with immune infiltrates in solid tumors. 2022 ,	0
227	Identification and validation of immunotherapy for four novel clusters of colorectal cancer based on the tumor microenvironment. 13,	1
226	Forkhead box M1 recruits FoxP3 + Treg cells to induce immune escape in hilar cholangiocarcinoma. 2022 , 10,	0
225	A predictive signature based on enhancer RNA associates with immune infiltration and aids treatment decision in clear cell renal cell carcinoma. 12,	0
224	Colorectal Cancer and Purinergic Signalling: An Overview. 2022 , 14, 4887	0
223	Clinical application of cell-based therapies opportunities and challenges. 2022 , 2,	0
222	Biological and Exploitable Crossroads for the Immune Response in Cancer and COVID-19. 2022 , 10, 2628	0
221	Identification of Two Novel Immune Subtypes Characterized by Distinct Prognosis and Tumor Microenvironment in Osteosarcoma. 2022 , 2022, 1-12	0
220	Correlation of Glucose Metabolism with Cancer and Intervention with Traditional Chinese Medicine. 2022 , 2022, 1-17	0
219	A review of spatial profiling technologies for characterizing the tumor microenvironment in immuno-oncology. 13,	1
218	Comprehensive Analysis of NPSR1-AS1 as a Novel Diagnostic and Prognostic Biomarker Involved in Immune Infiltrates in Lung Adenocarcinoma. 2022 , 2022, 1-11	0
217	Oncolytic Virotherapy for Prostate Cancer: Lighting a Fire in Winter. 2022 , 23, 12647	0
216	Identification of an immune-related genes signature in lung adenocarcinoma to predict survival and response to immune checkpoint inhibitors.	0
215	Gut Microbiota and Tumor Immune Escape: A New Perspective for Improving Tumor Immunotherapy. 2022 , 14, 5317	1
214	The Mechanism of Alisol B23 Acetate Inhibiting Lung Cancer: Targeted Regulation of CD11b/CD18 to Influence Macrophage Polarization. Volume 16, 3677-3689	0
213	Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma.	0

212	Tumor-Infiltrating Dendritic Cells: Decisive Roles in Cancer Immunosurveillance, Immunoediting, and Tumor T Cell Tolerance. 2022 , 11, 3183	0
211	Modulation of the antitumor immune response by cancer-associated fibroblasts: mechanisms and targeting strategies to hamper their immunosuppressive functions. 598-629	0
210	Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. 2022 , 108301	0
209	Metabolic control of CD47 expression through LAT2-mediated amino acid uptake promotes tumor immune evasion. 2022 , 13,	1
208	Targeting RAS mutants in malignancies: successes, failures, and reasons for hope.	0
207	N6 -methyladenosine functions and its role in skin cancer.	0
206	Dissecting the effect of sphingolipid metabolism gene in progression and microenvironment of osteosarcoma to develop a prognostic signature. 13,	0
205	High expression of TTC21A predicts unfavorable prognosis and immune infiltrates in clear cell renal cell carcinoma. 13,	0
204	Inhibition of the CCR6-CCL20 axis prevents regulatory T cell recruitment and sensitizes head and neck squamous cell carcinoma to radiation therapy.	0
203	The emerging roles of exosome-derived noncoding RNAs in the tumor immune microenvironment and their future applications. 2022 , 156, 113863	1
202	Prognostic and immunological role of FCER1G in pan-cancer. 2022 , 240, 154174	0
201	Engineering 2D silicene-based core/shell nanomedicine for GSDME-induced synergistic pyroptosis and photonic hyperthermia of melanoma carcinoma. 2023 , 454, 140175	1
200	Cancer cell-intrinsic XBP1 drives immunosuppressive reprogramming of intratumoral myeloid cells by promoting cholesterol production. 2022 ,	1
199	Anticancer Effects of Thymoquinone through the Antioxidant Activity, Upregulation of Nrf2, and Downregulation of PD-L1 in Triple-Negative Breast Cancer Cells. 2022 , 14, 4787	0
198	A prognostic signature based on cuproptosis-related long non-coding RNAs predicts the prognosis and sensitivity to chemotherapy in patients with colorectal cancer. 9,	0
197	Inhibiting ACK1-mediated phosphorylation of C-terminal Src kinase counteracts prostate cancer immune checkpoint blockade resistance. 2022 , 13,	1
196	Engineering metal-phenolic networks for enhancing cancer therapy by tumor microenvironment modulation.	0
195	Nanomaterials: small particles show huge possibilities for cancer immunotherapy. 2022 , 20,	0

- 194 Potential role of long noncoding RNA RP5-881L22.5 as a novel biomarker and therapeutic target of colorectal cancer. 14, 2108-2121 ○
- 193 Effects of gut microbiota on immune responses and immunotherapy in colorectal cancer. 13, ○
- 192 E3 Ubiquitin Ligase RNF125 Suppresses Immune Escape in Head and Neck Squamous Cell Carcinoma by Regulating PD-L1 Expression. ○
- 191 In-situ clickable prodrug nanoplatform locally activates T lymphocytes to potentiate cancer immunotherapy. 2022, 47, 101661 1
- 190 Chiral-Selective Antigen-Presentation by Supramolecular Chiral Polymer Micelles. 2208157 ○
- 189 Intralesional Bacillus Calmette-Guérin injections and hypo-fractionated radiation synergistically induce systemic antitumor immune responses. 2023, 114, 109542 ○
- 188 Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agents. 2023, 187, 106568 1
- 187 Cancer/testis antigen HEMGN correlated with immune infiltration serves as a prognostic biomarker in lung adenocarcinoma. 2023, 153, 226-237 ○
- 186 Attenuated WNV-poly(A) exerts a broad-spectrum oncolytic effect by selective virus replication and CD8+ T cell-dependent immune response. 2023, 158, 114094 ○
- 185 Manganese immunotherapy for treating osteosarcoma: Glycosylating 1V209 anchored MnO₂ nanosheets prompt pro-inflammatory macrophage polarization. 2023, 48, 101670 ○
- 184 Cancer nanomedicine in preoperative therapeutics: Nanotechnology-enabled neoadjuvant chemotherapy, radiotherapy, immunotherapy, and phototherapy. 2023, 24, 136-152 1
- 183 Comparison of dynamic changes in the peripheral CD8+ T cells function and differentiation in ESCC patients treated with radiotherapy combined with anti-PD-1 antibody or concurrent chemoradiotherapy. 13, ○
- 182 Comprehensive Analysis of Cuproptosis-Related Genes in Prognosis and Immune Infiltration of Hepatocellular Carcinoma Based on Bulk and Single-Cell RNA Sequencing Data. 2022, 14, 5713 ○
- 181 Molecular Cluster Mining of Adrenocortical Carcinoma via Multi-Omics Data Analysis Aids Precise Clinical Therapy. 2022, 11, 3784 1
- 180 The clinicopathological significance and relapse predictive role of tumor microenvironment of intrahepatic cholangiocarcinoma after radical surgery. ○
- 179 Macrophage-derived exosomes regulate gastric cancer cell oxaliplatin resistance by wrapping circ 0008253. 1-13 ○
- 178 Marker-free characterization of full-length transcriptomes of single live circulating tumor cells. gr.276600.122 ○
- 177 Prognosis stratification in breast cancer and characterization of immunosuppressive microenvironment through a pyrimidine metabolism-related signature. 13, ○

- 176 Identification of subtypes of hepatocellular carcinoma and screening of prognostic molecular diagnostic markers based on cell adhesion molecule related genes. 13, 0
- 175 Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis. 0
- 174 Multifunctional plant virus nanoparticles: An emerging strategy for therapy of cancer. 0
- 173 SLC11A1 as a stratification indicator for immunotherapy or chemotherapy in patients with glioma. 13, 0
- 172 A comprehensive prognostic and immune infiltration analysis of EXOC3L1 in pan-cancer. 13, 0
- 171 Construction of Pyroptosis-Related Prognostic and Immune Infiltration Signature in Bladder Cancer. **2022**, 2022, 1-22 0
- 170 Reinventing the human tuberculosis (TB) granuloma: Learning from the cancer field. 13, 0
- 169 Study of epirubicin sustained release chemoablation in tumor suppression and tumor microenvironment remodeling. 13, 1
- 168 Prognosis and immune features of pyroptosis-related RNA patterns in low-grade glioma. 12, 0
- 167 Dendritic cells direct circadian anti-tumor immune responses. 1
- 166 Insights and Strategies of Melanoma Immunotherapy: Predictive Biomarkers of Response and Resistance and Strategies to Improve Response Rates. **2023**, 24, 41 1
- 165 Inflammation in Wound Healing and Pathological Scarring. 0
- 164 Investigation of M2 macrophage-related gene affecting patients prognosis and drug sensitivity in non-small cell lung cancer: Evidence from bioinformatic and experiments. 12, 0
- 163 Nanoparticle-Mediated Radiotherapy Remodels the Tumor Microenvironment to Enhance Antitumor Efficacy. 2206370 0
- 162 Introduction on Personalized Immune-Oncology. **2023**, 1-25 0
- 161 A prognostic model and immune regulation analysis of uterine corpus endometrial carcinoma based on cellular senescence. 12, 0
- 160 Plasma cell subtypes analyzed using artificial intelligence algorithm for predicting biochemical recurrence, immune escape potential, and immunotherapy response of prostate cancer. 13, 0
- 159 Immune subtype identification and multi-layer perceptron classifier construction for breast cancer. 12, 0

158	Tumor Microenvironment Cellular Crosstalk Predicts Response to Adoptive TIL Therapy in Melanoma.	0
157	Clear-Box Machine Learning for Virtual Screening of Two-Dimensional Nanozymes to Target Tumor Hydrogen Peroxide. 2202925	2
156	TGF-beta signal transduction: biology, function and therapy for diseases. 2022 , 3,	0
155	m5C regulator-mediated modification patterns and tumor microenvironment infiltration characterization in colorectal cancer: One step closer to precision medicine. 13,	0
154	Infiltration of LPAR5+ macrophages in osteosarcoma tumor microenvironment predicts better outcomes. 13,	0
153	A Combined Risk Score Model to Assess Prognostic Value in Patients with Soft Tissue Sarcomas. 2022 , 11, 4077	0
152	Phytochemicals as Chemo-Preventive Agents and Signaling Molecule Modulators: Current Role in Cancer Therapeutics and Inflammation. 2022 , 23, 15765	0
151	Characterization of circulating immune cells and correlation with Tie2/Angiopoietins level in well differentiated neuroendocrine gastroenteropancreatic tumors: a cross-sectional analysis.	1
150	A tumor microenvironment preoperative nomogram for prediction of lymph node metastasis in bladder cancer. 12,	0
149	Immunotherapy for Esophageal Cancer. 2023 , 1-22	0
148	An evaluation of KIF20A as a prognostic factor and therapeutic target for lung adenocarcinoma using integrated bioinformatics analysis. 10,	0
147	The causal relationship between white blood cell counts and hepatocellular carcinoma: a Mendelian randomization study. 2022 , 27,	0
146	O2-Supplying Nanozymes Alleviate Hypoxia and Deplete Lactate to Eliminate Tumors and Activate Antitumor Immunity.	0
145	ENO2 affects the EMT process of renal cell carcinoma and participates in the regulation of the immune microenvironment. 2022 , 49,	0
144	The function of natural compounds in important anticancer mechanisms. 12,	0
143	Novel M7G-Related lncRNA Signature for Predicting Overall Survival in Patients with Gastric Cancer.	0
142	Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. 13,	0
141	The effect of Wnt/Ectenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer. 2022 , 30, 99-116	0

- 140 Dysfunctional epigenetic protein-coding gene-related signature is associated with the prognosis of pancreatic cancer based on histone modification and transcriptome analysis. **2023**, 13, 0
- 139 A modifiable universal cotinine-chimeric antigen system of NK cells with multiple targets. 13, 0
- 138 Novel strategies to improve efficacy of treatment with tumor-infiltrating lymphocytes (TILs) for patients with solid cancers. Publish Ahead of Print, 0
- 137 Prognostic value of NOX2 as a potential biomarker for lung adenocarcinoma using TCGA and clinical validation. **2023**, 27, 0
- 136 Mussel-inspired Adhesive Hydrogels for Local Immunomodulation. 0
- 135 Editorial: Impact of tumor microenvironment on lung cancer. 13, 0
- 134 Necroptosis Related Genes Predict Prognosis and Therapeutic Potential in Gastric Cancer. **2023**, 13, 101 0
- 133 The Tumor Microenvironment in Tumorigenesis and Therapy Resistance Revisited. **2023**, 15, 376 3
- 132 Dendritic cells and natural killer cells: The road to a successful oncolytic virotherapy. 13, 0
- 131 Emphasis on Adipocyte Transformation: Anti-Inflammatory Agents to Prevent the Development of Cancer-Associated Adipocytes. **2023**, 15, 502 1
- 130 Development and validation of a novel ferroptosis-related lncRNA prognostic signature for pancreatic adenocarcinoma. **2023**, 27, 0
- 129 A novel pyroptosis scoring model was associated with the prognosis and immune microenvironment of esophageal squamous cell carcinoma. 13, 0
- 128 A pyroptosis-related gene signature provides an alternative for predicting the prognosis of patients with hepatocellular carcinoma. **2023**, 16, 0
- 127 Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy. **2023**, 1
- 126 The E3 ubiquitin ligases regulate PD-1/PD-L1 protein levels in tumor microenvironment to improve immunotherapy. 14, 0
- 125 HAT1 regulates the immune microenvironment and promotes the malignant pathology of lower-grade gliomas. 0
- 124 Low expression of NR1H3 correlates with macrophage infiltration and indicates worse survival in breast cancer. 13, 0
- 123 Computed tomography-detected extramural venous invasion-related gene signature: a potential negative biomarker of immune checkpoint inhibitor treatment in patients with gastric cancer. **2023**, 21, 0

- 122 Machine learning-based tumor malignancy prediction based on PBMC methylome landscape in canine mammary tumor. ○
- 121 Physiological relevance of in-vitro cell-nanoparticle interaction studies as a predictive tool in cancer nanomedicine research. **2023**, 632, 122579 ○
- 120 Tumor microenvironment-responsive manganese-based nanomaterials for cancer treatment. **2023**, 480, 215027 ○
- 119 Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer. **2022**, 135, 2436-2445 ○
- 118 Advancements in Cancer Immunotherapies. **2023**, 11, 59 ○
- 117 T-Cell Exhaustion in Cancers. **2023**, 1-29 ○
- 116 Biomimetic, pH-Responsive Nanoplatforms for Cancer Multimodal Imaging and Photothermal Immunotherapy. **2023**, 15, 1784-1797 ○
- 115 Prognostic Role of Neutrophil-to-Lymphocyte Ratio (NLR), Lymphocyte-to-Monocyte Ratio (LMR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-C Reactive Protein Ratio (LCR) in Patients with Hepatocellular Carcinoma (HCC) undergoing Chemoembolizations (TACE) of the Liver: The Unexplored Corner Linking Tumor Microenvironment, Biomarkers and Interventional Radiology. **2023**, 15, 257 ○
- 114 Breast cancer combined prognostic model based on lactate metabolism genes. **2022**, 101, e32485 ○
- 113 SHP-2 and PD-1-SHP-2 signaling regulate myeloid cell differentiation and antitumor responses. **2023**, 24, 55-68 ○
- 112 The PTEN-associated immune prognostic signature reveals the landscape of the tumor microenvironment in glioblastoma. **2023**, 578034 ○
- 111 A flexible liposomal polymer complex as a platform of specific and regulable immune regulation for individual cancer immunotherapy. **2023**, 42, ○
- 110 GBP2 promotes clear cell renal cell carcinoma progression through immune infiltration and regulation of PD-L1 expression via STAT1 signaling. **2023**, 49, ○
- 109 Revamping the innate or innate-like immune cell-based therapy for hepatocellular carcinoma: new mechanistic insights and advanced opportunities. **2023**, 40, ○
- 108 One-Dimensional Rod-like Tobacco Mosaic Virus Promotes Macrophage Polarization for a Tumor-Suppressive Microenvironment. ○
- 107 Tumor-infiltrating lymphocyte (TIL) therapy. **2023**, 133-147 ○
- 106 Extracellular vesicles and co-isolated endogenous retroviruses differently affect dendritic cells. ○
- 105 Perspective Chapter: Impact of Tumor Metabolism on Immune Cells in the Tumor Microenvironment. ○

- 104 Systemic immune mediators reflect tumor-infiltrating lymphocyte intensity and predict therapeutic response in triple-negative breast cancer. ○
- 103 Targeting a check point receptor of human primary natural killer cells via CRISPR/Cas9 potentiates anti-tumor activity in allogeneic glioblastoma. ○
- 102 Vesicular Antibodies: Shedding Light on Antibody Therapeutics with Cell Membrane Nanotechnology. 2207875 ○
- 101 LncRNA LINC01833 is a Prognostic Biomarker and Correlates with Immune Infiltrates in Patients with Lung Adenocarcinoma by Integrated Bioinformatics Analysis. **2023**, 2023, 1-8 ○
- 100 Therapeutic effect of haploidentical peripheral blood stem cell treatment on relapsed/refractory ovarian cancer. **2023**, ○
- 99 Intercellular Interactions in the Tumor Stroma and Their Role in Oncogenesis. **2022**, 37, 167-172 ○
- 98 Prognostic prediction and expression validation of NSD3 in pan-cancer analyses. **2023**, 47, 1003-1019 ○
- 97 Role of Immune Cells in the Tumor Microenvironment. **2023**, ○
- 96 Tumor-Associated Macrophages (TAMs) in Cancer Resistance; Modulation by Natural Products. **2023**, 23, ○
- 95 Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 + tumor-infiltrating lymphocytes and patient prognosis. **2023**, 482, 755-766 ○
- 94 Novel exosome-related risk signature as prognostic biomarkers in glioblastoma. 14, ○
- 93 Development of a risk model to predict prognosis in breast cancer based on cGAS-STING-related genes. 14, ○
- 92 Identification of a novel Immune-Related prognostic model for patients with colorectal cancer based on 3 subtypes. **2023**, 228, 152352 ○
- 91 Epithelial-mesenchymal transition is the main way in which glioma-associated microglia/macrophages promote glioma progression. 14, ○
- 90 An emerging role of inflammasomes in spinal cord injury and spinal cord tumor. 14, ○
- 89 Comprehensive analysis of prognostic value, immune implication and biological function of CPNE1 in clear cell renal cell carcinoma. 11, ○
- 88 Nanomaterials-involved strategies for reversing the immunosuppressive factors and improving antitumor immunotherapy. **2023**, 50, 101831 ○
- 87 Unraveling the heterogeneity of cholangiocarcinoma and identifying biomarkers and therapeutic strategies with single-cell sequencing technology. **2023**, 162, 114697 ○

- 86 Impact of C-reactive protein/albumin/lymphocyte (CALLY) index on prognosis after hepatectomy for colorectal liver metastasis. **2023**, 47, 101911 ○
- 85 A Pan-cancer Analysis of Ferroptosis-related Gene Arachidonic Acid 15-Lipoxygenase-1 (ALOX15): Its Prognostic and Immunotherapeutic Values. ○
- 84 Intercellular interactions in the tumor stroma and their role in oncogenesis. **2022**, 40, 3 ○
- 83 Monoclonal antibodies in breast cancer: A critical appraisal. **2023**, 183, 103915 ○
- 82 Hypoxia induced lactate acidosis modulates tumor microenvironment and lipid reprogramming to sustain the cancer cell survival. 13, ○
- 81 Immune Checkpoint Inhibitors in Urological Cancers. **2023**, 1-25 ○
- 80 Development of a risk model based on autophagy-related genes to predict survival and immunotherapy response in ovarian cancer. **2023**, 160, ○
- 79 Vaccination-Based Immunoprevention of Colorectal Tumors. **2023**, 57, 246-252 1
- 78 Molecular characteristics, oncogenic roles, and relevant immune and pharmacogenomic features of NEK2 in gastric cancer. **2023**, 116, 109737 ○
- 77 Pathological images for personal medicine in Hepatocellular carcinoma: Cross-talk of gene sequencing and pathological images. **2022**, 30, 243-258 ○
- 76 Identification of stemness subtypes and features to improve endometrial cancer treatment using machine learning. **2023**, 51, 57-73 ○
- 75 A combined analysis of bulk and single-cell sequencing data reveals metabolic enzyme, pyruvate dehydrogenase E1 subunit beta (PDHB), as a prediction biomarker for the tumor immune response and immunotherapy. **2023**, 9, e13456 ○
- 74 Identification and vitro verification of the potential drug targets of active ingredients of Chonglou in the treatment of lung adenocarcinoma based on EMT-related genes. 14, ○
- 73 A prospective diagnostic and prognostic biomarker for hepatocellular carcinoma that functions in glucose metabolism regulation: Solute carrier family 37 member 3. **2023**, 1869, 166661 ○
- 72 Two birds with one stone: Strategy for the lung cancer therapy with bioinspired AIE aggregates. **2023**, 21, ○
- 71 Identification of three metabolic subtypes in gastric cancer and the construction of a metabolic pathway-based risk model that predicts the overall survival of GC patients. 14, ○
- 70 A human pan-cancer system analysis of regulator of chromatin condensation 2. **2023**, 9, e13599 ○
- 69 Systematic analysis identifies XRCC4 as a potential immunological and prognostic biomarker associated with pan-cancer. **2023**, 24, ○

- 68 The Immunology of Brain Tumors. **2023**, ○
- 67 Roles of cancer-associated fibroblasts (CAFs) in anti- PD-1/PD-L1 immunotherapy for solid cancers. **2023**, 22, ○
- 66 Dysfunction of the ST7-AS1/miR-301b-3p/BTG1 ceRNA network promotes immune escape of triple-negative breast cancer. **2023**, 116, 109805 ○
- 65 Engineered Apoptosis-Bioinspired Nanoparticles Initiate Immune Cascade for Cancer Immunotherapy of Malignant Ascites. **2023**, 15, 10371-10382 1
- 64 Research progress on the immunomodulatory mechanism of acupuncture in tumor immune microenvironment. 14, ○
- 63 Targeting immune cell types of tumor microenvironment to overcome resistance to PD-1/PD-L1 blockade in lung cancer. 14, ○
- 62 Are charged particles a good match for combination with immunotherapy? Current knowledge and perspectives. **2023**, 1-36 1
- 61 Characterization and Clinical Verification of Immune-related Genes in Hepatocellular Carcinoma to Aid Prognosis Evaluation and Immunotherapy. ○
- 60 Patient-derived spheroids and patient-derived organoids simulate evolutions of lung cancer. **2023**, 9, e13829 ○
- 59 DSN1 may predict poor prognosis of lower-grade glioma patients and may be a potential target for immunotherapy. ○
- 58 LCP2 expression is correlated with an abundance of immune infiltrates and is a potential prognostic biomarker in lung adenocarcinoma. ○
- 57 Systematic analysis identifies REST as an oncogenic and immunological biomarker in glioma. **2023**, 13, ○
- 56 Construction of Two Independent RAB Family-Based Scoring Systems Based on Machine Learning Algorithms and Definition of RAB13 as a Novel Therapeutic Target for Hepatocellular Carcinoma. **2023**, 24, 4335 ○
- 55 An immune-related prognostic signature associated with immune landscape and therapeutic responses in gastric cancer. ○
- 54 How organoids can improve personalized treatment in patients with gastro-esophageal tumors. **2023**, 69, 102348 1
- 53 Targeting tumor microenvironment for non-small cell lung cancer immunotherapy. **2023**, ○
- 52 Tumor Microenvironment Regulation and Cancer Targeting Therapy Based on Nanoparticles. **2023**, 14, 136 ○
- 51 The role of ubiquitin pathway-mediated regulation of immune checkpoints in cancer immunotherapy. ○

50	Correlation of 18F-FDG PET/CT metabolic parameters with the expression of immune biomarkers in the tumour microenvironment in lung adenocarcinoma. 2023 ,	0
49	Hepatocellular carcinoma subtypes based on metabolic pathways reveals potential therapeutic targets. 13,	0
48	ImmuneScore of eight-gene signature predicts prognosis and survival in patients with endometrial cancer. 13,	0
47	Development of alternative herbals remedy for gastric cancer based on transcriptomic analysis of immune infiltration and ferroptosis. 14,	0
46	iATMEcell: identification of abnormal tumor microenvironment cells to predict the clinical outcomes in cancer based on cell-cell crosstalk network. 2023 , 24,	0
45	Interleukin-37 promotes DMBA/TPA skin cancer through SIGIRR-mediated inhibition of glycolysis in CD103 + DC cells. 2023 , 4,	0
44	The Functions of TRIM56 in Antiviral Innate Immunity and Tumorigenesis. 2023 , 24, 5046	1
43	The Role of Different Immunocompetent Cell Populations in the Pathogenesis of Head and Neck CancerRegulatory Mechanisms of Pro- and Anti-Cancer Activity and Their Impact on Immunotherapy. 2023 , 15, 1642	0
42	Predictive value of neutrophil-to-lymphocyte, lymphocyte-to-monocyte, and platelet-to-lymphocyte ratios in adult and pediatric acute lymphoblastic leukemia patients. 2022 , 47, 239	0
41	Systemic treatment for metastatic colorectal cancer. 29, 1425-1444	0
40	Cervical cancer immune infiltration microenvironment identification, construction of immune scores, assisting patient prognosis and immunotherapy. 14,	0
39	Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy. 2023 , 9, e14450	0
38	The Influence of Ambient Temperature on Adipose Tissue Homeostasis, Metabolic Diseases and Cancers. 2023 , 12, 881	0
37	Bone marrow adipocytes induce cancer-associated fibroblasts and immune evasion, enhancing invasion and drug resistance.	1
36	Systemic treatment for metastatic colorectal cancer. 29, 1569-1588	0
35	Construction of a Prognostic Model for Predicting Colorectal Cancer Prognosis and Response to Immunotherapy Based on Cuproptosis-Associated lncRNAs. 2023 , 2023, 1-16	0
34	Deregulated bile acids may drive hepatocellular carcinoma metastasis by inducing an immunosuppressive microenvironment. 12,	0
33	Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironment.	0

- 32 An integrative pan-cancer analysis illustrating the key role of LRP11 in cervical cancer. **2023**, 102, e33201 ○
- 31 Novel m7G-related lncRNA signature for predicting overall survival in patients with gastric cancer. **2023**, 24, ○
- 30 Regular Voluntary Running is Associated with Increased Tumor Vascularization and Immune Cell Infiltration and Decreased Tumor Growth in Mice. ○
- 29 Virus-like particle-based nanocarriers as an emerging platform for drug delivery. 1-23 ○
- 28 Cancer Immunotherapy: A Brief History, The Latest Development of Typical Subtypes and Therapy Combination. 30, 34-43 ○
- 27 Identification of a centrosome-related prognostic signature for breast cancer. 13, ○
- 26 Towards a consensus definition of immune exclusion in cancer. 14, ○
- 25 Immune microenvironment and clinical feature analyses based on a prognostic model in lymph node-positive breast cancer. 13, ○
- 24 Senescent Stromal Cells in the Tumor Microenvironment: Victims or Accomplices?. **2023**, 15, 1927 ○
- 23 mRNA challenge predicts brain cancer immunogenicity and response to checkpoint inhibitors. ○
- 22 Prediction of clear cell renal cell carcinoma prognosis based on an immunogenomic landscape analysis. ○
- 21 Prioritizing exhausted T cell marker genes highlights immune subtypes in pan-cancer. **2023**, 26, 106484 ○
- 20 The role of dendritic cells in radiation-induced immune responses. **2023**, ○
- 19 Recent Organic Photosensitizer Designs for Evoking Proinflammatory Regulated Cell Death in Antitumor Immunotherapy. 2201614 ○
- 18 Targeted therapy and immunotherapy: Diamonds in the rough in the treatment of epithelial ovarian cancer. 14, ○
- 17 Substances of Natural Origin in Medicine: Plants vs. Cancer. **2023**, 12, 986 ○
- 16 Current Understanding of Flavonoids in Cancer Therapy and Prevention. **2023**, 13, 481 ○
- 15 Emerging Targeted Therapies for HER2-Positive Breast Cancer. **2023**, 15, 1987 ○

- | | | |
|----|--|---|
| 14 | Identification of calcium metabolism related score associated with the poor outcome in papillary thyroid carcinoma. 13, | ○ |
| 13 | Pan-cancer analysis of BRK1 as a potential immunotherapeutic target. 1-23 | ○ |
| 12 | Exploring immune interactions in triple negative breast cancer: IL-1 β inhibition and its therapeutic potential. 14, | ○ |
| 11 | Long non-coding RNA AL137789.1 promoted malignant biological behaviors and immune escape of pancreatic carcinoma cells. 2023 , 18, | ○ |
| 10 | Deciphering the Prognostic and Therapeutic Significance of Cell Cycle Regulator CENPF: A Potential Biomarker of Prognosis and Immune Microenvironment for Patients with Liposarcoma. 2023 , 24, 7010 | ○ |
| 9 | Investigation of Diagnostic and Prognostic Value of CLEC4M of Non-Small Cell Lung Carcinoma Associated with Immune Microenvironment. Volume 16, 1317-1332 | ○ |
| 8 | Complete Remission of a Patient With HER-2 amplification Gastric Cancer Treated With Sintilimab Combined With Trastuzumab. | ○ |
| 7 | Identification of anoikis-related genes signature to predict the prognosis in cervical cancer. | ○ |
| 6 | SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. 2023 , 24, 7505 | ○ |
| 5 | Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer. 2023 , 12, | ○ |
| 4 | New Roles for Old Friends: Involvement of the Innate Immune System in Tumor Progression. 2023 , 24, 7604 | ○ |
| 3 | Developing four cuproptosis-related lncRNAs signature to predict prognosis and immune activity in ovarian cancer. 2023 , 16, | ○ |
| 2 | A ferroptosis-related gene in Helicobacter pylori infection, SOCS1, serves as a potential prognostic biomarker and corresponds with tumor immune infiltration in stomach adenocarcinoma: In silico approach. 2023 , 119, 110263 | ○ |
| 1 | Current and promising applications of Hf(IV)-based MOFs in clinical cancer therapy. | ○ |